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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and 
the questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. These are typically composed of ESAC members and other external 
experts relevant to the test method under review. These experts may be nominated by 
ESAC, EURL ECVAM and partner organisations within the International Cooperation on 
Alternative Test Methods (ICATM). ESAC ultimately decides on the composition of these 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' 
and 'Working Group Reports' at the end of the peer review. ESAC may also issue 
Opinions on other scientific issues of relevance to the work and mission of EURL ECVAM 
but not directly related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the EURL ECVAM 
Eye Irritation Validation Study (EIVS) on EpiOcular™ EIT and SkinEthic™ HCE and a 
related Cosmetics Europe study on HPLC/UPLC-spectrophotometry as an alternative 
endpoint detection system for MTT-formazan. 
 
 EUROPEAN COMMISSION 
DIRECTORATE-GENERAL 
JOINT RESEARCH CENTRE 
Directorate F - Health, Consumers and Reference Materials 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 
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Ispra, 17 November 2014 
Summary of the ESAC Opinion 
 
The ESAC was requested (see Annex 2) to conduct a scientific peer review of and provide 
an ESAC opinion on 
(1) the EURL ECVAM Eye Irritation Study (EIVS); co-sponsored by EURL ECVAM and 
Cosmetics Europe) evaluating the EpiOcular Eye Irritation Test (EIT) and SkinEthic 
Human Corneal Epithelium (HCE), both based on Reconstructed human Tissue 
(RhT); with the ESAC review addressing the study design, results and conclusions. 
The review examined the scientific basis of the assays, their reproducibility and 
transferability as assessed during the study, as well as their predictive capacity. 
The latter was examined in the context of the test methods' envisaged use within 
an in vitro testing strategy (Scott et al., 2010) based on strategic combinations of 
alternative test methods to replace the Draize eye test, either as the initial step in 
a Bottom-Up Approach or a second or subsequent step in a Top-Down Approach to 
discriminate chemicals (substances and chemical mixtures) not requiring 
classification for serious eye damage/eye irritancy (No Category) from chemicals 
requiring classification and labelling as Category 1 and Category 2 (UN 2011; EU 
2008). The term "strategic combinations" here refers to the placement of methods 
in a sequential manner in view of either identifying first negatives (high 
sensitivity: bottom-up approach) or first positives (high specificity: top-down 
approach). 
(2) The usefulness, based on a study conducted by Cosmetics Europe and submitted 
to EURL ECVAM, of HPLC/UPLC-photometry as an alternative endpoint detection 
system in particular for highly coloured chemicals interfering with the conventional 
formazan endpoint measurement by OD-photometry. 
 
EIVS 
The ESAC concludes that the study was generally well planned and executed. Briefly, 
reproducibility, transferability and predictive capacity of both test methods were assessed 
in a three laboratory ring trial testing 104 chemicals plus an additional 8 solids for 
assessing the optimised EpiOcular™ EIT protocol. The chemicals represented a wide 
range of irritancy scores and chemical and use classes. The aims of the study were well 
described and clear target criteria for test method performance had been predefined. 
Using appropriate provisions for retesting, the study generated almost complete data 
sets as a solid basis for evaluating test method performance. However, the ESAC does 
not agree with the approach chosen by the Validation Management Team (VMT) to 
calculate the predictive capacity based on the individual test runs: the ESAC believes that 
confidence limits based on the number of test chemicals are more appropriate. The ESAC 
believes that the approach chosen by the Validation Management Team (VMT), over-
estimated the sample size, produced overly narrow confidence limits, and resulted in a 
seemingly high degree of certainty with respect to the point estimates of sensitivity and 
specificity. In addition rather than relying only on single test runs to calculate accuracy, 
the ESAC believes that, in case single runs are used for analysing predictive capacity, 
reliance is better placed on bootstrapping or worst-case/best-case scenarios of predictive 
capacity. 
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EpiOcular™ EIT 
The EpiOcular™ EIT test method was found to be highly reproducible within laboratories, 
irrespective of the protocol used. The ESAC considers that the VMG predictive capacity 
criteria are deemed to have been met with the 60% cut-off value using protocol V8.0. 
This version was the result of optimisation phase during the validation study aiming to 
improve results for solids while maintaining the accuracy obtained for liquid test 
materials.  
The ESAC concludes that the EIVS study findings with respect to transferability, 
reproducibility and predictive capacity, taking account of the supplementary analysis 
undertaken by the ESAC WG, justify the EpiOcular™ EIT test method (SOP V 8.0) being 
considered for use within a test strategy to determine the eye irritation potential of 
chemicals, specifically to detect non-irritants as part of a Top-Down or Bottom-Up 
approach (Scott et al, 2010). 
However, the ESAC believes that confidence in the test method would be further 
increased if supplementary studies confirm that the test method correctly classifies a 
small but representative sample of labelled products or mixtures as defined by REACH 
and from various sectorial use classes: for products containing mixtures of substances, 
such as plant protection products or cosmetic products, the testing of the mixture is 
considered more representative of the expected exposure situation in actual practice than 
testing its constituent substances separately.  
 
SkinEthic™ HCE 
The ESAC agrees with the VMG's view that this test method does not meet the 
performance criteria that would be required to consider it as part of a test strategy. ESAC 
also agrees that with the VMG that there is potential for improvement but that the 
necessary work is beyond the scope of the validation study. 
 
The Cosmetics Europe Report 
The Cosmetics Europe Report is not a Validation Study Report (VSR) relating to a 
predictive alternative test method, but is a report of a study which evaluated the 
performance of a bio-analytical endpoint measurement system that overcomes a 
limitation of the conventional OD-photometry measurements. 
The ESAC believes the evidence presented tends to confirm that for chemicals compatible 
with these RhT methods, the measurements obtained of formazan values by OD-
photometry and the suitably qualified HPLC/UPLC endpoint detection systems are 
comparable. ESAC appreciates that an advantage of the HPLC/UPLC endpoint detection 
measurement is that it can also be used in the case of strongly coloured chemicals 
incompatible with formazan measurement by OD-photometry (e.g. colorants used in 
cosmetics and other consumer products). The report also provides plausible arguments 
that this endpoint measurement system is suitable for use with other RhT test methods 
relying on measurement of the same endpoint. 
The ESAC concludes that the use of HPLC/UPLC would overcome the current limitation of 
RhT test methods with respect to problems encountered with strongly-coloured chemicals 
which interfere with the measurement of formazan levels by OD-photometry.   
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1. Mandate of the ESAC 
The 38th ESAC plenary (19 June 2013) established an ESAC Working Group (WG)1 to 
undertake a detailed scientific review of an EURL ECVAM/Cosmetics Europe Eye Irritation 
Validation Study (EIVS) evaluating two in vitro test methods based on Reconstructed 
human Tissue (RhT) models for assessing acute eye irritation caused by chemicals: the 
EpiOcular™ EIT and the SkinEthic™ HCE.  
A revised EURL ECVAM Request for ESAC advice (Annex 2) was adopted at the 39th ESAC 
plenary (11/12 March 2014) extending the ESAC mandate to include a scientific review of 
a Cosmetics Europe study of HPLC/UPLC-photometry as an alternative formazan endpoint 
measurement system. 
 
2. Detailed Opinion of the ESAC 
Taking into account (a) the report of the detailed review undertaken by the ESAC WG; 
(b) the information made available to ESAC by EURL ECVAM (Including the EIVS VSR, the 
Cosmetics Europe report, and other supporting documentation), and; (c) the ECVAM 
request for ESAC advice (Annex 2) - the ESAC has adopted the following opinion. 
 
2.1 Background, regulatory and scientific rationale  
 
Both the EIVS and the Cosmetics Europe reports describe the potential role of the RhT-
based test methods, and the endpoint measurement system, in the context of the 
regulatory testing. 
 
EIVS 
The ESAC considers that the VSR provides plausible arguments supporting the use of 
these RhT test methods, when combined with other in vitro methods, within a tiered 
approach using strategic combinations of alternative test methods. This tiered approach 
(Scott et al, 2010) is supposed to be integrated into future more complete "Integrated 
Testing Strategies" (ITS) or "Integrated Approaches to Testing and Assessement" (IATA) 
to replace the Draize eye test. The tiered approach is argued to have the potential to be 
at least as relevant and reliable as the current in vivo test system for the identification of 
non-irritants, either as the initial step in a Bottom-Up Approach or a second or 
subsequent step in a Top-Down Approach test to discriminate chemicals not requiring 
classification for serious eye damage/eye irritancy (No Category) from chemicals 
requiring classification and labelling (UN GHS Category 1 and Category 2). 
Taking account of the probably rather small prevalence of chemicals inducing serious eye 
damage (Adriaens et al, 2014) RhT test methods validated for this purpose would 
significantly reduce animal testing by identifying the large number of chemicals not 
requiring classification. 
 
                                                          
1
 The WG was established according to the ESAC Rules of Procedure and included experts nominated by 
international partner organisations of EURL ECVAM collaborating under the ICATM (International Collaboration 
on Alternative Test Methods) framework.  
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SkinEthic™ HCE  
The tissue component of the test kit is manufactured by controlled culture of 
immortalised human corneal epithelial cells to produce a multi-layered epithelium 
resembling in vivo corneal epithelium. Although derived from cultured human corneal 
cells the cells used have been transformed and immortalised. The ESAC offers no opinion 
on whether these cells are inherently more biologically relevant in the context of eye 
irritation testing than other epithelial cells (e.g. RhT models derived from normal 
untransformed human keratinocytes). 
 
EpiOcular™ EIT 
The EpiOcular™ EIT tissue construct is prepared from normal human-derived epidermal 
keratinocytes grown under defined conditions. The resulting 3D tissue is a non-
keratinized multi-layered and stratified (but non-cornified) epithelium intended to model 
properties of human corneal epithelium. 
 
The Cosmetics Europe Report 
The Cosmetics Europe Report is not a Validation Study Report (VSR): the study evaluated 
the performance of a bio-analytical endpoint measurement system (which is not itself a 
test method). 
The Scientific Committee on Consumer Safety (SCCS) of the European Commission 
Directorate General for Health and Consumers previously advised that “...for coloured 
substances, a different endpoint, not involving Optical Density (OD) quantification, should 
be envisaged. Analytical methods such as HPLC/UPLC might be more appropriate to 
detect formazan in the in vitro assay...” (McNamee et al. 2009). An alternative endpoint 
detection measurement for RhT/MTT reduction product test methods that overcomes this 
current limitation would extend the applicability domain of these RhT tests.  
The Cosmetics Europe study proposes the use of suitably qualified HPLC/UPLC endpoint 
measurement in this context. The ESAC believes The Cosmetics Europe Report describes 
a bio-analytical system that has the potential to overcome a current limitation on the use 
of these and other RhT test methods. 
 
2.2 Design and conduct of the study 
 
2.2.1 Definition of the study objectives 
EIVS 
The ESAC believes these are clearly defined. 
 
The Cosmetics Europe Report 
The ESAC considers the study objectives to have been sufficiently clearly defined. 
 
2.2.2 Study design for the prospective part 
EIVS 
The ESAC concludes that, subject to specific qualifications set out elsewhere in this 
Opinion, the study design was generally appropriate and sufficiently robust with respect 
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to determining the relevance and reliability of these test methods for the purposes 
defined in the VSR. 
 
SkinEthic™ HCE 
The protocol for the SkinEthic™ HCE test method described the following testing 
strategy: 
(1) The first step was an "Eye irritation Peptide Reactivity Assay" (EPRA). 
(2) For EPRA reactive chemicals the SkinEthic™ HCE Short-time Exposure protocol 
(HCE SE). 
(3) For EPRA non-reactive chemicals the SkinEthic™ HCE Long-time Exposure protocol 
(HCE LE). 
However, for the purposes of the EIVS study all chemicals were tested using both the 
HCE SE and HCE LE protocols. 
104 coded chemicals were blind-tested using both the SE and LE protocols in three runs 
with three replicate tissues per run, in three laboratories. A test strategy combining, in a 
sequential manner, the Eye Irritation Peptide Reactivity Assay (EPRA) with both the SE 
and LE variants of the SkinEthic™ HCE test method was also assessed. 
 
EpiOcular™ EIT 
In the ring trial 104 coded chemicals were blind-tested (three runs with two replicate 
tissues per run, in three laboratories) using EpiOcular™ EIT SOP (V 6.0), using separate 
protocols for liquid and solid chemicals, and two prediction models (50% and 60% cell 
viability). 
With the original EpiOcular™ EIT protocol (SOP V6.0) all of the VMG acceptance criteria 
were met for liquid chemicals: however, some of the VMG predictive capacity acceptance 
criteria were not met for solid chemicals.  
The VMG considered that test method performance might be improved if a. Test 
optimisation was undertaken by the test developer within EIVS.  
To improve the performance of the test methods with solid chemicals, test optimisation 
was undertaken within EIVS to produce a balanced increase in sensitivity offset by some 
decrease in specificity using 11 of the most challenging EIVS solid chemicals. An 
amended optimised for solid chemicals protocol, V 8.0, was used for a post-optimisation 
validation study of the EpiOcular™ EIT optimised in one laboratory with 60 solid 
chemicals. The post-optimisation findings are incorporated and analysed in the VSR, and 
form the basis of the VMG conclusions on the performance of the EpiOcular™ EIT. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC believes the Cosmetics Europe study was well-designed, and is satisfied that a 
sufficient number of RhT MTT-reduction product test methods, chemicals, and 
laboratories were used. 
In the first phase of the study, three laboratories qualified HPLC/UPLC systems using 
appropriate qualification criteria in accordance with the May 2001 US Food and Drug 
Administration (FDA) guidance for industry “Bioanalytical Method Validation”.  
Next, three laboratories tested up to 26 chemicals using one of three RhT test methods 
measuring three different toxicological endpoints (EpiOcular™ EIT as per the EIVS 
protocol v6.0 for eye irritation, SkinEthic™ RhE as per OECD TG 431 for skin corrosion, 
and the EpiSkin™ as per OECD TG 439 for skin irritation). The three laboratories with the 
suitably qualified HPLC/UPLC systems for tested the samples and applied the Prediction 
Models using both endpoint measurements.  
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Chemical selection:  
EIVS 
The ESAC believes the method by which the test chemicals were selected, and the 
number and nature of the test chemicals, were appropriate. 
 
The Cosmetics Europe Report 
The ESAC believes that the 26 chemicals selected were adequate for this study, and 
represent the almost the full dynamic range of the relevant toxicological endpoints. 
 
2.2.3 Study design for the retrospective part  
Not applicable. 
 
2.2.4 Statistical analysis used in both part of the study 
The ESAC believes that whist the data management systems for both studies were 
robust, elements of the statistical analysis were not best practice. 
 
EIVS 
Almost complete datasets are available for both RhT test methods, but ESAC has some 
concerns about some of the statistical methods applied - see 2.3.3 below. 
 
The Cosmetics Europe Report 
The ESAC believes that all of the reference and new data relied upon are of sufficient 
quality.  
However, the statistical method by which the formazan measurements by OD-
photometry and HPLC/UPLC were correlated in the study report is not ideally suited to 
situations where the true value of the variable of interest in unknown, and in producing 
this Opinion the ESAC has taken account of an alternative approach developed for use in 
these situations (Bland and Altman, 1986).  
 
2.3 Study results and conclusions 
 
2.3.1 Standardised use   
EIVS 
The ESAC considers that the SOPs used in the EIVS validation study are sufficiently 
detailed and complete, with SOP V 8.0 being considered the definitive protocol for 
EpiOcular™ EIT. 
 
The Cosmetics Europe Report 
The ESAC considers the qualification process and parameters described for suitably 
qualified HPLC/UPLC to be appropriate and sufficiently clear. 
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2.3.2 Within- and between laboratory reproducibility  
Within-Laboratory Reproducibility (WLR) 
EIVS 
Both RhT test methods proved to be highly reproducible within laboratories, satisfying 
the acceptance WLR criteria established by the VMG. 
 
EpiOcular™ EIT  
The possible short-comings of the VMG WLR calculations are described elsewhere in this 
Opinion. The ESAC WG, having re-analysed the data set on the basis of the number of 
chemicals tested estimated the 95% Confidence Interval (95%-CI) for the WLR using the 
60% cut off to be 89.0% to 94.4%, satisfying the VMG acceptance criteria (WLR ≥ 85%). 
The WLR of the EpiOcular™ EIT optimised for solid chemicals protocol (SOP V8.0) at the 
one laboratory that conducted the supplementary testing satisfied the VMG acceptance 
criteria. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
During the Phase 1 (qualification) reproducibility was addressed with both intra- and 
inter-day evaluations of the formazan calibration reproducibility calculated by regression 
analysis. Whilst the ESAC accepts that variations on this method of assessing agreement 
between two test methods are commonly used, the use of correlation for this purpose 
can be misleading and make it difficult to recognise differences, and the significance of 
the differences, between the findings with different measurement systems when the true 
value of the variable of interest is unknown. The ESAC takes account of an alternative 
approach (Bland and Altman, 1986), developed for use in these situations, which also 
confirms the limits of agreement are good. 
Within laboratory reproducibility (WLR) of formazan measurement by HPLC/UPLC was 
evaluated in one laboratory: the results obtained were 100% concordant.  
 
Between-Laboratory Reproducibility (BLR) 
EIVS 
The ESAC notes that all of the BLR values reported in the VSR are significantly above the 
acceptance criteria set by the VMG (BLR ≥ 80%), but that there was no BLR study 
conducted using the EpiOcular™ EIT optimised protocol for solids (SOP V 8.0).  
 
The Cosmetics Europe Task Force Eye Irritation Report 
There was 100% concordance between OD-photometry and HPLC/UPLC formazan 
endpoint measurements for non-interfering chemicals. 
 
2.3.3 Predictive Capacity 
EIVS 
The ESAC believes that the VMG’s determination of confidence limits for the predictive 
capacity based on the number of test runs, rather than the number of chemicals tested, 
produces confidence limits which may be inappropriately narrow, and has taken account 
revised calculations based on the number of chemicals tested.  
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Furthermore, the ESAC considers that accuracy figures should reflect the way decisions 
will be made in practice. Specifically, as chemical classification will be based upon one 
qualifying test run, the study results should have been evaluated to produce an accuracy 
range determined by the best- and worst-cases based on data from single runs rather 
than aggregating data from different test runs with the same chemical. Additional 
analysis was undertaken along these lines. 
 
SkinEthic™ HCE 
The SkinEthic™ HCE, SE and LE protocols, failed to meet the 'definitely acceptable' 
criteria for sensitivity and overall accuracy defined by the VMG (specificity ≥ 60%; 
sensitivity ≥ 90%, overall accuracy ≥ 75%). 
The SkinEthic™ HCE sensitivity, as judged by the VMG criteria (specificity < 50%; 
sensitivity < 80%, overall accuracy < 65%), was 'definitely unacceptable' 2. 
 
EpiOcular™ EIT 
ESAC believes that with SOP V 8.0 and a 60% cut off all of the VMG acceptance criteria 
can be deemed to have been met. 
When used for liquid chemicals, the original EpiOcular™ EIT SOP V6.0 protocol the VSR 
reported results satisfying all of the VMG predictive capacity acceptance criteria. A 60% 
cut-off resulted in a better sensitivity.  For solid chemicals the results with protocol 
version (V6.0) did not satisfy all of the VMG acceptance criteria: six chemicals were 
under-predicted, one of which (misclassified by two of the laboratories) is classified in 
vivo as Category 1. 
When the solid chemicals were tested in one laboratory by the protocol optimised for 
solid chemicals (SOP V 8.0) and a 60% cut-off all of the VMT definitely acceptable values 
were achieved. 
The ESAC notes that with respect to accuracy using the best-case/worse-case calculation 
model even the worst-case values satisfy VMG criteria for sensitivity and accuracy, and 
that the worst-case specificity is very close to the VMG acceptance criterion. As the ESAC 
considers that the true predictive capacity falls somewhere between the best- and worst-
case calculations based on all  test runs, the VMG predictive capacity criteria are deemed 
to have been met with the 60% cut-off value. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Where comparisons can be made between HPLC/UPLC data and in vivo classification 
data, the HPLC/UPLC data did not under-estimate the in vivo classification. In case of 
EpiOcular™ EIT data, for test substances that do not exhibit colour interference or direct 
MTT reduction, the tissue viability values obtained are almost identical whether using 
absorbance (OD-photometry) or HPLC/UPLC, with the OD-photometry values being 
consistently, marginally above the values obtained with the HPLC/UPLC test method. 
 
 
 
                                                          
2
 The VMG defined a three tier system for judging the acceptability of performance of the assays by using a three category 
system – “definitely acceptable” and “definitely unacceptable”, with the values between these figures being borderline 
acceptable. The same approach had been chosen by EURL ECVAM for validating the skin corrosion assays (Fentem et al., 
1998). 
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2.3.4 Applicability and possible limitations  
EIVS 
The EpiOcular™ EIT and SkinEthic™ HCE test methods were not developed, designed, or 
evaluated to differentiate between UN GHS / EU CLP Category 1 (serious eye damage) 
and Category 2 (eye irritation) classifications. There is limited information available on 
the performance of the test methods with chemical mixtures. 
 
EpiOcular™ EIT 
The ESAC believes that the available evidence on the relevance and reliability of the 
EpiOcular™ EIT supports its consideration for use within an integrated, tiered approach 
using strategic combinations of alternative test methods to replace the Draize eye test, 
either as the initial step in a Bottom-Up Approach or a second or subsequent step in a 
Top-Down Approach, to discriminate chemicals (substances and chemical mixtures) not 
requiring classification for serious eye damage/eye irritancy (No Category) from 
chemicals requiring classification and labelling (Category 1 and Category 2) according to 
the UN GHS Classification and Labelling of Chemicals (UN GHS) and as implemented by 
the EU CLP regulation (EU CLP). 
With respect to the chemicals that were misclassified when the EpiOcular™ EIT findings 
were judged against the Draize eye test reference data, the ESAC has identified no 
specific additional limitations or exclusions.  
 
SkinEthic™ HCE 
The ESAC believes that the reported predictive capacity of the SkinEthic™ HCE test 
method does not justify it being considered for regulatory use. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC believes that the evidence presented suggests that for chemicals compatible 
with the three RhT methods used within this study comparable classifications are 
obtained using both OD-photometry and HPLC/UPLC endpoint detection systems; that 
with these RhT test methods HPLC/UPLC endpoint detection measurement can be used in 
the case of strongly coloured chemicals which are incompatible with formazan 
measurement by OD-photometry; and that there are plausible and reasoned arguments 
for why this endpoint measurement system might be applicable to other RhT test 
methods relying on measurement of the same endpoint. 
 
2.3.5 Identified gaps between study design and study conclusions 
EIVS 
On the basis of the EIVS data the VMG concluded that the use of 2 tissue replicates in 
similar or modified RhT/MTT-based test method aiming at identifying chemicals not 
requiring classification for serious eye damage/eye irritation is statistically and 
scientifically justified.  However, the ESAC does not accept that this can be generalised to 
all RhT test methods on the basis of the available evidence. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Nil of note. 
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2.4 Potential regulatory use of the test method 
 
EIVS 
EpiOcular™ EIT 
The ESAC believes that the available evidence on the relevance and reliability of the 
EpiOcular™ Eye Irritation Test (EIT) supports its consideration for use within an 
integrated, tiered approach using strategic combinations of alternative test methods to 
replace the Draize eye test, either as the initial step in a Bottom-Up Approach or a 
second or subsequent step in a Top-Down Approach, to discriminate chemicals 
(substances and chemical mixtures) not requiring classification for serious eye 
damage/eye irritancy (No Category) from chemicals requiring classification and labelling 
(Category 1 and Category 2) according to the UN GHS Classification and Labelling of 
Chemicals (UN GHS) and as implemented by the EU CLP regulation (EU CLP). 
 
SkinEthic™ HCE 
The ESAC believes that the predictive capacity of the SkinEthic™ HCE test method 
reported in the EIVS VSR does not currently justify it being considered for regulatory use. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC judges that the Cosmetics Europe Report provides evidence, and sets out 
plausible and reasoned arguments, for in the case of regulatory testing this endpoint 
measurement system being considered for RhT test methods relying on the quantification 
of formazan. 
 
2.5 Recommendations 
 
EIVS 
SkinEthic™ HCE 
ESAC agrees with the VMG and the test method developer's decision to not advance the 
SkinEthic™ HCE test method in this validation on the basis of insufficient predictive 
capacity (in particular specificity) for considering the test method, at present, for a 
bottom up test strategy within a tiered approach for inclusion into an Integrated Testing 
Strategy (ITS) / Integrated Approach to Testing and Assessment (IATA). ESAC 
understands that the test method developer is currently optimising the test method 
protocol before re-entering the validation process. ESAC supports the decision for 
optimisation, including considering developing and evaluating different protocols for liquid 
chemicals and solid chemicals. 
 
EpiOcular™ EIT  
1. The ESAC recommends that the EpiOcular™ EIT test method SOP V 8.0 using the 
60% cut off be considered for use within an integrated, tiered approach using 
strategic combinations of alternative test methods to replace the Draize eye test, 
either as the initial step in a Bottom-Up Approach or a second or subsequent step in a 
Top-Down Approach, to discriminate chemicals (substances and chemical mixtures) 
not requiring classification for serious eye damage/eye irritancy (No Category) from 
chemicals requiring classification and labelling (Category 1 and Category 2) according 
Page | 12 
to the UN GHS Classification and Labelling of Chemicals (UN GHS) and as 
implemented by the EU CLP regulation (EU CLP). 
2. Based on the data generated during validation, the ESAC recommends that 
EpiOcular™ EIT be considered applicable to a wide range of liquid and solid chemicals. 
However, confidence in the ability of the EpiOcular™ EIT test method to detect solid 
irritants (using SOP version 8.0) would be increased if more chemicals were tested 
under blind conditions by the other two laboratories. 
3. The ESAC recommends that the SOP should be amended to better define the protocol 
to be used for test chemicals with an unclear physical state, specifically that all 
viscous, waxy and gel-like chemicals are placed in a water bath for 15 minutes at 
37°C before deciding if they should be tested with the liquids or the solids protocol; 
and that the test chemical should be applied directly from the water bath and should 
not be brought to room temperature before testing. 
 
General 
4. The ESAC recommends that a range of labelled chemical mixtures be identified for 
use as test substances within future eye irritation validation studies. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
5. The ESAC recommends that the use of suitably qualified HPLC/UPLC systems for the 
detection and quantification of formazan be proposed for inclusion in relevant 
regulatory guidelines to extend the applicability domain of RhT test methods to 
include coloured chemicals interfering with formazan measurement by OD-
photometry. However, the HPLC/UPLC provided marginally but systematically lower 
values for formazan levels than OD photometry. This may impact on some of the 
prediction models which currently rely on formazan quantification by OD-photometry  
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1. TYPE OF REQUEST 
Request Type Identify request ("YES") 
R1 ESAC Peer Review  
of a Prevalidation Study or Validation Study 
YES 
If R1)applies please specify further: 
►Prevalidation Study NO 
►Prospective Validation Study YES 
 
In December 2008, EURL ECVAM, together with Cosmetics 
Europe, initiated a prospective validation study (=Eye 
Irritation Validation Study, EIVS) on two in vitro test 
methods for acute eye irritation caused by chemicals 
(substances and chemical mixtures). Both test methods, the 
EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ 
Human Reconstructed Corneal Epithelium (HCE) are based 
on Reconstructed human Tissue (RhT). The goal of the study 
was to assess their relevance (predictive capacity) and 
reliability (transferability; within and between laboratory 
reproducibility). Both test methods did not meet all of the 
acceptance criteria set by the VMG. For SkinEthic™ HCE 
none of the protocols under validation (SE and LE) nor 
their combination in a test strategy with the Eye irritation 
Peptide Reactivity Assay (EPRA) was able to meet all of the 
acceptance criteria. For the EpiOcular™ EIT some difficulties 
were encountered with regard to meeting the acceptance 
criteria when using the protocol for solid chemicals, while 
the liquids protocol was able to meet all of these criteria. 
As there was scope for improvement, the VMG allowed 
optimization within the EIVS. The study on the optimised 
EpiOcular™ EIT solids protocol has been completed in 2013. 
 
In contrast, the optimisation work on the SkinEthic™ HCE 
protocol will take longer and will thus be carried out outside 
the EIVS. It is foreseen however that this study concerning 
the SkinEthic™ HCE will be forwarded to ESAC review at a 
later stage.  
►Retrospective Validation Study NO 
►Validation Study based on Performance 
Standards 
NO 
R2 Scientific Advice on a test method submitted to 
EURL ECVAM for validation  
(e.g. the test method's biological relevance etc.) 
NO 
R3 Other Scientific Advice  
(e.g. on test methods, their use; on technical issues such as cell 
culturing, stem cells, definition of performance standards etc.) 
NO 
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2. TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE 
ESAC IS REQUESTED 
Prospective validation study on two in vitro test methods using Reconstructed human Tissue (RhT) 
for the detection of acute eye irritation caused by chemicals: EpiOcular™ Eye Irritation Test (EIT) 
and SkinEthic™ Human Reconstructed Corneal Epithelium (HCE) 
 
 
3. BRIEF DESCRIPTION OF THE STUDY OR PROJECT 
1) Background of Serious Eye Damage/Eye Irritation and current testing strategies 
 
Serious Eye Damage/Eye irritation 
Serious Eye Damage/Eye irritation is an adverse effect that produces changes in the eye following 
exposure of the anterior surface of the eye to a test substance. According to UN GHS (UN, 2013), 
serious eye damage is the production of tissue damage in the eye, or serious physical decay of vision, 
following application of a test substance to the anterior surface of the eye, which is not fully 
reversible within 21 days of application. Eye irritation is the production of changes in the eye 
following the application of a test substance to the anterior surface of the eye, which are fully 
reversible within 21 days of application. Currently, serious eye damage/eye irritation is determined 
through in vivo and in vitro assays. The traditional Draize eye test uses rabbits as model for ocular 
irritation (OECD Test Guideline 405; OECD, 2012). Validated in vitro alternative methods are available 
based on organotypic assays (Bovine Corneal Opacity and Permeability test, Isolated Chicken Eye 
test), adopted in 2009 and revised in 2013 (TG 437, TG 438) and on cell-based methods (Fluorescein 
Leakage, Cytosensor Microphysiometer and Short Time Exposure), adopted in 2012 (TG 460) or 
currently undergoing regulatory acceptance (draft TGs on the Cytosensor Microphysiometer and the 
Short Time Exposure assays). 
 
Testing strategies composed of in vitro methods 
It is generally accepted that, in the foreseeable future, no single in vitro test method will be able to 
replace the in vivo Draize eye test in its capacity to predict ocular irritation for the full range of 
irritancy and for a broad spectrum of chemical classes (wide applicability domain). However, strategic 
combinations of several alternative test methods within (tiered) testing strategies may be able to 
replace the Draize eye test. A possible conceptual framework for such (tiered) testing strategies was 
developed within an EURL ECVAM workshop (Scott et al., 2010). The framework is based on 
alternative serious eye damage/eye irritation methods that vary in their capacity to detect either 
chemicals inducing serious eye damage (GHS 'Category 1') or chemicals not requiring classification 
for serious eye damage/eye irritation ("non-irritants") (GHS 'No Category'). According to this 
framework, the entire range of irritancy may be resolved by arranging tests in a tiered (sequential) 
strategy that may be operated bidirectional, i.e. from either end: to detect first eye damage and 
resolve absence of irritancy ("Top-Down Approach") or to proceed inversely, starting with the 
identification of non-irritants first ("Bottom-Up Approach"). Ocular irritant chemicals (GHS cat. 2) will 
be resolved in a last tier in both approaches. When considering the tiered in vitro strategy described 
above, it should be kept in mind that ocular toxicity is already and will be evaluated in the future on 
the basis of integrated approaches making use also of inter alia, physicochemical properties, (Q)SARs 
and empirical testing tools. The tiered testing strategy suggested by Scott et al. (2010) should be seen 
as an empirical module within such an integrated approach. For example, the ECHA Guidance on 
information requirements and Chemical Safety Assessment provides guidance on the integration of 
testing and non-testing data for the assessment of eye damage/irritation and this guidance is 
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regularly updated (last version: ECHA, 2014). 
 
2) Background of the EpiOcular™ Test method 
The EpiOcular™ tissue construct is a non-keratinized multi-layered and stratified (but not cornified) 
epithelium prepared from normal human-derived epidermal keratinocytes. It is intended to model 
properties of the corneal epithelium. The reconstructed tissue is prepared in inserts with a porous 
membrane (MTI-003) through which the nutrients pass to the cells. A cell suspension is seeded into 
the MTI-003 membrane in specialized medium. After a period of initial cell proliferation, the medium 
is removed from the top of the tissue so that the epithelial surface is in direct contact with the air. 
This allows the test chemical to be directly applied to the epithelial surface, mimicking exposure of 
the corneal epithelium in vivo / in situ. This topical exposure is essential for modelling the same kind 
of progressive injury expected in vivo, allowing moreover the application of both solid and liquid 
chemicals. In the EpiOcular™ EIT, liquids and solids are applied using different exposure and post-
exposure incubation times (i.e., liquids: 30 min exposure followed by 120 min post-treatment 
incubation, and solids: 90 min exposure followed by 18 hours post-treatment incubation- the 
optimized protocol for solids requires now an exposure time of 6 hrs. Post-treatment time remains 
unchanged.).  
 
2) Background of the SkinEthic™ HCE Test method 
To construct SkinEthic™ HCE tissues, immortalized human corneal epithelial cells are cultured in a 
chemically defined medium and seeded on a polycarbonate membrane at the air–liquid interface. 
The tissue construct obtained is a multi-layered epithelium resembling the in vivo corneal epithelium. 
As in vivo, columnar basal cells are present, including Wing cells. The model is characterized by the 
presence of ultra-structural features such as intermediate filaments, mature hemi-desmosomes and 
desmosomes that characterize the relevant epithelium in situ. Specific cytokeratins 64kD (K.3) have 
also been described (Nguyen D.H. et al., 2003). 
 
The SkinEthic™ HCE test method, when submitted to EURL EVCAM, comprised a small test strategy 
based on three separate assays:  
(1) the "Eye irritation Peptide Reactivity Assay" (EPRA) followed by  
(2) either the SkinEthic™ HCE Short-time Exposure protocol (HCE SE) or  
(3) the SkinEthic™ Long-time Exposure protocol (HCE LE),  
depending on the reactivity measured in the initial EPRA (method (1) of the strategy).  
The HCE SE uses 10 min exposure without post-treatment incubation, while the HCE LE is based on 1 
h exposure followed by 16 h post-treatment incubation. Following treatment with a test chemical as 
described above (using EpiOcular™ EIT, SkinEthic™ HCE SE or HCE LE), the relative tissue viability is 
determined against the negative control-treated constructs by the reduction of the vital dye MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-111 diphenyltetrazolium bromide). Tissues treated with chemicals 
inducing eye irritation or serious eye damage (UN GHS/EU CLP Category 2 or Category 1, 
respectively) are expected to show a decrease in viability below a certain threshold in respect to the 
negative control. 
 
 
Study objectives and design 
 
In December 2008, EURL ECVAM, together with Cosmetics Europe, initiated a prospective validation 
study on two in vitro test methods, using Reconstructed human Tissue (RhT) test systems 
(EpiOcular™ Eye Irritation Test (EIT) and SkinEthic™ Human Reconstructed Corneal Epithelium (HCE)) 
for the detection of acute eye irritation caused by chemicals (substances and chemical mixtures). 
 
The goal of the present study was to assess the relevance (predictive capacity) and reliability 
(transferability and reproducibility within and between laboratories) of the EpiOcular™ EIT and 
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SkinEthic™ HCE test methods. If found valid, both test methods may be incorporated into a tiered 
test strategy (so-called Bottom-Up/Top-Down test strategy, as defined in an EURL ECVAM workshop 
held in 2005, Scott et al., 2010) as e.g. the initial step in a Bottom-Up approach or the second step 
in a Top-Down Approach. The test methods are not intended to differentiate between GHS Category 
1 (irreversible effects) and 2A-B (reversible effects). This differentiation would be left to another tier 
of the Bottom-up/Top-down testing strategy (Scott et al., 2010). 
The ultimate purpose of a tiered testing strategy comprising these and other in vitro assays (e.g. 
BCOP, ICE, FL, CM) is to replace the traditional in vivo Draize eye irritation test [Method B.5 of EC 
Regulation 440/2008 (EC, 2008a) or OECD TG 405 (OECD, 2012)] as an empirical testing tool to 
generate information on the eye irritation potential of chemicals. 
 
More specifically, EIVS aimed to assess the validity of the SkinEthic™ HCE SE, LE and test strategy and 
of the EpiOcular™ EIT as stand-alone (independent) test methods to reliably discriminate chemicals 
not classified for serious eye damage/eye irritation (“non-irritants”) from chemicals requiring 
classification (in the framework of a Bottom-Up/Top-Down test strategy, Scott L. et al., 2010), 
defined according to the United Nations Globally Harmonized System (GHS) of Classification and 
Labelling of Chemicals (UN GHS: No Category versus Category 1/Category 2A/Category 2B; UN, 2013) 
and as implemented in the European Commission Regulation (EC) No 1272/2008 on classification, 
labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC 
and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (EU CLP: No Category versus Category 
1/Category 2). 
 
Relevance and reliability were assessed by testing, in a ring trial, a statistically significant number of 
coded test chemicals (substances and mixtures), supported by complete and quality assured in vivo 
Draize eye irritation data for comparative evaluation of results. 
 
 
Study results 
 
The study results were analyzed by an independent statistician (Carina Rubingh, Nederlandse 
Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek (TNO, i.e. Dutch Organization for 
Applied Scientific Research).  
 
SkinEthic™ HCE 
Two different protocols of SkinEthic™ HCE, a short-time exposure protocol (SE), and a long-time 
exposure protocol (LE) where fully assessed in EIVS. A test strategy combining SE and LE with the Eye 
irritation Peptide Reactivity Assay (EPRA) was also assessed for its predictive capacity. 
 
Reproducibility: Based on the results for the fraction of complete test sequences (about 100% in 
total), the SkinEthic™ HCE SE and LE protocols are highly reproducible: within-laboratory 
reproducibility was about 94% (SE) and about 96% (LE), while between laboratory reproducibility was 
about 92% for both SE and LE. The acceptance criteria for these characteristics were fulfilled and 
were above the acceptance criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 80%). 
 
Predictive capacity: The values are as follows: 
 
a) SE: 89% specificity, 43% sensitivity and 66% overall accuracy. 
 
b) LE: 66% specificity, 72% sensitivity and 69% overall accuracy. 
 
c) Test Strategy with EPRA (Reactive  SE; Non-Reactive  LE): 77% specificity, 55% sensitivity and 
66% overall accuracy. 
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The SkinEthic™ HCE was not able to meet the 'definitely acceptable' criteria for sensitivity and overall 
accuracy defined by the VMG (specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy ≥ 75%) in any of 
the options above, and the sensitivity was even considered to be 'definitely unacceptable' (specificity 
< 50%; sensitivity < 80%, overall accuracy < 65%). 
 
EpiOcular™ EIT 
The predictive capacity of the EpiOcular™ EIT method was analysed on the basis of two viability 
thresholds: 50% and 60%. Since concordance of predictions was used as measure for reproducibility, 
for both WLR and BLR two sets of values are available, one calculated on the basis of a 50% viability 
cut-off, one on the basis of a 60% viability cut-off. 
 
Reproducibility: Based on the results for the fraction of complete test sequences (about 100% in 
total), the EpiOcular™ EIT test method is highly reproducible: within-laboratory reproducibility was 
about 94% (50% cut off) and about 95% (60% cut off), while between laboratory reproducibility was 
about 91% (50% cut off) and 93% (60% cut off). The acceptance criteria for these characteristics were 
fulfilled and were above the acceptance criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 80%). 
 
Predictive capacity: Since the purpose of the test methods will be the identification of chemicals not 
classified for serious eye damage/eye irritation (UN GHS/EU CLP No Category) as an initial step of a 
Bottom-Up test strategy (Scott L. et al. 2010) and not the discrimination between UN GHS/EU CLP 
Categories 1 and 2, the VMG considered that it is acceptable to have a lower specificity than 
sensitivity (higher false positives than false negatives). Nevertheless, specificity should not be too low 
in order to allow for the correct identification of the majority of the chemicals not classified as 
irritant to the eye. The values are as follows: 
 
a) 50% cell viability cut-off:  
75% specificity, 81% sensitivity and 78% overall accuracy when considering all chemicals, 
irrespective of physical state (solid/liquid) for which different protocols are available. When 
considering liquids only, the values area slightly higher, when considering solids only they are slightly 
lower, indicating that the test methods performs better with chemicals in liquid state. 
 
b) 60% cell viability cut-off:  
71% specificity, 88% sensitivity and 79% overall accuracy when considering all chemicals irrespective 
of physical state (solid/liquid). Similarly than for the 50% cut-off, predictions for liquid chemicals 
showed higher accuracy than for solid chemicals. Moreover, using a 60% cut-off, specificity and 
sensitivity for solids were basically equal (about 75% and 77%). 
 
The liquids protocol met all of the 'definitely acceptable' criteria for specificity, sensitivity and overall 
accuracy defined by the VMG (specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy ≥ 75%) while the 
sensitivity of the solids protocol was 'definitely unacceptable' according to the acceptance criteria 
defined by the VMG (sensitivity < 80%). Therefore, the EpiOcular™ EIT solids protocol underwent 
optimization by the method developer and further validation within EIVS.  
 
The overall predictive capacity of EpiOcular™ EIT obtained in EIVS (including the main study and the 
post-optimization validation study) is summarised in table 1. 
 
 
Table 1: Predictive capacity values of the EpiOcular™ EIT for liquids and solids and on the basis of two 
viability cut-offs for the prediction model: 50% and 60% and considering the data obtained during the 
main study (A) and those compiling data of the main study and those of post-optimization validation. 
Data for liquids (1) and solids (2) were generated on the basis of different protocols. Results obtained 
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with the solids protocol (2) did not meet the targets set by the VMG and the protocol underwent 
optimization within the scope of the EIVS. Subsequently, the optimized protocol was assessed through 
a validation set of chemicals (4). The combined performance of EpiOcular EIT on the basis of liquids 
and solids are presented before optimization of the solids protocol (3) and after optimization (5). 
 
 50 % cut-off 60% cut-off 
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity 
(A) Results obtained during main study (before optimization of solids protocol) 
(1) Liquids 
82.5% 96.2% 69.8% 81.9% 98.3% 
66.7% 
 
(2) Solids  
73.0% 66.7% 79.7% 75.9% 76.9% 
74.8% 
 
(3) Liquids 
and solids  
 
77.9% 81.4% 74.5% 79.0% 87.6% 70.5% 
(B) Results obtained through post-optimisation testing (solids) and during main study 
(liquids) 
(4) Solids 
 
76.8% 88.2% 64.3% 78.0% 93.5% 60.7% 
(5) Liquids 
and solids  
 
79.4% 91.8% 66.5% 79.7% 95.7% 63.0% 
 
All of the 'definitely acceptable' criteria for specificity, sensitivity and overall accuracy defined by the 
VMG (specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy ≥ 75%) were met by the liquids protocol 
and the optimized solids protocol using a 60% cut-off in the prediction model. 
 
 
VMG decisions and conclusions 
The experimental part of the EIVS was completed in March 2012 and the data generated with both 
test methods were analysed subsequently. For EpiOcular™ EIT, the protocol for liquids met all the 
acceptance criteria set by the VMG, whereas not all acceptance criteria were met by the protocol for 
solids, nor for any of the protocols or test strategy of SkinEthic™ HCE. Analysis of the EpiOcular™ EIT 
validation study data for solids identified that there was scope for improvement. Thus, the VMG 
allowed the optimization of the EpiOcular™ EIT solids protocol. The test method developer (MATTEK) 
successfully optimized the solids protocol between April and October 2012 and results were made 
available to the VMG. As a result, the optimized solids protocol was allowed to enter validation 
within the framework of the current study. The added experimental work relating to the validation 
study took place in the lead laboratory (Beiersdorf) between March and June 2013. The finalized data 
analysis was performed by the EURL ECVAM statistician also preparing the statistical report for the 
optimized EpiOcular™ protocol for solids. The report has been finalised and has been made available 
to ESAC (ESAC CIRCA) last week of February 2014. On the basis of the study results, the VMG made 
the following conclusions: 
 
Conclusions and Recommendations of the VMG 
 
- The VMG considers the EpiOcular™ EIT original liquids protocol and the optimised solids 
protocol as scientifically valid (reproducible and accurate) to identify chemicals not requiring 
classification for serious eye damage/eye irritation under UN GHS. 
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- The VMG recommends that the 60% cut-off (as submitted by the method developer) is used 
rather than the 50% cut-off due to higher sensitivity and accuracy, and lower number of total 
mispredictions. 
- A wide range of chemical types, chemical classes, molecular weights, LogP, chemical 
structures, etc. were tested and no clear limitations regarding applicability could be 
identified. The VMG therefore recommends that EpiOcular™ EIT is considered applicable to 
the testing of all types of chemicals, until proven contrary. 
-  The VMG does not recommend the use of the SE or LE protocols of SkinEthic™ HCE to 
identify chemicals not requiring classification for serious eye damage/eye irritation under UN 
GHS. 
- The VMG also does not recommend the use of EPRA to orient chemicals to the SE (reactive) 
or LE (non-reactive) protocols as proposed in the SkinEthic™ HCE test strategy. 
- The VMG recommends the optimisation of the SkinEthic™ HCE test method considering 
different protocols for liquid chemicals and solid chemicals (as in EpiOcular™ EIT). 
- The VMG recommends the use of positive control(s) and associated acceptance criteria that 
are strict enough to allow easy detection of inappropriate conduct of the assay (e.g., in the 
optimised SkinEthic™ HCE). 
- The VMG concludes that the use of 2 tissue replicates in similar or modified RhT/MTT-based 
test method aiming at identifying chemicals not requiring classification for serious eye 
damage/eye irritation is statistically and scientifically justified. 
-  The VMG considers the current endpoint detection system using standard photometry as 
appropriate to assess direct MTT-reducers and coloured chemicals, when tissue viability falls 
within the linear range of the spectrophotometer (e.g., < 140%), or when the uncorrected 
viabilities already identify the test chemical as requiring classification. 
- For coloured chemicals interfering too strongly with the MTT-reduction assay an alternative 
endpoint detection system should be used (e.g., HPLC/UPLC-photometry). 
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4. OBJECTIVES, QUESTIONS, TIMELINES 
4.1  OBJECTIVE 
Objective 
Why does EURL 
ECVAM require 
advice on the 
current issue? 
The opinion of ESAC on the EIVS should support EURL ECVAM with respect to the 
development of an EURL ECVAM Recommendation on the EpiOcular™ EIT test 
method for serious eye damage/eye irritation testing. The EURL ECVAM 
Recommendation will address (1) the scientific basis of the assay in relation to the 
adverse effect (serious eye damage/eye irritation), (2) the reproducibility and 
transferability of the assay as assessed during the study, (3) the predictive capacity 
of the assay as assessed during the study and its usefulness in an in vitro test 
strategy as proposed by Scott et al. (2010), either as an initial step in the Bottom-
Up approach or the second step in the Top-Down Approach of this strategy, (4) its 
applicability (considering the two protocols available for solids and liquids) and its 
known limitations. N.B. the proposed in vitro test strategy should be understood 
as a testing tool potentially replacing the current in vivo test, but being used within 
a more integrated approach for ocular toxicity assessment, combining non-testing 
with testing data (e.g. REACH guidance, ECHA 2014). 
ESAC's advice should enable EURL ECVAM to conclude, within its EURL ECVAM 
Recommendation, on the potential adequacy of the EpiOcular™ EIT test method 
for routine testing of serious eye damage/eye irritation for regulatory purposes 
(e.g. EU test method, OECD Test Guideline), outlining the possible complementary 
information that will be required, in addition to EpiOcular™ EIT data, to make 
decisions on the presence/absence of ocular toxicity. 
The advice of ESAC should support EURL ECVAM with respect to an analysis of 
possible remaining data gaps that need to be addressed in view determining 
EpiOcular™ EIT's potential use and usefulness within the proposed test strategy 
supporting serious eye damage/eye irritation testing of chemicals (substances and 
mixtures). 
Moreover, the ESAC scientific peer review of the EIVS should provide scientific 
advice on the plausibility and adequacy of the decisions of the Validation 
Management Group that concluded on the necessity of conducting optimisation 
work of both test methods assessed in the EIVS (EpiOcular™ EIT and SkinEthic™ 
HCE).  
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4.2  QUESTION(S) TO BE ADDRESSED 
Questions 
What are the 
questions and 
issues that should 
be addressed in 
view of achieving 
the objective of 
the advice? 
1) DESIGN & CONDUCT OF STUDY: The ESAC is requested to review whether the 
EURL ECVAM Eye Irritation Validation Study (EIVS) was conducted appropriately in 
view of the objective of the study. The study objective concerned both EpiOcular™ 
EIT and SkinEthic™ HCE. The study objective was to assess: 
(1) reproducibility of the test method within one laboratory (WLR) 
(2) transferability of the test method to other laboratories  
(3) reproducibility of the test method between laboratories (BLR) 
(4) predictive capacity of the test method for distinguishing chemicals not 
requiring classification from chemicals requiring classification as Category 1 
(serious eye damage) or Category 2 (eye irritation).  
(5) the applicability domain and possible limitations of the test method. The 
selection of the test chemicals and analyses of possible reasons for 
misclassifications in view of determining patterns reg. chemical class or 
physicochemical property should be carefully reviewed. 
 
When reviewing the design and conduct of the study, the following issues should 
be addressed in particular: 
(a) Clarity of the test definition (module 1)  
(b) Clarity of the definition of the study objective and study management 
(c) Appropriateness of the study design & execution in view of the study 
objectives, inter alia: 
o Is the number of tested chemicals sufficient for the purposes of 
the study? 
o Are the reference data used for assessing in particular the 
predictive capacity appropriate and of good quality? 
o Was the identification of validation chemicals conducted in an 
appropriate manner (i.e. presence or absence of selection criteria, 
justification etc.)? 
o Is the adverse effect range of the selected chemicals appropriate 
for the purpose of the study 
o In case of gaps (chemical class etc.) – are these justified? 
o Is the number of laboratories sufficient? 
(d) Appropriateness of the study execution (e.g. were there pre-defined test 
acceptance criteria, were these respected? How were exceptions / 
deviations handled? Were provisions specified for retesting? Was the 
number of repetitions sufficient? etc.) 
(e) Appropriateness of the statistical analysis used for analysing WLR, 
transferability, BLR and predictive capacity. 
(f) Was the decision and conclusion that there was a need to optimise the 
SkinEthic™ HCE test method and the solids protocol of the EpiOcular™ EIT 
test method justified by the data produced in the context of the study? 
(g) Is the conclusion of the VMG concerning the use of only two instead of 
three tissue replicates per test chemical and controls scientifically justified 
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by the data? 
2) CONCLUSIONS OF STUDY: The ESAC is requested to assess whether the 
conclusions, as presented in the material made available to ESAC, are 
substantiated by the information generated in the study and are plausible with 
respect to existing information and current views (e.g. literature). 
In particular:  
(a) Are the conclusions on reproducibility (WLR and BLR) as well as 
transferability justified and plausible? 
(b) Are the conclusions on predictive capacity justified and plausible with 
respect to existing information and with respect to the intended use of the 
test method within an in vitro test strategy (bottom-up, top-down) 
(c) Are there possible gaps between study design and study conclusions 
which remain to be addressed in view of the suggested conclusions / use 
(see also point 3)? 
(d)  Do the data generated with validation set of chemicals together with 
possible available existing data provide sufficient information on the 
applicability and possible limitations of the test method, in particular in 
view of its potential use within an in vitro test strategy (Scott et al, 2010)? 
(e) Based on the Cosmetics Europe study, performed in the context of the 
EURL ECVAM/Cosmetics Europe eye irritation validation study, the 
usefulness of HPLC/UPLC-photometry has been analysed as an alternative 
endpoint detection system in particular for highly coloured chemicals 
interfering with the conventional endpoint measurement through 
standard photometry. Are the conclusions of this report (furnished 
separately from the VSR) scientifically justified, in particular when 
considering the study design including the chemicals assessed and the 
statistics used? 
 
3) SUGGESTED USE OF THE TEST METHOD: The ESAC is requested  
(a) to evaluate, on the basis of the data summarised in the validation study report, 
the intended use of the test method within the proposed test strategy (Scott et al., 
2010) and keeping in mind that this in vitro test strategy will be part of an 
integrated approach, using non-testing as well as testing information. 
(b) to make additional recommendations (as required) on the proper scientific use 
of the test method within the proposed test strategy (Scott et al., 2010) taking 
specific aspects of this method into account (e.g. applicability, technical limitations 
etc.), 
(c) to identify possible further information required (i.e. are there data gaps or 
gaps with regard to mechanistic understanding?) to be able to determine the 
potential use and usefulness of the test method within test strategies and 
integrated approaches, duly considering the need to test both substances and 
mixtures. 
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4.3  TIMELINES 
Timelines 
concerning this 
request 
When does EURL 
ECVAM require 
the advice? 
Timeline Indication 
Finalised ESAC Opinion required by: ESAC39 
Request to be presented to ESAC by 
written procedure (e.g. due to 
urgency) prior to the next ESAC 
No 
Request to be presented to ESAC at 
ESAC plenary meeting 
Either at ESAC meeting in 4Q 2013 or 
through written procedure. 
At ESAC 39 
 
 
5.  EURL ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN 
ESAC 
5.1  EURL ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIRED 
Specific 
structures 
required within 
ESAC to address 
the request 
Does the advice 
require an ESAC 
working group, an 
ESAC rapporteur 
etc.? 
Structure(s) required Required according to EURL ECVAM? 
(YES/NO) 
S1 ESAC Rapporteur NO 
S2 ESAC Working Group YES (already set-up) 
S3 Invited Experts NO 
Ad S3: If yes – list names and 
affiliations of suggested 
experts to be invited and 
specify whether these are 
member of the EEP 
 
If other than above (S1-S3):   
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5.2  DELIVERABLES AS PROPOSED BY EURL ECVAM 
Deliverables 
What deliverables 
(other than the 
ESAC opinion) are 
required for 
addressing the 
request? 
Title of deliverable other 
than ESAC opinion 
Required? (YES/NO) 
D1 ESAC Rapporteur Report 
and draft opinion  
NO 
D2 ESAC Working Group 
Report and draft opinion 
YES 
If other than above (D1-D2):  
 
 
6. LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESAC 
At the time of circulating this ESAC request (21/2/2014), the validation study report has not 
yet been finalised. The table below lists and describes the available documentation (n=40 
documents) in view of discussions on this mandate at ESAC 39 and in view of the upcoming 
ESAC WG meeting (18-20/3/2014). The documents are logically structured at the highest 
level in: 
1. GENERAL STUDY DOCUMENTS 
2. EPIOCULAR SPECIFIC DOCUMENTS 
3. SKINETHIC SPECIFIC DOCUMENTS. 
Subfolders further structure the available documents. 
Count Description of document Already 
available? 
(YES/NO) 
File name 
FOLDER: 1. GENERAL STUDY DOCUMENTS 
Subfolder 1.1 Study Management 
1 Project plan for EYE IRRITATION 
VALIDATION STUDY (EIVS) 
Describes validation project of 
the SkinEthic™ HCE SE (short 
exposure), LE (long exposure) 
and test strategy (combining 
EPRA and HCE EIT methods) as 
well as the EpiOcular™ EIT for the 
prediction of acute eye irritation 
yes EIVS_VMG_ProjectPlan_V1.pdf 
2 Guidance on EIVS conduct and 
test method performance criteria  
yes EIVS_VMG_PerformanceCriteria_V2.pdf 
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3 
Addendum to the guidance on 
the EIVS- Instructions for the 
testing of direct MTT-reducers 
and/or coloured test chemicals 
 
yes Addendum - Testing of MTT reducers and 
colorants-v3.pdf 
Subfolder 1.2 Chemicals Selection 
4 
Explanatory document regarding 
the selection of chemicals (test 
items) for the EIVS 
yes 
01-Report_EIVS chemicals selection 
[17Feb14].doc 
5 
Table of selected test chemicals, 
including properties and GHS 
classification 
yes 02-Tables_EIVS chemical selection.pdf 
6 
Figures for the chemicals 
selection report yes 03-Figures_EIVS chemicals selection.pdf 
7 
Appendix 1: summary tables of 
EIVS chemicals, sorted according 
to phys./chem. properties, GHS 
classification  
yes App 1 EIVS_chemicals_summary data.xlsx 
8 
Appendix 2: condensed 
information, i.e. graphs, and in 
vivo Draize eye test results for 
each test chemical  
yes App 2 EIVS_chemicals_in-vivo master.xlsx 
9 
Appendix 3: EIVS chemicals and 
results for OECD QSAR analysis 
yes App 3 EIVS chemicals_OECD QSAR 3.1 
analysis.xlsx 
10 
Appendix 4: EIVS chemicals with 
representation of their chemical 
structure 
yes App 4 EIVS_chemicals_molecular 
structures.pdf 
 
Subfolder 1.3 Status update EIVS study 
11 
Status Update of the 
ECVAM/Cosmetics Europe Eye 
Irritation Validation Study (as 
communicated during the 9th 
meeting of the Validation 
Management Group (VMG) held 
on 10-11 May 2012) 
yes EIVS Status Update Communication.pdf 
Subfolder 1.4 Validation Study Report 
12 
Core document regarding the 
course ,the outcome and 
conclusions of the EIVS 
yes EIVS report 
FOLDER: 2. SPECIFIC DOCUMENTS EpiOcular EIT 
Subfolder 2.1 Validation Study Report 
13 
Report on the ECVAM Quality 
assurance audit at the 
production site of MATTEK, 25-
26 May 2010 
yes 2.1 QA audit of tissue production site.pdf 
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Subfolder 2.2 Statistics on replicate number 
14 
Statistical analyses for using two 
replicates with the EpiOcular™ 
test method by a statistical 
consultant to NICEATM 
yes NICEATM Summary Statistics - EpiOcular 
Replicates_10May10(VMG).pdf 
Subfolder 2.3 Training & Transferability 
15 
Report on training and transfer 
of the test method to the three 
participating laboratories 
Beiersdorf, Harlan UK and IIVS  
yes Training EpiOcular Labs MatTek Report VF 
HK 12.12.13.pdf 
Subfolder 2.4 SOP & Data Reporting 
16 
Standard Operating Procedure 
for: Ocular Irritation Assay for 
Chemicals using EpiOcular™ EIT 
in the Eye Irritation Validation 
Study (EIVS), version 6.0 of 9 
February 2011 
Yes EpiOcular_SOP_Final 
Version_6_February_9_2011.pdf 
17 
Reporting spreadsheets for 
measurements ad results 
Yes EIVS_lab_protocol_batch_week_number.xls 
Subfolder 2.5 Statistical Report EpiOcular 
18 
Statistical Analysis and Reporting 
on the EpiOcular™ EIT in the 
EIVS, version of 10 February 2014 
yes TNO report_EpiOcular_last final final.pdf 
Subfolder 2.6 Optimisation of solids protocol 
19 
Standard Operating Procedure 
for: Ocular Irritation Assay for 
Chemicals using EpiOcular™ EIT 
in the Eye Irritation Validation 
Study (EIVS), version 7.0 as of 11 
October 2012. Version 7.0 has 
been amended to include 
extended exposure time for solid 
test substances 
Yes EpiOcular_SOP_Version_7-
solids_Oct_11_2012.pdf 
20 
Update on the optimization of 
the EpiOcular Solids protocol- 
presentation by Dr. Yulia 
Kaluzhny, Mattek. 
Yes EpiOcular-EIT-Solids-
MatTek_updated_101212-.pdf 
21 
Summary of the optimization of 
the EpiOcular Solids protocol- by 
Dr. Yulia Kaluzhny, Mattek. 
Yes Solids protocol optimisation Summary by 
Yulia  Kaluzhny.pdf 
Subfolder 2.7 Post-optimisation of validation 
Subfolder 2.7.1 SOP final for postopt validation 
22 
Standard Operating Procedure 
for: Ocular Irritation Assay for 
Chemicals using EpiOcular™ EIT 
in the Eye Irritation Validation 
Study (EIVS), final version 8.0 as 
of 5 March 2013. 
 EpiOcular_SOP_8_2013.3.5.pdf  
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Subfolder 2.7.2 Reporting Template 
23 
Reporting spreadsheets for 
measurements ad results, 
updated version 
yes EIVS_batch week.xls  
 
Subfolder 2.7.3 Statistical report 
24 Statistical Report yes EIVS_stat_report.pdf 
FOLDER: 3. SPECIFIC DOCUMENTS SkinEthic HCE 
Subfolder 3.1 QA audit of tissue production site 
25 
Report on the ECVAM Quality 
assurance audit at the 
production site of EpiSkin (Lyon 
France), 19 March 2010 
Yes ECVAM audit report EpiSkin signed.pdf 
Subfolder 3.2 Training & Transferability 
Subfolder 3.2.1 EPRA 
26 
Letter from TNO (9 February 
2010) containing statement on 
the transferability study for the 
Cysteine and Lysine Direct 
Peptide Reactivity Assays 
Yes TNO - Brief Lammers 09.02.2010.pdf 
27 
TNO-Report of the training on 
the Cysteine and Lysine Direct 
Peptide Reactivity Assays, 
performed on 3-4 June 2009 
(Procter & Gamble, Cincinnati, 
Ohio, USA). 
Yes TNO - DPRA Training Report 03.11.2009.pdf 
28 
TNO-Report of the Transferability 
Study on the Cysteine and Lysine 
Direct Peptide Reactivity Assays 
as of 3 November 2009 
Yes TNO - DPRA Transfer Report V8590_02 
03.11.2009.pdf 
29 
Final TNO-Report of the 
Transferability Study on the 
Cysteine and Lysine Direct 
Peptide Reactivity Assays as of 9 
February 2010 (signed) 
Yes TNO - DPRA Transfer Report V8590_02 
FINAL_signed.pdf 
30 
ECVAM comments on the TNO 
Transferability study on the 
Cysteine and Lysine Direct 
Peptide Reactivity Assays (16 
November 2009) 
Yes TNO - ECVAM Comments 
ARES(2009)326935.pdf 
Subfolder 3.2.2 SkinEthic HCE 
31 
Report on the training at L’Oréal 
of experimental steps with 
CARDAM representatives, 
participating in the EIVS, 19-22 
January 2010  
Yes EIVS_SkinEthic HCE_Final Training 
report_Cardam_VMG.pdf 
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32 
Report on the training at L’Oréal 
of experimental steps with 
Ceetox representatives, 
participating in the EIVS, 26-29 
January 2010 
Yes EIVS_SkinEthic HCE_Final Training 
report_Ceetox_VMG.pdf 
33 
Report on the transfer of the 
method to participating 
laboratories (CARAM & Ceetox), 
participating in the EIVS, 8 
February- -9 April 2010 
Yes EIVS_SkinEthic HCE_Final Transfer 
report.pdf 
Subfolder 3.3 SOPs (EPRA & HCE) 
34 
Standard operation procedure 
(version 3.0 of 28 June 2011) for 
Eye irritation Peptide Reactivity 
Assay (EPRA) for use in the RhT 
Test Methods Eye Irritation 
Validation Study (EIVS) 
Yes EPRA Protocol EIVS v3 28.06.11.pdf 
35 
Standard operation procedure 
for eye irritation test with the 
SkinEthic™ Human Corneal 
Epithelial Model (version 1.0 of 
18 June 2010) 
Yes EIVS_SkinEthic HCE SOP_ V1_ 
2010June18.pdf 
Subfolder 3.4 Data Reporting Templates 
36 
Reporting spreadsheets for 
measurements and results 
Yes EIVS_LABNAME_SE_BATCHNUMBER_ 
WEEKNUMBER_v1.0.xls 
37 
Summary tables for data 
submissin 
Yes Summary table for data submission v1.xls 
Subfolder 3.5 Statistical reports 
Subfolder 3.5.1 Stats replicate number on EIVS data 
38 
Analysis of Long Time Exposure 
Data regarding the impact of 
reducing the number of samples 
in a given run from three to two 
by a statistical consultant to 
NICEATM 
Yes Analysis of Long Time Exposure Data.pdf 
39 
Analysis of Short Time Exposure 
Data regarding the impact of 
reducing the number of samples 
in a given run from three to two 
by a statistical consultant to 
NICEATM 
Yes Analysis of Short Time Exposure Data.pdf 
Subfolder 3.5.2 Statistical report EIVS SkinEthic HCE 
40 
Final report from TNO on the 
statistical analysis and reporting 
on the SkinEthicTM HCE 
performance in the EIVS, final 
version of 14 February 2014 
Yes DRAFT_TNO report_SkinEthic_last final 
final.pdf 
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7. TERMS OF REFERENCE OF THE ESAC WORKING GROUP 
7.1 ESTABLISHMENT OF THE ESAC WORKING GROUP 
During its 39th meeting on 19/19 June 2013, the ESAC plenary unanimously decided to establish an 
ESAC Working Group "Eye Irritation" charged with the detailed scientific review of a study on two in 
vitro test methods for eye irritation testing based on reconstructed human tissue (EpiOcular EIT and 
SkinEthic HCE). 
 
7.2 TITLE OF THE ESAC WORKING GROUP 
Full title:  
ESAC WG charged with the review of the EpiOcular™ EIT and SkinEthic™ HCE test methods for eye 
irritation testing. 
 
Abbreviated title: 
ESAC WG Eye Irritation 
 
7.3 MANDATE OF THE ESAC WORKING GROUP 
The EWG is requested to conduct a scientific review of the EIVS study concerning the EpiOcular™ test 
method and, at a later point in time, of the optimised SkinEthic™ HCE test method. The review needs 
to address the questions put forward to ESAC by EURL ECVAM (section 4.2). 
 
In essence, the review should focus on the appropriateness of design and conduct of the study in 
view of the study objective and should provide an appraisal to which extent the conclusions of the 
Validation Management Team (VMT) are substantiated by the information generated during the 
study and how the information generated relates to the scientific background available. 
 
7.4 DELIVERABLES OF THE ESAC WORKING GROUP 
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Coordinator a detailed 
ESAC Working Group Report outlining its analyses and conclusions. A reporting template has been 
made available (Appendix 1) intended to facilitate drafting of the report. 
 
The conclusions drawn in the report should be based preferably on consensus. If no consensus can 
be achieved, the report should clearly outline the differences in the appraisals and provide 
appropriate scientific justifications. 
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7.5 PROPOSED TIMELINES OF THE ESAC WORKING GROUP 
The Coordinator has proposed timelines which should be agreed upon during the first 
Teleconference (Item 1 in the table): 
Item Proposed date/time Action Deliverable 
1 18-20 March 2014  Discussion of review 
material, 
 Resolution of issues possibly 
contentious between WG 
members 
 Clarification (hearing 
session) of questions on the 
study 
 Drafting of WG report 
First draft of WG 
report 
2 End of April / beginning of 
May 
Teleconference to discuss 
draft report 
 
3 Further teleconferences as 
needed in the subsequent 
weeks 
TBD TBD 
4 Early June Consolidation of WG report 
and drafting of ESAC opinion 
Draft WG report / 
draft ESAC opinion 
5 End of June Final WG report and draft 
ESAC opinion to ESAC 
 
 July  Adoption of WG Report and 
ESAC opinion by ESAC  
Final WG report and 
ESAC opinion 
 
7.6 QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WORKING GROUP 
When preparing the final ESAC WG report to address these questions, the ESAC WG is requested to 
use a pre-defined reporting template. This template (see appendix 1) follows EURL ECVAM's modular 
approach and addresses to which extent the standard information requirements have been 
addressed by the study. The template allows moreover for addressing the study-specific questions 
outlined in section 4.2. 
 
APPENDIX 1   REPORTING STRUCTURE FOR THE ESAC WORKING GROUP REPORT 
The following suggested structure follows the EURL ECVAM information requirements ("modules") 
for scientific review following validation and allows at the same time for the description of the 
analysis and conclusions concerning more specific questions. A template (ESAC WG consensus report 
template) has been created and will be made available to the ESAC.  
 
The template can be used for various types of validation studies (e.g. prospective full studies, 
retrospective studies, performance-based studies and prevalidation studies). Depending on the study 
type and the objective of the study, not all sections may be applicable. However, for reasons of 
consistency and to clearly identify which information requirements have not been sufficiently 
addressed by a specific study, this template is uniformly used for the evaluation of validation studies. 
 
The current template is 
 
TEMPLATE_ESAC-WG_REPORT-v5.doc 
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COMMITTEE 
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ESAC Working Group Peer Review Consensus* Report 
on the 
EURL ECVAM-coordinated 
Eye Irritation Validation Study (EIVS) 
Title page information 
File name 
ESAC_WG_REPORT_EIVS&HPLC.doc 
Abbreviated title of ESAC 
request 
EURL ECVAM Eye Irritation Validation Study 
Relating to ESAC REQUEST No. 2013-03 – v2.01 
Request discussed through ESAC38 (preliminary); ESAC39 (final including review mandate) 
Report to be handed over to 
ESAC Chair and EURL ECVAM 
Coordinator by 
Q2/Q3 2014 
Version tracking 
Date Version Author(s) Description 
2014 07 25 1.1 ESAC WG Draft 
2014 09 10 1.2 ESAC WG Final draft, containing description of contentious 
issue and majority / minority position 
*) The ESAC WG reached consensus on all review questions but one, which is described in more detail 
in Appendix 1 to this report and which includes an outline of the majority opinion (five WG members) 
and the minority opinion (one WG member). The WG was composed of six members. 
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ESAC Working Group 
 
Full title:  
ESAC WG charged with the review of the EpiOcular™ EIT and SkinEthic™ HCE test methods for eye 
irritation testing, and the HPLC/UPLC alternative endpoint measurement. 
 
Abbreviated title:  ESAC WG 
 
The 38th ESAC plenary (19 June 2013) unanimously decided to establish an ESAC Working Group "Eye 
Irritation" (referred to below as 'ESAC WG") to undertake a detailed scientific review of an EURL 
ECVAM/Cosmetics Europe Eye Irritation Validation Study (EIVS) evaluating two in vitro test methods 
for acute eye irritation caused by chemicals, both of which are based on Reconstructed human Tissue 
(RhT): the EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ Human Reconstructed Corneal 
Epithelium (HCE). The ESAC WG was established according to the ESAC Rules of Procedure and 
included experts nominated by international partner organisations of EURL ECVAM collaborating 
under the ICATM (International Collaboration on Alternative Test Methods) framework.  
A revised EURL ECVAM Request for ESAC advice was unanimously adopted at the 39th ESAC plenary 
(11/12 March 2014) to include a scientific review of a related Cosmetics Europe study of HPLC/UPLC 
as an alternative endpoint detection system, particularly for highly coloured chemicals interfering 
with the conventional endpoint measurement of formazan by OD-photometry. 
The ESAC WG conducted the peer review between 18 March 2014 and 10 September 2014, this 
Report was endorsed by the ESAC WG on 10 September 2014 apart from the contentious issue 
described in Appendix 1. The WG met in 18 to 20 March 2014 and further communicated by written 
procedure and teleconferences (10 April and 21 May 2014). 
 
The ESAC WG members appointed by ESAC were1: 
 Dr. Jon Richmond (ESAC Member, WG Chair) 
 Dr. Annette Kopp-Schneider (ESAC Member) 
 Dr. Renate Krätke (ESAC Member) 
 Dr. Kristina Kejlova (ESAC Member) 
 Dr. Tohru Marunouchi  (Fujita-Health University; ICATM nomination by JaCVAM) 
 Dr. Jill Merrill (FDA; ICATM nomination by NICEATM/ICCVAM)  
 
ESAC Coordination:  
 Dr. Claudius Griesinger (ESAC Coordinator) 
 Dr. Michael Schäffer 
                                                 
1. One member of the ESAC WG (JM) had been the ICCVAM liaison to the EIVS VMG during the validation study. She 
had not been a member of the core Validation Management Group (VMG). Although all decisions during the 
validation study were taken by the core VMG, JM advised and commented on some elements of the study design. 
The ESAC WG does not believe that this liaison role constitutes a significant conflict of interest with respect to the 
work of the ESAC WG.  
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Abbreviations used in the document 
 BLR   Between-laboratory reproducibility 
 CLP   Classification, Labelling and Packaging regulation (EU CLP) 
 ECHA   European Chemicals Agency 
 ECVAM   European Centre for the Validation of Alternative Methods 
 EIT   Eye Irritation Test 
 EIVS    Eye Irritation Validation Study 
 ESAC   ECVAM Scientific Advisory Committee 
 ESAC WG  ESAC Working Group 
 EURL ECVAM   European Union Reference Laboratory for Alternatives to  
   Animal Testing 
 FDA   Food and Drug Administration 
 GCCP    Good Cell Culture Practice 
 GLP   Good Laboratory Practice 
 HCE   Human Reconstructed Corneal Epithelium 
 HPLC/UPLC  High Performance Liquid Chromatography/Ultra Performance Liquid 
Chromatography 
 IATA   Integrated Approach to Testing and Assessment 
 ICATM   International Collaboration on Alternative Test Methods 
 MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
 OD   Optical density 
 OECD   Organisation for Economic Co-operation and Development  
 PC   Positive Control 
 RhT   Reconstructed Human Tissue 
 SCCS   European Commission Directorate General for Health and Consumer      
   Protection: Scientific Committee on Consumer Safety 
 SOP   Standard Operating Procedure 
 UN GHS  United Nations  Globally Harmonized System for the Classification    
                                            and Labelling of Chemicals. 
 VC   Vehicle Control 
 VMG   Validation Management Group 
 VSR   Validation Study Report 
 VMT   Validation Management Team 
 WLR   Within-laboratory reproducibility 
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Executive summary 
 
The ESAC WG was established by ESAC in response to a formal request from EURL ECVAM for a peer 
review of, and scientific advice on: 
1. An Eye Irritation Validation Study (EIVS) co-sponsored by EURL ECVAM and Cosmetics Europe 
evaluating two Reconstructed human Tissue (RhT) in vitro test methods (the EpiOcular™ Eye 
Irritation Test (EIT) and the SkinEthic™ Human Reconstructed Corneal Epithelium (HCE)) for 
acute eye irritation caused by chemicals: and  
2. A related Cosmetics Europe study of HPLC/UPLC as an alternative endpoint detection system, 
particularly for highly coloured chemicals interfering with the conventional endpoint 
measurement of formazan by OD-photometry. 
The ESAC WG was charged with conducting a detailed scientific peer review of these studies and 
advise on: 
1. The relevance (biological/mechanistic relevance and predictive capacity; the latter in the 
context of an Integrated Approach to Testing and Assessment (IATA) (OECD, 2008)) and 
reliability (transferability; within and between laboratory reproducibility) of the EpiOcular™ 
Eye Irritation Test (EIT) and the SkinEthic™ Human Reconstructed Corneal Epithelium (HCE).  
2. The usefulness of HPLC/UPLC-photometry as an alternative endpoint detection system in 
particular for highly coloured chemicals interfering with the conventional endpoint 
measurement by OD-photometry.  
 
The analysis and conclusions of the ESAC WG are based primarily on the: 
 
1. March 2014 Validation Study Report on “THE EURL ECVAM - COSMETICS EUROPE 
PROSPECTIVE VALIDATION STUDY OF RECONSTRUCTED HUMAN TISSUE-BASED TEST 
METHODS FOR IDENTIFYING CHEMICALS NOT REQUIRING CLASSIFICATION FOR SERIOUS EYE 
DAMAGE/EYE IRRITATION TESTING”, the study ANNEXES listed with the ESAC request, 
supplementary information obtained during the preparation of this report; and 
 
2. The Cosmetics Europe Task Force Eye Irritation (TF-EI) “Use of HPLC/UPLC for Endpoint 
Detection in In Vitro Reconstructed human Tissue (RhT) Test Methods to Expand Applicability 
to Strongly Coloured Test Substances” report, dated 1 March 2014, and other supporting 
documents supplied to ESAC WG. 
Eye Irritation Validation Study (EIVS)  
After the initial EIVS ring-trial of chemical testing neither of the RhT test methods satisfied the 
acceptance criteria set by the VMG.  
 
1. SkinEthic™ HCE SE and LE protocols, and their use in combination in a test strategy with the Eye 
irritation Peptide Reactivity Assay (EPRA), failed to meet the predetermined acceptability values 
set by the VMG for sensitivity, specificity or overall accuracy. The SE and LE protocols were, 
however, found to be highly reproducible. The VMG advised, and the manufacture agreed, to 
undertake test method optimisation outside the EIVS.  
 
1.1. The ESAC WG believes this was a sound decision. 
1.2. The ESAC WG supports the VMG view that the supplementary EPRA testing did not add value 
to the use of the SkinEthic™ HCE protocols used in this validation study. 
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2. With the original EpiOcular™ EIT protocol (SOP V 6.0) some acceptance predictive capacity 
criteria were not met for solid chemicals. The VMG allowed further test optimisation within the 
EIVS.  The findings with the revised solid chemicals protocol (SOP V 8.0) met the acceptance 
criteria established by the VMG. These post-optimisation findings are incorporated and analysed 
in the VSR, and form the basis of the conclusions and recommendations of the ESAC WG.  
 
Having taken account of supplementary data analysis commissioned by the ESAC WG and referenced 
elsewhere in this report, ESAC WG supports this test method now being considered for regulatory 
use. 
  
HPLC/UPLC 
1. On the basis of Cosmetics Europe Report, and supplementary analysis undertaken during the WG 
Review, the ESAC WG believes that suitably qualified HPLC/UPLC assay systems can be used as an 
alternative endpoint detection system in particular for highly coloured chemicals interfering with 
the conventional endpoint measurement by OD-photometry.  
2. However, the HPLC/UPLC provided marginally but systematically lower values for formazan levels 
than OD-photometry. This may impact on some of the prediction models which currently rely on 
formazan quantification by OD-photometry. 
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1. Study objective and design 
1.1 Analysis of the clarity of the study objective's definition 
NOTE: (a) please summarise briefly in your own words the study objective as outlined in the VSR and 
(b) provide an appraisal as to whether the study objective is clearly and comprehensibly defined in the 
VSR. 
(a) ESAC WG summary of the study objective as outlined in the VSR 
 
EIVS 
The EIVS Validation Study Report (VSR) title serves as a concise, simplified summary of the main 
study objective: “PROSPECTIVE VALIDATION STUDY OF RECONSTRUCTED HUMAN TISSUE-BASED TEST 
METHODS FOR IDENTIFYING CHEMICALS NOT REQUIRING CLASSIFICATION FOR SERIOUS EYE 
DAMAGE/EYE IRRITATION TESTING”. 
 
Section 2.1 of the VSR fully defines the study objectives. These were to evaluate the relevance 
(predictive capacity) and reliability (transferability; and within and between laboratory 
reproducibility) of two RhT test methods, the EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ 
Human Reconstructed Corneal Epithelium (HCE), to discriminate chemicals (substances and chemical 
mixtures) not requiring classification for serious eye damage/eye irritancy (No Category) from 
chemicals requiring classification and labelling (Category 1 and Category 2) according to the UN GHS 
Classification and Labelling of Chemicals (UN GHS) and as implemented by the EU CLP regulation (EU 
CLP). The test methods were not designed, intended, or evaluated to differentiate between GHS 
Category 1 (irreversible effects) and 2A-B (reversible effects). 
The relevance and reliability of the two RhT test methods, the EpiOcular™ Eye Irritation Test (EIT) and 
the SkinEthic™ Human Reconstructed Corneal Epithelium (HCE), were evaluated within a ring trial 
testing 107 chemicals (substances including chemical mixtures) with a view to consideration of their 
use in future in vitro tiered test strategies (Scott et al, 2010) within an integrated, tiered approach 
using strategic combinations of alternative test methods to replace the Draize eye test, either as the 
initial step in a Bottom-Up Approach or a second or subsequent step in a Top-Down Approach. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The Cosmetics Europe Task Force Eye Irritation report entitled “Use of HPLC/UPLC for Endpoint 
Detection in In Vitro Reconstructed human Tissue (RhT) Test Methods to Expand Applicability to 
Strongly Coloured Test Substances” (referred to below as the Cosmetics Europe Report) is the 
essential reference document for the HPLC/UPLC endpoint detection system relied upon by the ESAC 
WG.    
 
The Cosmetics Europe Report is not a Validation Study Report (VSR): the study evaluated the 
performance of a bio-analytical endpoint measurement system (which is not itself a test method).  
 
The Cosmetics Europe Report confirms that the aim of the study was to determine the relevance 
(reliability and reproducibility) of suitably qualified analytical HPLC/UPLC systems to measure the 
MTT reduction product formazan generated by the use of three different RhT test methods which 
currently rely on the photometric detection and quantification by photometric measurement of 
optical density (OD) of formazan as the endpoint measurement for cytotoxicity. Each of the three 
ESAC WORKING GROUP REPORT  Page | 48 
RhT test methods used within the study was relevant to one of three discrete toxicity endpoints (skin 
corrosion, skin irritation and eye irritation). 
 
The starting point for the Cosmetics Europe study is the need to devise RhT/MTT-reduction product 
measurement systems that can be used with highly coloured chemicals which interfere with the OD-
photometric measurement of the formazan endpoint. The study also evaluated the use of the 
HPLC/UPLC endpoint measurement system for chemicals that do not have this property.  
 
The HPLC/UPLC study was conducted with the intention of using the findings to: 
 
 Extend the applicability of in vitro RhT test methods for skin corrosion, skin irritation and eye 
irritation to include strongly coloured chemicals which interfere with current endpoint 
measurement - the OD-photometric detection and quantification of the MTT reduction 
product formazan. 
 Establishing the suitability of qualified HPLC/UPLC systems for consideration as an alternative 
endpoint detection system for these and other RhT/MTT-based in vitro test methods and 
other chemicals, and demonstrating the Within Laboratory Reproducibility (WLR) and 
Between Laboratory Reproducibility (BLR) of HPLC/UPLC for this purpose – with different 
suitably qualified HPLC/UPLC systems used in the different laboratories participating in the 
study. 
 
(b) Appraisal of clarity of study objectives as outlined in the VSR 
 
EIVS  
With respect to EIVS, the ESAC WG believes that the study objectives were sufficiently clear, and 
reflected in the way the study was designed, conducted, analysed, and reported in the VSR. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The Cosmetics Europe Report has no “Objectives” section. The information summarised above was 
compiled from various sections of the report.  
 
The ESAC WG believes that the full text of The Cosmetic Europe Report clearly and sufficiently 
defines the study objectives. 
 
1.2 Quality of the background provided concerning the purpose of the test method  
NOTE: What is, according to the VSR, the overall purpose of the test method? Examples are a) 
scientific use (e.g. basic/applied research, b) screening for product development c) regulatory testing 
etc. 
Both the EIVS and the Cosmetics Europe HPLC/UPLC reports describe the intended application of the 
RhT test methods and suitably qualified HPLC/UPLC bio-analytical measurement systems as being for 
regulatory testing.  
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EIVS 
The study reported in the VSR was undertaken with a view to determining if the two RhT test 
methods, the EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ Human Reconstructed Corneal 
Epithelium (HCE), are ready to be considered for regulatory use.  
The EIVS study and the VSR conclusions and recommendations are relevant to the possible future use 
of these RhT test methods in a future in vitro tiered test strategy (Scott et al, 2010) used within an 
integrated approach using strategic combinations of alternative test methods to replace the Draize 
eye test to discriminate chemicals not requiring classification for serious eye damage/eye irritancy 
(No Category) from chemicals requiring classification and labelling (Category 1 and Category 2) 
according to the United Nations Globally Harmonized System of Classification and Labelling of 
Chemicals (UN GHS) and as implemented by the EU Classification, Labelling and Packaging regulation 
(EU CLP). 
 
The Cosmetics Europe Task Force Eye Irritation Report 
A number of RhT test methods are already validated, accepted and used by manufacturers, test 
laboratories, and regulatory authorities for evaluation of skin corrosion (OECD Test Guideline (TG) 
431 (OECD, 2013)) and skin irritation ((OECD TG 439 (OECD, 2013)). Other RhT test methods are 
currently undergoing validation for use as part of integrated testing strategies (Scott et al, 2010) for 
eye irritation.  
 
The Scientific Committee on Consumer Safety (SCCS) of the European Commission Directorate 
General for Health and Consumers previously advised that “...for coloured substances, a different 
endpoint, not involving Optical Density (OD) quantification, should be envisaged. Analytical methods 
such as HPLC/UPLC might be more appropriate to detect formazan in the in vitro assay...” (McNamee 
et al. 2009). The Cosmetics Europe study proposes the use of suitably qualified HPLC/UPLC endpoint 
measurement in this context. 
The use of suitably qualified HPLC/UPLC endpoint measurement is proposed for consideration for 
regulatory use as an alternative endpoint detection measurement for in vitro RhT test methods 
which currently rely on the detection and quantification by OD-photometry of the MTT reduction 
product formazan as a measure of cytotoxicity – specifically to extend the range of chemicals which 
such test methods can evaluate to include highly coloured chemicals which interfere with the 
conventional endpoint measurement by OD-photometry. An alternative endpoint detection 
measurement for RhT/MTT reduction product test methods that overcomes this current limitation 
would extend the applicability domain of these RhT tests. 
The ESAC WG believes The Cosmetics Europe Report describes a bio-analytical that has the potential 
to overcome a current limitation on the use of these test methods. 
 
(a) Analysis of the scientific rationale provided in the VSR 
NOTE: Is the scientific rationale of the test method AND (consequently) for conducting the study 
clearly explained? Consider how the test method may contribute 
(a) to the scientific understanding of the specified health/environmental effect or aspects of it?, i.e. 
does it provide relevant mechanistic information such as physiological pathways relevant for toxicity 
("toxicity pathways") or other key physiological events leading to toxicity? 
(b) to the prediction of the specified downstream health/environmental effect or aspects of it? 
Moreover, does the VSR make sufficient reference to the relevant body of scientific literature? 
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EIVS 
The EIVS VSR describes the scientific rationale of the EpiOcular™ Eye Irritation Test (EIT) and the 
SkinEthic™ Human Reconstructed Corneal Epithelium (HCE) partly in terms of other validated and 
accepted RhT models’ proven ability to measure cytotoxicity by the OD-photometric quantification of 
MTT reduction products (Mosmann, 1983) as a reliable surrogate measurement of a range of 
toxicological endpoints after the controlled exposure of an RhT air-tissue interface to solid or liquid 
test materials (substances , including  chemical mixtures).  
The VSR also provides a scientific rationale and justification in the specific context of eye irritation, 
reasoning that RhT test system cytotoxicity/tissue viability is a potentially plausible surrogate 
measure of eye irritancy capable of discriminating between UN GHS eye irritants (CLP Category 1 and 
Category 2) and non-irritants produced by a variety of relevant, known, in vivo mechanisms of ocular 
toxicity. The ESAC WG also notes that in other contexts (for example skin irritation) cytotoxicity/cell 
viability following chemical exposure is a recognised surrogate measure for chemically induced in 
vivo toxicity: with the in vivo cytotoxicity stimulating  an inflammatory response involving the innate 
immune system in proportion to the degree of cytotoxicity produced by the chemical. 
 
The VSR concedes that not all of the relevant in vivo mechanisms of ocular toxicity are addressed by 
the EpiOcular™ Eye Irritation Test (EIT) and the SkinEthic™ HCE test methods, and the ESAC WG notes 
that no histopathological evaluation is performed as part of the test methods. If these RhT test 
methods are to be used to identify non-irritants within an integrated testing strategy then the ESAC 
WG believes other test methods will be needed to assess mechanisms of toxicity where the relevant 
adverse outcome pathway has a vascular component or is marked by changes other than cell death.  
The arguments advanced in the VSR in support of the test methods take account of the findings of 
previous pre-validation studies and other peer reviewed publications. The ESAC WG notes that some 
of the peer reviewed papers cited in the VSR narrative are not listed in the VSR bibliography. 
The VSR provides plausible evidence and reasoned arguments in favour of these RhT test methods 
having the potential to be at least as relevant and reliable as the current in vivo test system for the 
identification of non-irritants when combined with other in vitro methods within an integrated, 
tiered approach using strategic combinations of alternative test methods within future (tiered) 
testing strategies to replace the Draize eye test (Scott et al, 2010). 
The VSR acknowledges that, for the foreseeable future, the in vivo Draize rabbit eye test is unlikely to 
be replaced by a single in vitro test (Eskes et al, 2005). Instead the VMG proposes that the intended 
use of these RhT test methods would be within a larger testing strategy designed to replace or 
reduce animal testing for determining chemical-induced eye irritation potential for regulatory 
purposes (Scott et al., 2010).  
It is proposed by Scott et al (2010) that within such future testing strategies, based on the expected 
ocular toxicity profile of the test chemical, and using one of two tiered testing approaches (Bottom-
Up or Top-Down), the systematic and sequential application of one or more in vitro test method 
would be used to determine chemically induced eye irritation potential. The full details of the 
appropriate integrated testing strategies and test methods have yet to be defined. 
The validation study was designed and conducted to provide evidence of whether the EpiOcular™ 
Eye Irritation Test (EIT) and the SkinEthic™ Human Reconstructed Corneal Epithelium (HCE) test 
methods are sufficiently relevant and reliable to identify chemicals not requiring classification, i.e. 
chemicals that are not UN GHS CLP Category 1 (serious eye damage) or Category 2 (eye irritant). The 
results of the study (i.e. prediction of non-classified chemicals) are to be considered for use within a 
testing strategy (Scott et al, 2010).   
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The Cosmetics Europe Task Force Eye Irritation Report 
The Cosmetics Europe Report describes an HPLC/UPLC endpoint detection system, not a test method. 
In the view of the ESAC WG The Cosmetics Europe Report adequately describes and explains a known 
limitation of the currently used OD-photometric endpoint detection system - its inability to reliably 
assess the cytotoxic effects of chemicals which interfere with the OD-photometric endpoint 
measurement - and provides the rationale for the development and use of a suitably qualified 
HPLC/UPLC endpoint detection system as an alternative endpoint measure. 
The Cosmetics Europe Report summarises relevant peer-reviewed literature and other reference 
material explaining the relevance and limitations of RhT test methods which rely on the OD-
photometric quantification of the MTT reduction product formazan as a means of estimating 
cytotoxicity as a surrogate measure of skin corrosion, skin irritation, and eye irritation, and other 
toxicological endpoints.  It also relies on references explaining the likely relevance and reliability of 
suitably qualified HPLC/UPLC measurement systems for MTT reduction products for the same 
purposes.  
 
In the view of the ESAC WG, the breadth and quality of the reference materials cited in the Cosmetics 
Europe Report is both informative and supports the claims made by the authors of the Cosmetics 
Europe Report with respect to the underlying science and the need for and potential benefits of 
improved RhT formazan endpoint detection systems to accurately estimate cytotoxicity when 
cytotoxicity measurements cannot be reliably derived by OD-photometric methods. 
 
(b) Analysis of the regulatory rationale provided in the VSR 
NOTE: Is a regulatory rationale specified, i.e. a specific application of the test method for purposes of 
generating data with respect to regulatory requirements as specified in legislation or internationally 
agreed guidelines etc.? If so, how does the study and its objective and design relate to this regulatory 
rationale? Are the relevant regulatory documents appropriately referenced? 
 
Both the EIVS VSR and the Cosmetics Europe HPLC/UPLC report identify relevant regulatory 
requirements. In the view of the ESAC WG the relevant legislation and regulations are appropriately 
referenced; and the regulatory requirements and the role of the RhT-based methods in the context 
of the regulatory requirements are adequately specified. 
EIVS 
If validated for eye irritancy determination, RhT test methods such as the EpiOcular™ EIT and the 
SkinEthic™ HCE would have the potential to reduce animal testing by reliably identifying chemicals 
not requiring classification when used within an appropriate non-animal testing strategy (Scott et al, 
2010).  
The VMG makes the point that considering the small prevalence of chemicals inducing serious eye 
damage (Adriaens et al, 2014) RhT test methods validated for this purpose would significantly reduce 
animal testing by identifying the much larger number of chemicals not requiring classification. 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC WG believes the regulatory rationale is clearly set out in the Cosmetics Europe Report. 
RhT test methods relying on the detection and quantification of formazan as the endpoint 
measurement are already validated, accepted and used by manufacturers, test laboratories , and 
regulatory authorities for evaluation of skin corrosion (OECD Test Guideline (TG) 431 (OECD, 2013a)) 
and skin irritation ((OECD TG 439 (OECD, 2013b)). Other RhT test methods are currently undergoing 
validation for use as part of a proposed testing strategy (Scott et al, 2010) for eye irritation (EIVS 
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Report). One of the major limitations of the current MTT OD-photometric assay is interference with 
the endpoint measurement by chemicals with absorbance measurements at or close to that of 
formazan. 
 
The SCCS previously advised that “...for coloured substances, a different endpoint, not involving 
Optical Density (OD) quantification, should be envisaged. Analytical methods such as HPLC/UPLC 
might be more appropriate to detect formazan in the in vitro assay...” (McNamee et al. 2009).  
 
An alternative endpoint detection measurement for RhT/MTT reduction product formazan that 
overcomes the current limitation on their use for chemicals which interfere with the OD-photometric 
detection and quantification of formazan would extend the applicability domain of RhT test methods 
that rely on the measurement of formazan. 
 
The Cosmetics Europe Report also references the EIVS study, pointing out that two test chemicals 
used within EIVS demonstrated strong colour interference with the measurement by OD-photometric 
absorbance of formazan.  
 
1.3 Appraisal of the appropriateness of the study design 
NOTE: Is the study design appropriate in view of the stated objective of the study? This includes an 
analysis of the number of laboratories involved in the study, the organisation of study management 
including chemical selection, quality check of data, and independence of statistical analysis, i.e. was 
the statistician independent from the test method submitter/developer and, depending on the study, 
from the VMG. More technical aspects can also be considered such as an appraisal of the nature and 
number of test items used (details however to be provided in section 6, test materials), retesting in 
case of unqualified tests, pre-defined test acceptance criteria etc.  
 
EIVS 
The VSR describes a validation study of two RhT test methods, the EpiOcular™ EIT and the SkinEthic™ 
HCE, and provides a detailed and reasoned rationale for the validation study design. An Annex to the 
VSR, “Eye Irritation Validation Study (EIVS), Guidance on the Eye Irritation Study (EIVS) Conduct for 
the Reconstructed Human Tissue (RhT) Assays and Performance Criteria to Assess the Scientific 
Validity of SkinEthicTM HCE and the EpiOcularTM EIT”, describes in detail how the study was planned 
and conducted. 
EIVS complies with the principles and criteria set out in the OECD Guidance Document on the 
Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment 
(No. 34, OECD, 2005), and described in the generally accepted Modular Approach to validation 
(Hartung et al, 2004). 
 
The SkinEthicTM HCE (in combination with EPRA) and the EpiOcularTM EIT (with separate protocols for 
liquids and solids) were assessed for their usefulness as test methods to identify chemicals not 
requiring classification for serious eye damage/eye irritation (UN GHS / EU CLP No Category; “non-
irritants”) and their reliable discrimination from all classes of classified chemicals with a view to their 
forming an initial step of a Bottom-Up approach or a later stage of a Top-Down approach (Scott et al., 
2010). 
 
The relevance and reliability of the two RhT test methods, the EpiOcular™ EIT and the SkinEthic™ HCE, 
were assessed by a ring trial using a number of coded test chemicals (substances and chemical 
mixtures, N=107) as determined by the statistician to ensure a study of appropriate power, and 
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supported by the best available quality-assured in vivo Draize eye irritation reference data for the 
comparative evaluation of the accuracy of the results. 
 
The EIVS VMG established test method performance acceptance criteria to evaluate the performance 
and validity of the SkinEthicTM HCE SE and LE test methods, the SkinEthicTM HCE/EPRA test strategy, 
and the EpiOcularTM EIT as stand-alone test methods for the identification of chemicals not classified 
as eye irritants in the framework of Bottom-Up/Top-Down test strategies. In setting those criteria the 
VMG took into account of: 
 
1. The background and specific objectives of the validation study; 
2. The requirements of regulatory authorities and industry when testing and classifying 
chemicals for eye irritation;  
3. The within test variability inherent in the in vivo Draize eye irritation data and the manner in 
which these data are currently used for classifying eye irritants according to UN GHS / EU 
CLP;  
4. The standards of performance which are expected from in vitro test methods; 
5. The way in which the in vitro tests are to be used (as one test within a tiered test strategy); 
and 
6. The statistical power of the validation study. 
 
In its scientific review of the study, the study findings, and the VMG conclusions the ESAC WG 
concludes that, subject to specific qualifications set out below, the study design was generally 
appropriate and robust, the acceptance criteria appropriate at the time, and that the study findings 
have provided the evidence and analysis required to satisfy the study objectives.  
 
SkinEthic™ HCE 
 
A total of 107 coded chemicals were tested in two different protocols in three runs with three 
replicate tissues per run, in three laboratories. The same chemicals were also tested in Eye Irritation 
Peptide Reactivity Assay (EPRA) in one run with three replicate measurements in one laboratory 
(TNO). 
The RhT testing was performed by three laboratories (CARDAM, CeeTox, and L'Oréal). As the lead 
laboratory, L'Oréal provided training and support to the two naïve laboratories during the training 
and transfer phase of the study. 
Two different protocols of SkinEthic™ HCE, a short-time exposure protocol (SE), and a long-time 
exposure protocol (LE) were evaluated. A test strategy combining, in a sequential manner, the Eye 
Irritation Peptide Reactivity Assay (EPRA) with both the SE and LE variants of the SkinEthic HCE test 
method was also assessed. 
 
The SkinEthic™ HCE SE and LE protocols were developed in the expectation that the SE protocol 
would be better suited for use with EPRA reactive chemicals, and the LE better suited for use with 
EPRA non-reactive chemicals. The EPRA data were generated before the chemical selection was 
finalised to ensure the chemicals set selected for the main study had a balanced set of EPRA-reactive 
and EPRA non-reactive chemicals.  All chemicals were evaluated using both the SkinEthic™ HCE SE 
and LE protocols. 
 
The VMG set acceptance criteria for the maximum number of non-acceptable/non-qualifying test run 
sequences that any laboratory could make during the study. The study documents made provision 
for reporting if certain threshold numbers of non-acceptable/non-qualifying test run sequences were 
reached, in which case the lead laboratory would seek to identify and remedy the cause of the 
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problem. This was the only inter-laboratory contact permitted during the testing phase of the study: 
it did not take place during the testing phase of the study.  
However, early in the transfer phase, a series of non-qualified runs was reported by one laboratory 
(CeeTox, USA) on the basis of unacceptable Positive Control values. The plausible explanation offered 
in the VSR is that the tissue component of the test kits had been compromised whilst in transit: the 
transport arrangements were reviewed and improved, and the SOP amended to include an 
assessment of Positive Control values as confirmation of tissue viability. This problem was not seen 
again after these changes were implemented.  
 
EpiOcular™ EIT 
 
In the ring trial a total of 107 coded chemicals were tested (three runs with two replicate tissues per 
run, in three laboratories) using EpiOcular™ EIT SOP (V 6.0), using separate protocols for liquid and 
solid chemicals, and two alternate cut-off points (50% and 60% cell viability). 
The VMG set acceptance criteria for the maximum number of non-acceptable/non-qualifying test run 
sequences that any laboratory could make during the study. The study documents made provision 
for reporting if certain threshold numbers of non-acceptable/non-qualifying test run sequences were 
reached, in which case the lead laboratory would seek to identify and remedy the cause of the 
problem. This was the only inter-laboratory contact permitted during the testing phase of the study: 
in the event, there was no inter-laboratory contact during the testing phase of the study.  
The RhT testing was performed by three laboratories (Beiersdorf, Germany (the lead laboratory); 
Harlan, UK; and IIVS, USA). The manufacturer and lead laboratory provided training and support to 
the other laboratories during the training and transfer phase of the study. 
The original EpiOcular™ EIT SOP V6.0 protocol for liquid chemicals produced results satisfying all of 
the VMG acceptance criteria for sensitivity, specificity and overall accuracy. The 60% cut-off was 
preferred as it resulted in a better sensitivity and generated no false negatives based on the mode of 
all predictions (the 50% cut-off generated one false negative for a Category 2B chemical). 
With the original EpiOcular™ EIT protocol (SOP V6.0) some of the VMG acceptance criteria were not 
met for solid chemicals. Six chemicals were under-predicted with the 60% cut-off based on the mode 
of all predictions, one of which (which was misclassified by two of the laboratories) is classified in 
vivo as Category 1. 
 
The VMG considered that there was scope for improved test method performance if a balanced 
increase in sensitivity offset by some decrease in specificity could attain a compromise sensitivity ≥ 
90% with specificity maintained ≥ 60%. Further optimisation was therefore recommended for the 
EpiOcular™ EIT protocol for solid chemicals. The VMG allowed test optimisation to be undertaken 
within EIVS by the test developer in an attempt to improve sensitivity (lowering the false negative 
rate) without unduly compromising specificity (misclassifying true negatives).   
 
The VSR describes the test optimisation process. This was undertaken using 11 of the most 
challenging EIVS solid chemicals: the six EIVS solid chemicals that had been under-predicted (false 
negatives), and five EIVS chemicals that had correctly been predicted as non-irritants but which had 
given borderline results. Having considered the new results and an amended SOP (V 8.0), the VMG 
commissioned a post-optimisation validation study of the EpiOcular™ EIT optimised solid chemicals 
protocol, undertaken in one laboratory with a total of 60 solid chemicals (the original 52 EIVS solid 
chemicals plus eight additional chemicals to compensate for the 11 EIVS chemicals used during the 
optimisation of the protocol) - effectively increasing the EIVS chemicals set to N=115.   
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The post-optimisation testing was undertaken only in the lead laboratory (Beiersdorf). The VMG 
reasoned that, in view of the high reproducibility of the test method during the original ring-trial, 
supplementary testing in one laboratory would be sufficient to determine the predictive capacity of 
the revised EpiOcular™ EIT optimised solid chemicals protocol.  
 
The ESAC WG considered whether the choice of the one laboratory that conducted the 
supplementary testing using the protocol optimised for the testing of solid chemicals might have 
unintentionally introduced a source of bias – for example had the chosen laboratory produced the 
best values with the original protocol. The ESAC WG believes the choice of this laboratory did not 
introduce any such bias. The performance values obtained at the chosen laboratory when it used the 
protocol not optimised for solid chemicals were comparable to the values obtained by all three 
laboratories that participated in the validation of the original protocol (SOP V6.0).   
 
The post-optimisation findings are incorporated and analysed in the VSR, and form the basis of the 
VMG conclusions on the performance of the EpiOcular™ EIT. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC WG believes the Cosmetics Europe Report provides a detailed and reasoned rationale for 
the HPLC/UPLC study design. 
 
With respect to the selection of test laboratories: Cosmetics Europe as a co-sponsor of the study 
determined general and specific requirements that any participating laboratory must fulfil, and then 
nominated the laboratories which undertook the testing. There was no tendering and selection 
process. This is not best practice, but the ESAC WG found no evidence of this having compromised or 
biased the study findings.   
 
The ESAC WG noted that as this was not a test method validation study, rather it was the evaluation 
of an analytical method, and there was no SOP for the qualified HPLC/UPLC measurements. The 
Cosmetics Europe Report states that the suitably qualified HPLC/UPLC systems were used in 
accordance with the criteria required for qualification. 
 
Two study phases are described in the Cosmetics Europe Report.  
 Phase 1: qualifying the HPLC/UPLC test systems; and  
 Phase 2: the use of suitably qualified HPLC/UPLC for endpoint measurement for formazan 
detection and quantification when a range of chemicals were evaluated with three RhT test 
methods - each used for one of three different toxicological endpoints.  
The ESAC WG considered the study design for both phases of the reported study: 
 
Phase 1: Qualification 
The Cosmetics Europe Report describes the qualification of the HPLC/UPLC systems in detail. 
The specific HPLC/UPLC systems at each of the three laboratories were qualified according to the 
May 2001 US Food and Drug Administration (FDA) guidance for industry “Bioanalytical Method 
Validation”. In this context “qualification” is a technical term for the validation of bio-analytical 
methods, encompassing all of the procedures required to demonstrate that a particular bio-analytical 
method used for quantitative measurement of specified analytes in a given biological matrix is both 
reliable and reproducible for its intended use. The qualification process involves the use of specific 
laboratory investigations documenting and confirming that the performance characteristics of the 
bio-analytical method are suitable and reliable for its intended analytical use. 
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Based on the information contained in the Cosmetics Europe Report (including detailed technical 
specifications, conditions, and performance data on the HPLC/UPLC systems; information on sample 
preparation; and analysis of key parameters) the ESAC WG is satisfied that: 
 
1. Determination of the reliability and reproducibility of HPLC/UPLC as an alternative endpoint 
for detection of formazan in the MTT assay in in vitro RhT test methods falls within the scope 
of the FDA guidance document. 
2. The fundamental parameters (in this case selectivity, precision and accuracy, matrix effect, 
carryover, reproducibility, and stability) for the qualification of HPLC/UPLC for measurement 
of formazan in RhT extracts were relevant and appropriate. 
 
Phase 2: 
The ESAC WG is satisfied that for the purposes of this study a sufficient number of RhT MTT-
reduction product test methods, chemicals, and laboratories were used. 
The ESAC WG analysis of some elements of study design (e.g. the adequacy of the number of 
laboratories involved in the study, the organisation of study management, the statistical analysis, and 
the nature and number of test items used) is provided elsewhere in this report. 
The WG considers that the study design described in The Cosmetics Europe Report made proper 
provision to confirm that: 
1. Formazan extracts are stable during the operational conditions under which HPLC/UPLC 
was performed, and for the conditions and duration of sample storage for the purposes 
of this study. 
2. Chemicals that compatible with the RhT MTT-reduction product test methods give 
comparable results when the endpoint in the same samples is measured using both OD-
photometric measurement and the suitably qualified HPLC/UPLC system. 
3. For chemicals that are incompatible with RhT test method because they interfere with 
MTT OD-photometric assay, when the endpoint is measured by the suitably qualified 
HPLC/UPLC system the application of the RhT test method Prediction Models resulted in 
a generally appropriate classification (based on the RhT reference data) of the chemicals 
with respect to the relevant toxicological endpoint. The Cosmetics Europe Report also 
provides the classifications that would have resulted had in vivo reference data been 
used. 
Three laboratories (L’Oréal R&I, Pierre Fabre Laboratories, and VITO) each tested up to 26 chemicals. 
The three laboratories each used a different RhT test method measuring different toxicological 
endpoints (EpiOcular™ EIT as per the EIVS protocol v6.0 for eye irritation (the version of the SOP 
which pre-dated the optimisation of the test method for solid chemicals within EIVS) was performed 
by Pierre Fabre Laboratories - and the SkinEthic™ RHE as per OECD TG 431 for skin corrosion, and the 
EpiSkin™ as per OECD TG 439 for skin irritation were both performed at L’Oréal R&I). Where the RhT 
test method protocols made provision for the identification of MTT-reducers and chemicals 
incompatible with the OD-photometric endpoint measurement systems, the relevant SOP provisions 
were followed. 
The laboratories performing the RhT test methods also undertook the formazan extraction 
procedures (with the same samples then used for both the OD-photometry and the HPLC/UPLC 
measurements) and the OD-photometric endpoint measurement steps specified in the test method 
SOPs.  
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Three laboratories (L’Oréal R&I, Pierre Fabre Laboratories, and VITO) then used the suitably qualified 
HPLC/UPLC system for endpoint measurements of all of the samples, and applied the Prediction 
Models using both endpoint measurements.  
To evaluate intra-laboratory performance the Pierre Fabre Laboratories undertook two separate 
HPLC/UPLC endpoint measurements of the same EpiOcular™ eye irritation formazan samples. 
 
1.4 Appropriateness of the statistical evaluation 
NOTE: Consider whether the statistical approaches chosen are appropriate. This includes statistical 
calculations performed ex-ante such as sample size calculations as well as ex post statistical analysis 
of the data (e.g. for purposes of variability and predictive capacity). Is the choice of methods 
sufficiently justified?  
 
EIVS 
The statistical reports annexed to the EIVS VSR are detailed and informative. However, see below, 
the ESAC WG takes a different view of the way predictive capacity should be calculated in the context 
of this study: in the VSR the VMG relies on calculations based on all individual test runs rather than 
the number of test chemicals; the ESAC WG believes the VMG approach artificially increases the 
sample size, produces inappropriately narrow confidence limits, and results in an inappropriate 
degree of certainty with respect to the point estimates of sensitivity and specificity.    
 
The VSR records that having taken independent statistical advice  “…statistical tools that were used 
for data analysis included in the final biostatistics reports were described in the Guidance document 
on the conduct of the EIVS and in a Statistical Analysis and Reporting Plan. The biostatistics analyses 
procedures reported in the Statistical Analysis and Reporting Plan were developed by the ECVAM and 
TNO biostatisticians before completion of the experimental phase of the study and were approved by 
the VMG before the biostatistics analyses began”. The study results were analysed by an 
independent statistician. 
 
The ESAC WG is satisfied on the basis of the documentation provided that these procedures were 
followed during the planning, conduct, analysis and reporting of the study. 
 
For statistical purposes four protocols were evaluated: two RhT in vitro test methods, including four 
alternative time combinations for exposure and incubation: with EpiOcular™ EIT separating liquids 
from solids; and SkinEthic™ HCE differentiating EPRA reactive from non-reactive chemicals. This 
required a balanced chemical selection of: (i) classified versus non-classified chemicals; (ii) solids 
versus liquids; and (iii) EPRA reactivity versus non-reactivity. 
 
Non-qualifying test runs were not included in the data used to calculate final BLR or Predictive 
Capacity values for the EpiOcular™ EIT and SkinEthicTM HCE test methods. 
 
For the SkinEthicTM HCE test method no test chemical used for the testing phase was considered 
incompatible with the test method by any of the three laboratories, with either the SE or the LE 
protocol. All chemicals were thus included in all of the statistical analyses of this test method. 
For the EpiOcular™ EIT in one laboratory one of the original chemicals (#33) proved incompatible 
with the test system due to colour interference with the OD-photometry measurement of formazan: 
the same was true of one of the non-EIVS chemicals (#98) used for retesting after protocol 
optimisation for solid test chemicals.  
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The ESAC WG gave careful consideration to the means by which the data generated could be used to 
best reflect the predictive performance of the methods without overestimating accuracy values. The 
ESAC WG believes the relevant confidence limits for the predictive capacity must be based on the 
number of chemicals tested, rather than the number of test runs performed as in the context of this 
study the chemical is the sampling unit and the test runs are technical replicates of each sampling 
unit. As a result, two separate classes of variability have to be considered: variability between runs 
for each chemical and variability between chemicals. An evaluation of predictive capacity on the 
basis of the number of test runs, and disregarding the fact that there were multiple runs with each 
chemical, does not take proper account of the two-level nature and structure of the data. The length 
of the confidence interval decreases with sample size, and artificially increasing sample size in this 
way results in confidence limits that are too narrow. The ESAG WG believes the confidence limits 
based on the number of test runs relied upon in the VMG Report are likely to be optimistic. The ESAC 
WG therefore requested additional analysis with confidence limits derived from the number of 
chemicals tested rather than the number of test runs. See Section 10.1. 
 
Furthermore, the ESAC WG considers that the predictive capacity calculation should reflect the way 
decisions will be made in practice. Specifically, as chemical classification will be based upon one test 
run, the analysis of the study results should allow for an accuracy range to be determined based 
upon the best and worst case based on data from single runs (i.e. using each single run per chemical 
and selecting the runs in view of obtaining (a) the worst possible results or (b) best possible results in 
terms of concordance of predictions with the reference data) rather than aggregating the data from 
different test runs with the same chemical. There was agreement within the ESAC WG that values 
calculated on the basis of best-case/worst-case scenarios would provide sufficiently robust 
performance values to better determine whether the performance levels envisaged by the VMG had 
been met. The ESAC WG commissioned additional data analysis from EURL ECVAM based on this 
approach, and the result were discussed at the May 2014 ESAC WG teleconference. See Section 10.1.  
 
Although the ESAG WG settled on the best-case/worst-case option, consideration was also given to 
bootstrapping. The ESAC WG agreed to recommend to EURL ECVAM that, in cases where data 
matrices of all performed runs are used as a basis for the assessment of the predictive capacity of 
assays, bootstrap calculations should be performed as the best practice approach in order to derive 
accurate and appropriate figures.  
 
SkinEthicTM HCE 
 
All of the chemicals selected were tested in both the SkinEthicTM HCE SE and the LE protocols, and the 
results obtained with the SE and LE protocols were then independently assessed with respect to their 
reproducibility and predictive capacity. 
 
The combined EPRA/SE/LE model as described in the SOP was evaluated for predictive capacity only.  
 
 Within-laboratory reproducibility  
 
For each laboratory, concordance of classifications and overall Standard Deviation (SD) were 
calculated based only on qualified tests for test chemicals for which at least two qualified tests were 
available.  
 
Standard Deviation associated with each laboratory was calculated using all available test sequences, 
i.e., including both qualified and non-qualified tests. 
 
Between-laboratory reproducibility  
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The reported BLR values are based on the final classification for each test chemical in each 
participating laboratory, based on the arithmetic mean value obtained from three acceptable test 
run sequences.  
 
Concordance of classifications between laboratories and overall Standard Deviations were calculated 
based only on qualified tests for chemicals for which at least one qualified test per laboratory was 
available. The overall Standard Deviation for the study was calculated using all available test 
sequences.  
 
Predictive capacity  
 
All qualified tests for each test chemical were used to calculate predictive capacity values. The 
calculations were based on the individual final prediction of each qualified test in each laboratory.  
See EIVS comments immediately above. 
 
EpiOcular™ EIT 
 
Although separate protocols are followed for liquid and solid chemicals, the reproducibility and 
predictive capacity of EpiOcular™ EIT were evaluated for the whole test method (the testing of 
liquids and solids). 
 
EpiOcular™ EIT was originally developed with, and the submission of the test method to EURL ECVAM 
for validation only referenced, a single threshold of 60% mean tissue viability in the prediction 
model. However, before training and transferability took place, out of necessity the manufacturer 
had to substitute the original test kit insert-membrane with another form of membrane insert. 
 
This change produced minor changes in the results obtained with the test kit. With the new 
membrane the manufacturer demonstrated that a sensitivity > 90% could potentially still be 
achieved by using a 50% mean tissue viability cut-off instead of 60%, with a significant gain in 
specificity. The VMG therefore decided that within EIVS the EpiOcular™ EIT test method performance 
would be evaluated using two alternate prediction models: 
 
1. The original cut-off at 60% mean tissue viability as in the submission to EURL ECVAM; and 
2. A cut-off at 50% mean tissue viability.  
 
The VMG conclusions and recommendations with respect to EpiOcular™ EIT are based upon an 
analysis of the initial round of testing in three laboratories, and the post-optimisation for solids 
testing data from one laboratory. 
 
The ESAC WG’s concerns about the basis of some of statistics set out in the VSR and relied upon by 
the VMG are set out above, and are discussed further at Sections 10.1 and 13.1. 
 
Within-laboratory reproducibility  
 
For each laboratory, concordance of classifications and overall Standard Deviation (SD) were 
calculated based only on qualified tests for test chemicals for which at least two qualified runs were 
available.  
 
ESAC WORKING GROUP REPORT  Page | 60 
Standard Deviations associated with each laboratory were calculated using all available test 
sequences, i.e., including both qualified and non-qualified tests were also calculated. 
 
Between-laboratory reproducibility  
 
The BLR values reported in the VSR are based on the final classification for each test chemical in each 
participating laboratory, based on the arithmetic mean value obtained from three acceptable test 
run sequences.  
 
Concordance of classifications between laboratories and overall Standard Deviations were calculated 
based only on qualified tests for chemicals for which at least one qualified test per laboratory was 
available. 
 
The overall Standard Deviations for the study were calculated using all available test sequences.  
 
As mentioned above, only one laboratory reported test results for solid chemicals after protocol 
optimisation for solid chemicals: therefore there are no BLR values for the use of the optimised 
protocol (SOP V 8.0). 
 
Predictive capacity  
 
All qualified tests for each test chemical were used to calculate predictive capacity values.  
The calculations were based on the individual final prediction of each qualified test in each 
laboratory. 
The VMG conclusions and recommendations with respect to EpiOcular™ EIT are based upon an 
analysis of the initial round of testing, the post-optimisation testing data, and the additional analysis 
referred to at Section 1.4 and 10.1. 
 
The Cosmetics Europe Task Force Eye Irritation Report  
Phase 1: Qualification 
 
The Cosmetics Europe Report details out how the acceptance criteria for, and statistical evaluation 
of, the parameters (selectivity, precision, accuracy, carryover, matrix effect (RhT insert effect), 
stability and reproducibility) were derived and performed. 
 
Phase 2: Testing 
 
The ESAC WG’s analysis takes account of this not being a formal test method validation study. 
Section 2.8 of the Cosmetics Europe Report, “Statistical analysis”, provides only limited and basic 
information, and the ESAC WG comments are therefore based on the full text of the Cosmetics 
Europe Report and additional information provided during and after a presentation of details of the 
study given to ESAC WG at its meeting at ECVAM in March 2014. 
Regression analyses of all MTT formazan calibration curves were consistent with high intra- and 
inter-day reproducibility.  
 
For the main study HPLC/UPLC measurements, which were conducted in three laboratories, the low 
SD values obtained tend to confirm that the viabilities measured by the HPLC/UPLC systems qualified 
by the different laboratories were comparable in all of the laboratories. These SD values were well 
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below the SD values previously reported for RhT test method validation studies (Pfannenbecker et al, 
2013: Zuang et al, 2002; Kandárová et al, 2006: Spielmann et al, 2007) using OD-photometric 
determination of the endpoint. The Cosmetics Europe Report concludes the study results 
demonstrate a very high level of reproducibility between the participating laboratories measuring 
formazan in solvent extracts using HPLC/UPLC as an endpoint detection system. 
 
For consistency checking of the HPLC/UPLC measurements over time, the formazan extract samples 
from the in vitro eye irritation RhT test methods were analysed twice in one participating laboratory 
(Pierre Fabre Laboratories) and showed 100% concordance.  
 
To determine whether the tissue viability values obtained by the OD-photometric and HPLC/UPLC 
endpoint measurement systems were consistent, the difference between the values obtained by 
HPLC/UPLC analysis and in a repeated HPLC measurement were divided by 2 (See the Cosmetics 
Europe Report, Table 15). The values thus derived (0.0-2.55) also tended to confirm a high level of 
consistency with qualified HPLC system measurements separated by time. The HPC/UPLC values 
were consistently and marginally lower than those obtained by OD-photometry. 
 
The ESAC WG accepts that variations on these methods of assessing agreement between two test 
methods are commonly used. However the use of correlation for this purpose can be misleading, 
particularly when the true value of the variable of interest is unknown (Bland and Altman, 1986).  The 
ESAC WG has taken account of an alternative approach developed for use in these situations (see 
Section 7.1). 
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2. Collection of existing data 
NOTE: Validation studies typically make use of existing data, e.g. either as reference data (prospective 
studies) OR as reference data and testing data (retrospective study). Moreover, validation studies 
may use other information such as data in the literature, data banks etc. 
2.1 Existing data used as reference data 
Which data sources were used for compiling the reference data associated with the test chemicals?  
EIVS 
The VSR and annexes provide detailed information on this point. The VSR references and relies on an 
extensive collection of information generated before and during the development and pre-validation 
of the RhT test methods. 
The same chemicals were selected and used for the evaluation of the two RhT test methods - the 
EpiOcular™ EIT and SkinEthic™ HCE test methods for eye irritation testing. Eight additional solid 
chemicals were also tested in one laboratory using the EpiOcular™ EIT post-optimisation protocol for 
solid chemicals testing. 
An essential requirement for chemical selection was the availability of complete and quality assured 
supporting in vivo data to allow comparative evaluation of the predictive capacity of the RhT test 
methods as measured against in vivo (Draize eye test) reference method.  
 
Toxicological and physicochemical properties were important secondary considerations.  
 
Attempts were made to identify and avoid chemicals known to have been used to develop and 
optimise the test methods.   
 
The databases consulted included:  
 
1. ECETOC database of eye irritation reference chemicals. 
2. EC (DG-SANCO) Cosmetics Ingredients (CosIng) database.  
3. EC New Chemicals Database (NCD) of notified substances. 
4. ICCVAM (NICEATM) database of eye irritation reference chemicals.  
5. US EPA database of pesticide actives. 
 
The ESAC WG believes that, although there is some overlapping content, these are appropriate and 
authoritative sources; that is was not necessary to commission additional in vivo testing; and that 
there are insufficient high quality human data that might have been used as reference data.  
There are only limited reference data available for the identification of mixtures of chemicals that 
might have served as test chemicals for this study. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Two primary sources were used for selection of test substances: 
 
1. The chemicals repository of the EURL ECVAM / Cosmetics Europe EIVS. 
2. The Scientific Committee for Consumer Safety (SCCS) Memorandum (addendum) on the in 
vitro test EPISKIN™ for skin irritation testing (SCCS, 2010). 
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These sources provided data on potential test substances including nomenclature, physical 
characteristics, source and in vivo classification of irritant/corrosive effects.  
 
In addition, to ensure the identification of a sufficient number of suitable chemicals, similar 
information was sought on proprietary chemicals held by Cosmetics Europe member companies. 
 
The quality controls on the information contained in the two primary sources are known: the quality 
controls applied to the reference data obtained for the Cosmetics Europe member companies are 
not explained in the Cosmetics Europe Report. 
 
2.2 Existing data used as testing data 
Point 2.2 only concerns retrospective validation studies or modular studies combining existing and 
newly generated data to assess an assay. Which data sources were used to collect existing testing 
data? 
EIVS 
Not applicable. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Not applicable. 
 
2.3 Search strategy for retrieving existing data 
NOTE: Please describe and evaluate whether and how the search for existing data was planned, 
organised and conducted. In particular: has a search strategy been described and consistently 
applied? 
 
EIVS 
 
See Section 2.1 above. 
 
The reference data were used to identify a balanced chemical selection based on classified versus 
non-classified chemicals, solids versus liquids, and EPRA reactivity versus non-reactivity. 
 
An operational master-list was generated short-listing 160 potentially eligible and available 
chemicals. The selection criteria were then refined to select compounds for the study. 
 
The subsequent chemical selection was managed in two stages, first determining eligible and 
available substances for preliminary EPRA assessment (N=135); followed by a definitive short-list 
(N=107) for evaluation in the study taking the EPRA results into account. 
 
Statistical power analysis (sample size calculation) stipulated a minimum requirement of 26 classified 
chemicals and 26 non-classified chemicals for each protocol.  
 
The selection criteria then devised to produce the best balanced and most proportionate set of 
chemicals for the study were:  
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1. Classified versus non-classified chemicals was set at 50±5%.  
2. A 50/50 weighting of category 1 and category 2.  
3. Adequate representation of sub-categories 2A and 2B.  
4. For physical state, liquids versus solids, 50±10%. 
5. The division of reactive versus non-reactive was set with a wider margin at 50±15%.  
 
After a set of 104 chemicals were selected to meet the above statistical provisions a further two 
chemicals, both known to cause permanent ocular colouration in vivo, were added to give some 
insight into whether such chemicals could be evaluated by the RhT test methods and the 
measurement endpoints being applied. These 106 chemicals were coded and distributed to the 
laboratories involved in the ring trial. 
A known MTT reducer, potentially incompatible with the test method endpoint measure system, was 
then identified amongst these 106 chemicals. By the time a substitute chemical had been identified 
and distributed to the laboratories, testing of the MTT reducer had already been done. Therefore this 
additional chemical, original intended to be substituted for one of the 106 chemicals, brought the 
total number of EIVS chemicals tested in the ring trial to 107. 
The majority of the EIVS test chemicals were pure single constituent substances, each represented by 
a discrete molecular structure. However, the selection included eight polymers (three homo-
polymers, five co-polymers), four occurring in aqueous medium. The EIVS set also included 10 quasi-
polymers (eight occurring as aqueous liquids) 
There was an absence of other types of chemical mixtures.  
Following the ring-trial in vitro testing of the 107 chemicals, and after statistical evaluation of the 
results, the EpiOcular™ EIT protocol for solid chemicals was subject to further optimisation. The 
EpiOcular™ EIT protocol optimised for solids (SOP V 8.0) was then subject to post-optimisation 
evaluation in one laboratory, with repeat testing of all 52 EIVS solid chemicals, and an additional 
eight solid chemicals, increasing the total number of chemicals used within the EIVS to 115.The eight 
supplementary solids comprised two GHS category 1, three category 2A, one category 2B and two 
GHS unclassified chemicals. 
An unexpected problem arose during the study. Each test laboratory was to decide whether each test 
chemical was a liquid or a solid: materials which could not be pipetted at 37°C were to be deemed to 
be, and were to be tested as, solids. Chemical #37 was classified and tested as a liquid using the 
EpiOcular™ EIT during the ring-trial (the main part of EIVS) but as a solid during the validation of the 
EpiOcular™ EIT optimised solid chemicals protocol. This is believed to be due to seasonal factors and 
the way the chemical was handled between being taken from storage and tested. The VMG 
recommended that the SOP be amended to better define the protocol to be used for test chemicals 
with an unclear physical state, specifically that all viscous, waxy and gel-like chemicals are placed in a 
water bath for 15 minutes at 37°C before deciding if they should be tested with the liquids or the 
solids protocol; and that the test chemical should be applied directly from the water bath and should 
not be brought to room temperature before testing. 
The ESAC WG would offer one additional comment. In places the RhT SOPs refer to elements of the 
test methods being undertaken at “room temperature”: this is an imprecise term, we believe that an 
appropriate temperature range should be specified instead. 
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The Cosmetics Europe Task Force Eye Irritation Report 
The sources described at 2.1 above were used to identify data with respect to test substances 
meeting the pre-defined primary selection criteria (see below). 
 
ESAC WG notes that no skin corrosive chemicals were included in the chemicals selected. This is 
discussed at Section 6.2 below. 
 
2.4 Selection criteria applied to existing data 
NOTE: Have consistent evaluation and decision criteria been pre-defined and applied in order to select 
the data and has the selection of data been explained in a transparent manner? 
EIVS  
See above 
 
The Cosmetics Europe Task Force Eye Irritation Report 
This section is not applicable to this study. The criteria applied to select the most appropriate 
chemicals are discussed elsewhere in this report. 
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3. Quality aspects relating to data generated during the study 
3.1 Quality assurance systems used when generating the data 
NOTE: Have quality assurance systems such as GLP (Good Laboratory Practice) or GCCP (Good Cell 
Culture Practice) been used when generating the data? 
EIVS  
 
Although five of the six laboratories that undertook the RhT testing are GLP accredited, all worked to 
the “spirit of GLP”, with no laboratory conducting the testing in compliance with the full GLP 
requirements. 
 
The VMG determined the minimum essential quality assurance requirements to be applied by all 
participating laboratories based on Balls et al, 1995. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Neither the RhT testing, nor the HPLC/UPLC measurements were performed to full GLP requirements 
 
3.2 Quality check of the generated data prior to analysis 
NOTE: Have the generated data been checked for quality including correct formatting (-> data 
reporting) prior to analysis. Has the quality check been performed by a staff member independent 
from the laboratory staff generating the data? 
EIVS 
Details of the data management procedures and statistical tools used for data analysis are included 
in the final biostatistics reports and the Guidance document on the conduct of the EIVS and in a 
Statistical Analysis and Reporting Plan.  
The biostatistics analysis procedures reported in the EIVS Statistical Analysis and Reporting Plan were 
developed by EURL-ECVAM and TNO biostatisticians before completion of the ring-test phase of the 
study, and approved by the VMG before the biostatistical analysis began. 
All laboratories conducting the RhT test methods used standard data-capture templates developed 
by the lead laboratory and approved by the VMG. The results of each run were entered by the 
technicians: these were checked against the raw data by the study director before the templates 
were forwarded to an independent statistician who compiled the results in an evaluation template: 
the evaluation template was then reviewed by the study directors. 
An independent statistician calculated the reliability and predictive capacity values using the error 
checked evaluation template, and these calculations were then separately reviewed by an EURL-
ECVAM biostatistician. 
All statistical reports were then quality checked by the VMG. 
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The Cosmetics Europe Task Force Eye Irritation Report 
Similar systems were applied to both Phases of the study, using data-capture templates developed 
by the Cosmetics Europe Eye Irritation Task Force.  
Raw data were entered by the technician performing the test/analysis. These data were error 
checked by the local study director prior to the data being submitted to the study organiser before 
being entered into an evaluation template which was then error checked before the final evaluation 
was performed.  
 
 
4. Quality of data used for the purpose of the study (existing and 
newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
NOTE: Please describe the quality of the testing data. This may concern data newly generated in the 
context of the study and/or existing data (e.g. in case of retrospective or modular studies). 
EIVS 
SkinETHIC™ HCE 
For SkinETHIC™ HCE the number of acceptable test run sequences was high (100% for the SE protocol, 
99.7% for the LE protocol). The minimum acceptance criterion set by the VMG for this characteristic 
was fulfilled (≥ 85%). 
The ESAC WG therefore concludes that the reported performance of the SkinEthic™ HCE was based 
on high-quality data.  
EpiOcular™ EIT 
99.7% of test runs met the validation study acceptance criteria (≥ 85%), therefore the ESAC WG 
concludes that the validation of the EpiOcular™ EIT was based on high-quality data.  
The only data gap is for chemical #33 which one laboratory considered to be incompatible with the 
test method due to colour interference with the MTT assay: that chemical was therefore excluded 
from the statistical analysis for that laboratory.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
The testing data for both phases of the study is almost complete. 
ESAC WG believes the data are of high quality. 
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4.2 Quality of the reference data for evaluating relevance2 
NOTE: What is the quality of the reference data used? Are the data and their quality sufficient in view 
of the study objective? To which extent has the quality of the reference data impacted on the 
conclusions drawn reg. performance of the assay studied? 
EIVS 
See Section 4.1 for in vitro data and Section 2 for the in vivo reference data. The data used is 
considered to be the best available Draize eye test reference data for the chemicals tested by both 
RhT test methods. The limitations of DET data are discussed at Section 14. 
The Cosmetics Europe Task Force Eye Irritation Report 
Reference data was used only to identify and characterise the chemicals selected for use in the study. 
4.3 Sufficiency of the evaluated data in view of the study objective 
NOTE: Having considered the quality of the testing data (section 4.1) and reference data (section 4.2), 
consider here whether the quality of the entire data set was sufficient to draw robust conclusions? 
EIVS 
SkinETHIC HCE 
For SkinEthic™ HCE the number of acceptable test run sequences was high (100% in total for the SE 
protocol, 99.7% in total for the LE protocol). 
ESAC WG concludes that the reported performance of the SkinEthic™ HCE to date has been based on 
high-quality data. The acceptance criterion set by the VMG for this characteristic was fulfilled (≥ 85%). 
EpiOcular™ EIT 
99.7% of test runs met the validation study acceptance criteria (≥ 85%), therefore the ESAC WG 
concludes that the validation of the EpiOcular™ EIT was based on high-quality data.  
However, the ESAC WG believes (see Section 9.1) it would have been better to conduct a formal 
three-laboratory study to evaluate the performance of the EpiOcular™ EIT optimised for solids 
protocol (SOP V 8.0). 
The Cosmetics Europe Task Force Eye Irritation Report 
ESAC WG believes all of the reference and new data relied upon in the study report are of sufficient 
quality and quantity bearing in mind the nature and objectives of the study. 
HPLC/UPLC data obtained for 24 of the 26 chemicals were evaluated. The two exceptions were for 
technical reasons: for chemical #7 insufficient test material was available (the Cosmetics Europe 
2
 OECD guidance document No. 34 on validation defines relevance as follows: "Description of relationship of the 
test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to 
which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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Report provides no explanation for this) and for chemical #26 there was a technical problem with the 
HPLC/UPLC column.  
Eye Irritation 
Chemicals #10 and #21 were found, using the acceptance criteria set out in the RhT SOPs, to be 
incompatible with the measurement of formazan by OD-photometry in the RhT test method. 
HPLC/UPLC data were obtained for these chemicals. 
Skin Corrosion 
Chemicals #21 and #26 were found, using the acceptance criteria set out in the SOP, to be 
incompatible with the measurement of formazan by OD-photometry in the RhT test method: cell 
viability was measured by the HPLC/UPLC system.  
Skin Irritation 
With respect to the HPLC/UPLC full data are available for 25 of the 26 chemicals: the one exception, 
chemical #26, was due to a technical problem with the HPLC/UPLC column. 
Chemicals #10, #11, #21 and #22 were found, using the acceptance criteria set out in the SOP, to be 
incompatible with the measurement of formazan by OD-photometry in the RhT test method. 
HPLC/UPLC data were obtained. 
 
 
5. Test definition (Module 1) 
5.1 Quality and completeness of the overall test definition  
NOTE: This included an analysis of the description of the (a) test system, (b) the protocol, (c) test 
acceptance criteria, (d) prediction models, (e) biological and/or mechanistic relevance of the test 
method for the target organ/species/system etc. 
 
EIVS  
 
SkinEthic™ HCE Test 
 
The SkinEthic™ HCE test method is based on RhT technology; the test material (solid or liquid 
chemicals) is applied directly to the air-tissue interface, and the eye irritation potential of the 
chemical is derived from a prediction model based on percentage tissue viability (adjusted against a 
negative control) as estimated by OD-photometry of the MTT reduction product formazan.   
 
The tissue component of the test kit is manufactured by controlled culture of immortalised human 
corneal epithelial cells in a chemically defined medium to produce a multi-layered epithelium similar 
to in vivo corneal epithelium with columnar basal cells, wing cells and squamous cells. The model is 
also characterised by the presence of relevant ultra-structural features (such as intermediate 
filaments, mature hemi-desmosomes and desmosomes) that characterise the corneal epithelium in 
situ. Specific cytokeratins 64kD (K.3) have also been described (Nguyen D.H. et al, 2003). 
 
The protocol for the SkinEthic™ HCE test method described the following testing paradigms: 
  
(1) The first step was an "Eye irritation Peptide Reactivity Assay" (EPRA).  This was done in 
laboratory before chemical selection was finalised. Depending on the chemical reactivity 
measured in this initial EPRA, the next step would be: 
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(2) For EPRA reactive chemicals the SkinEthic™ HCE Short-time Exposure protocol (HCE SE).  
 
(3) For EPRA non-reactive chemicals the SkinEthic™ Long-time Exposure protocol (HCE LE). 
 
However, for the purposes of the EIVS study all chemicals were tested using both the HCE SE and HCE 
LE protocols. 
 
The essential differences between the SkinEthic™ HCE Short-time Exposure protocol (HCE SE) and the 
SkinEthic™ Long-time Exposure protocol (HCE LE) were the length of time the air-tissue interface is in 
contact with the test material (the exposure time) and the presence or absence of a post-exposure 
incubation phase. The HCE SE used a 10 min exposure without post-treatment incubation, while the 
HCE LE was based on 1 h exposure followed by 16 h post-treatment incubation.  
 
Following treatment with a test chemical the relative tissue viability was determined against the 
negative control value by the reduction of the vital dye MTT to formazan as measured by OD-
photometry. Tissues treated with chemicals inducing eye irritation or serious eye damage (UN 
GHS/EU CLP Category 2 or Category 1, respectively) were expected to show a decrease in tissue 
viability below a specified threshold in comparison to the negative control. 
 
The histological and ultra-histological features of the test system, and the use of similar endpoints 
and endpoint detection systems within RhT systems validated for other toxicological endpoints, 
made it plausible that this test RhT system may provide insights into the likely eye irritancy potential 
of chemicals. 
 
Although derived from cultured human corneal cells, ESAC WG notes that the cells used have been 
transformed and immortalised. The ESAC WG offers no opinion on whether these cells are inherently 
more biologically relevant in this context than other epithelial cells (e.g. RhT models derived from 
normal untransformed human keratinocytes).  
 
EpiOcular™ EIT 
 
The EpiOcular™ tissue construct is prepared from normal human-derived epidermal keratinocytes 
grown under defined conditions. The VSR does not state if this is done in compliance with Good Cell 
Culture Practice. 
 
The resulting 3D tissue is a non-keratinized multi-layered (5-8 cell layers) and stratified (but non-
cornified) epithelium intended to model properties of human corneal epithelium.  
 
Test materials (solid and liquid chemicals) are applied directly to the epithelial surface, which is itself 
in direct contact with the air. Applying chemicals directly to the air-interface of the epithelial surface 
mimics in vivo exposure of the corneal epithelium.  
 
In the EpiOcular™ EIT, liquids and solids were applied using protocols specifying different exposure 
and post-exposure incubation times: 
  
1. Liquid chemicals - 30 min exposure followed by 120 min post-treatment incubation. 
  
2. Solid chemicals - in the original protocol (SOP V6.0) for solids - 90 minute exposure followed 
by 18 hours post-treatment incubation. 
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3. For the optimised protocol solids (SOP V 8.0) - the exposure time for solid chemicals was six 
hours with the post-treatment time unchanged.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
Although this was not a validation study of the RhT test methods used, the Cosmetics Europe Report 
provides summary details of the RhT test methods. 
The Report provides a detailed description of how HPLC/UPLC was suitably-validated (FDA, 2001) as 
an endpoint measurement for the quantification of formazan generated by RhT test methods reliant 
on the quantification of formazan as the endpoint measurement. 
The ESAC WG notes that as yet there has been no paper on this study published in the peer-reviewed 
scientific literature. 
 
5.2 Quality and completeness of the documentation concerning SOPs and prediction 
models 
NOTE: Are the SOPs sufficiently detailed and complete? Are the prediction models sufficiently well 
explained to be applied in the correct manner? 
 
EIVS 
The lead laboratories were responsible for preparing detailed SOPs for the EpiOcularTM EIT, SkinEthicTM 
HCE SE/LE and EPRA in collaboration with the test method developers. 
The ESAC WG notes that the EpiOcular™ EIT and The SkinEthic™ SOPs require the use of different 
extractants to obtain the samples used for formazan quantification. The reasons for this are not clear 
from the study documents.  
The SkinEthic™ 
The SOPs used during the practical testing phase of EIVS were approved by the VMG. 
The SOPs were clearly written, and the testing was performed by the three laboratories without 
difficulty. 
The one reported problem with obtaining acceptable test run sequences occurred in the training and 
transfer phase and was believed to relate to damage to test kits in transit. 
The Prediction Models are clearly described in the VSR. Within the study the Prediction Model was 
applied by a statistician using test data generated by the participating laboratories. 
EpiOcular™ EIT 
All of the protocols and SOPs used within EIVS were clear and well-written. 
The protocol changes are explained, justified and documented in the VSR and supporting documents. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
This was not a formal validation study, rather it was an assessment of the performance of a qualified 
bio-analytical system. SOPs for the use of the HPLC/UPLC systems were not prepared or required for 
the study. 
The SOPs used for the RhT test methods were as follows: 
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1. EpiOcular™ EIT as per OECD the EIVS protocol v6.0 for eye irritation (a version of the SOP 
which pre-dated the optimisation of the test method for solid chemicals within EIVS). 
2. SkinEthic™ RHE as per OECD TG 431  
3. EpiSkin™ as per OECD TG 439  
 
 
6. Test materials 
6.1 Sufficiency of the number of evaluated test items in view of the study objective 
NOTE: Is the number of test items sufficient in order to draw conclusions with respect to the objective 
of the study? If not, are there reasons for deviations and are these explained and justified? 
EIVS 
See 2.3 above. 
The statistical basis for the number of chemicals used is explained in the VSR and related annexes. 
Almost complete data sets were obtained in all laboratories, for all test methods, and with all 
chemicals. 
The ESAC WG believes the number of test chemicals was appropriate with respect to the study 
objectives, and the conclusions drawn by the VMG. 
EpiOcular EIT 
A total of 19 of the chemicals used for the ring trial and supplementary testing using the optimised 
for solids protocol had been used for the development and optimisation of the EpiOcular EIT using 
earlier test method SOPs (all of which pre-dated the optimisation of the protocol SOP V 6.0 used for 
the testing of solid chemicals within EIVS). For 17 of these 19 chemicals the results obtained in the 
EIVS study were consistent with the findings obtained by the manufacturer during test method 
development and optimisation.  
Based on the results of the initial ring trial with SOP V 6.0, the 11 chemicals used within EIVS for 
optimising the EpiOcular EIT protocol for solid chemicals were challenging.   
All 52 EIVS solid chemicals, and an additional eight solid chemicals, were retested in one laboratory 
using only the EpiOcular EIT optimised for solids protocol. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC WG believes that the 26 chemicals selected were adequate for this study, but notes that no 
skin corrosives were included in the test chemicals. 
In coming to this conclusion the ESAC WG has taken account of: 
 The primary and secondary criteria applied to ensure the chemicals selected were balanced 
and proportionate with respect to the aims of the study.  
 Some of the chemicals would not be testable in some or all of the chosen RhT test methods. 
These chemicals are discussed elsewhere in this report. 
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Using the primary and secondary selection criteria for chemical selection 24 different chemicals were 
identified using the sources listed at 2.1 above. Two of these chemicals were identified, on the basis 
that they are known to interfere with the OD-photometric determination of formazan, and tested 
both neat and diluted to 1% (w/v) aqueous. These chemicals and dilutions comprised the 26 test 
materials used for the study. 
 
Seventeen of the chemicals were from the EIVS chemicals repository, two from the SCCS 
Memorandum (addendum) on the in vitro test EpiSkin™ for skin irritation testing (SCCS, 2010), four 
from proprietary sources (excluding EIVS proprietary sources), and one from a general source. 
 
6.2 Representativeness of the test items with respect to applicability 
NOTE: Describe how suitable the selected test items are in order to gain – through empirical testing 
during the study – insight into the applicability domain / limitations of the test method. 
EIVS 
The EIVS chemicals were intended to be representative of the full range of chemicals for which in 
vivo test data are still required. The selection process and criteria are described above. 
The ESAC WG notes the difficulty of finding chemical mixtures (other than polymers, co-polymers, 
and quasi-polymers) as test chemicals for validation studies. Confidence in the performance of the 
test methods would have been enhanced had a wider range of chemical mixtures been available and 
used – for example chemical mixtures which had already been assessed and labelled as eye irritants 
or non-irritants, e.g. by using the additivity method in accordance with  GHS or CLP. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Details of the test substances including nomenclature, physical characteristics, source and in vivo 
identification of irritant/corrosive effects are shown in Table 2 of the Cosmetics Europe Report. Table 
9 confirms that these test substances were balanced according to the pre-defined selection criteria. 
 
In line with the objectives of the study, and consistent with other elements of the study design, the 
primary classes of chemicals were: 
 
1. Coloured chemicals anticipated to produce colour interference of formazan detection using 
OD-photometry.  
2. Coloured chemicals not anticipated to produce colour interference of formazan detection 
using OD-photometry. 
3. Non-coloured chemicals. 
 
Physical form was not a primary selection criterion, but attempts were made to ensure that the 
chemical set was balanced and representative with respect to physical form (solid and liquid 
chemicals).  
 
The ESAC WG notes that with respect to the toxicological endpoints relevant to the RhT test methods 
used for this study: 
1. The chemicals selected were intended to cover entire viability range (0-100%) for the in vitro eye 
irritation RhT test method. 
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2. There were no skin corrosives included in the chemicals set. The Cosmetics Europe Report offers 
a plausible explanation for this. Recent OECD analyses (Alépée et al, 2014a and 2014b) identified 
no in vivo corrosive chemicals which were coloured chemicals.  
 
2.1. The ESAC WG believes that the study would have been more robust had the test chemicals 
set also included one or more non-coloured skin corrosive chemical.  
 
 
7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory 
NOTE: How was variability and reproducibility within laboratories assessed? Possible parameters to 
study are (a) intrinsic data variability e.g. between replicates or runs; (b) concordance in predictions 
between replicates or runs. Regarding point (b), consider whether reproducibility and repeatability 
have been assessed separately. [repeatability = agreement of test results (same substance, identical 
conditions, e.g. equipment, operator etc.) while reproducibility = agreement of test results (same 
substance, same protocol, but not under identical conditions, e.g. different operator). 
EIVS 
SkinEthic 
The results presented in the VSR, based on the results of successfully completed test sequences 
(100% for the SE protocol, 99.7% for the LE protocol) for the SkinEthic™ HCE SE and LE protocols, 
tend to confirm high reproducibility. 
The reported within-laboratory reproducibility was 93.9% concordance of classification for the SE 
protocol, and 95.5% for the LE protocol. 
The SkinEthic™ HCE test method was found to be highly reproducible. The within-laboratory 
reproducibility (WLR) (93.9% and 95.5% concordance of classifications for the SE and LE, respectively) 
and the between-laboratory reproducibility (BLR) (92.3% concordance of classifications for both the 
SE and LE protocols) were significantly above the acceptance criteria set by the VMG (WLR ≥ 85% and 
BLR ≥ 80%). 
 
EpiOcular™ EIT 
Based on the results for the complete test sequences (99.7%), and using the SOP optimised for solid 
chemicals (V 8.0), the EpiOcular™ EIT test method was highly reproducible. Using the method of 
analysis set out in the VSR the WLR was 93.6% (50% cut off) and 95.2% (60% cut off).  
The basis, and possible limitations, of these calculations are described elsewhere in this report (for 
example, Section 1.4). The ESAC WG, having analysed the data set out in the statistical reports 
estimates the 95% Confidence Interval (95%-CI) for the WLR using the 60% cut off to be 89.0% to 
94.4%. 
The WLR of the EpiOcular™ EIT optimised for solid chemicals protocol (SOP V8.0) at the one 
laboratory that conducted this supplementary testing improved when using the protocol optimised 
for the testing of 60 solid chemicals, with a reported WLR of 93.6% concordance of classifications for 
the 50% cut-off Prediction Model, and 95.2% concordance of classifications for the 60% cut-off 
Prediction Model.  
All of these values are significantly above the acceptance criterion set by the VMG (WLR ≥ 85%).  
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The VSR gave separate consideration to the two sets of data generated by the one laboratory that 
tested the solid chemicals using both the original (SOP V6.0) and the “optimised-for-solids” protocol 
(SOP V8.0). Forty nine (49) chemicals were common to the two datasets. Using these to calculate the 
concordance of classifications obtained by the laboratory, the WLR values derived are 91.8% (with 
the 50% cut-off) and 95.9% (with the 60% cut-off) for the optimised protocol SOP V8.0), and 91.8% 
(with 50% cut-off) and 93.9% (with the 60% cut-off) for the original protocol (SOP V6.0). 
Again, all of these values are significantly above the acceptance criteria set by the VMG (WLR ≥ 85%). 
 
 
The Cosmetics Europe Task Force Eye Irritation Report 
During the Phase 1 (qualification) reproducibility was addressed with both intra- and inter-day 
evaluations of the formazan calibration curve (reference materials having been prepared by serial 
dilution): three times on the same day with different stock solutions for intra-day reproducibility and 
repeating the calibration curve. Very high intra- and inter-day reproducibility was confirmed by 
regression analysis. 
 
To evaluate intra-laboratory performance during Phase 2 (testing) the Pierre Fabre Laboratories 
undertook two separate HPLC/UPLC endpoint measurements of the same  EpiOcular™ eye irritation 
formazan samples. The datasets confirm the results were 100% concordant. 
Whilst the ESAC WG accepts that variations on these means of assessing agreement between two 
test methods are commonly used, the use of correlation for this purpose can be misleading and make 
it difficult to recognise differences, and the significance of the differences, between the findings with 
the different measurement systems, particularly when the true value of the variable of interest is 
unknown (Bland and Altman, 1986).   
ESAC WG has taken account of an alternative approach (Bland and Altman, 1986) developed for use 
in these situations (see Section 1.4) and has re-analysed the data for the results with 12 chemicals 
obtained by the Pierre Fabre Laboratory using the EpiOcular™ EIT test method (a subset of VSR Table 
15). The Bland-Altman Plot reproduced below plots for each chemical the difference between the 
OD-photometry and HPLC/UPLV values (Y-axis), against the average (arithmetical mean) of the OD-
photometry and HPLC/UPLC value (X-axis).  
Assuming that this sample is representative of the three RhT methods and the chemicals tested the 
plot also tends to confirm  that the limits of agreement are good. 
The plot also shows that the HPLC/UPLC values values are systematically, marginally lower than the 
OD-photometry: this suggests that HPLC/UPLC measurements, when judged against formazan levels 
estimated by OD-photometry, may slightly under-estimate the level of cytotoxicity.  
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7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
NOTE: Are the conclusions on within-laboratory variability and repeatability reproducibility justified 
by the data as evaluated? 
EIVS 
The SkinEthic™ HCE  
The statistical methods and findings are summarised above. 
The SkinEthic™ HCE test method was found to be highly reproducible within laboratories.  
The acceptance criterion for within-laboratory reproducibility (WLR ≥ 85%) set by the VMG was met, 
with the values obtained being significantly above the acceptance criteria set by the VMG. 
EpiOcular™ EIT 
The EpiOcular™ EIT test method was found to be highly reproducible within laboratories, with all of 
the protocols used, and endpoints applied, in the course of the study reported in the VSR.  
All of the BLR values discussed above are significantly better than the minimum acceptance (WLR ≥ 
85%) criterion set by the VMG.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
The ESAC WG believes the reported within-laboratory results are consistent with the findings 
expected from an evaluation of a suitably qualified bio-analytical endpoint measurement system. 
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8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
NOTE: Was the transfer phase appropriately planned, e.g. were there transfer instructions, training, 
minimum requirements, training SOP (if appropriate)? Were evaluation / decision criteria established 
beforehand defining successful transfer? If so, were these consistently applied during the analysis? 
EIVS 
SkinEthic™ HCE 
The two naïve laboratories participating in the validation of SkinEthic™ HCE were trained by the lead 
laboratory (L'Oréal). Suggestions for improvement and clarification of the SOP were implemented by 
L'Oréal in the final version of the SOP used in the ring trial of the validation study.  
 
Training and proficiency testing was done with 14 coded test chemicals: these included colourants 
and direct MTT reducers. 
 
The variability obtained with both the SE and LE protocols at the three laboratories was low, and 
concordance between results of the three laboratories was high. 
 
ESAC WG agrees with the VMG that the participating laboratories demonstrated adequate 
proficiency in performing the SkinEthic™ HCE and readiness to enter the formal validation study. 
 
EpiOcular™ EIT 
The three participating laboratories were trained by the manufacturer (MATTEK Corporation) to 
assure optimal transfer of the test protocol into their facilities and to ensure that the SOP did not 
allow for differing local-interpretations of the experimental steps.  
After training, the participating laboratories were required to demonstrate proficiency in performing 
the EpiOcular™ EIT and readiness to enter the formal validation study. The technicians undertaking 
the testing worked with eight coded proficiency chemicals. All test chemicals were consistently 
predicted by the three laboratories. The variability in the findings produced by individual operators 
was low: using the 60% cut-off in the prediction model, one liquid chemical was predicted differently 
by one operator in one laboratory. 
Suggestions for improvement and clarification of the SOP were implemented in the SOP (V6.0) that 
was used in the ring trial of the validation study.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
No transfer phase was necessary.  
Each laboratory undertaking the HPLC/UPLC endpoint measurement used its own suitably-qualified 
HPLC/UPLC system, and also had experience using the equipment for other purposes. 
Each laboratory performing the RhT test methods was already experienced in their use.   
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8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as assessed by 
the study 
NOTE: Are the conclusions justified by the data generated? Have critical issues that may impact on 
transferability been identified? 
EIVS 
SkinEthic™ HCE SE and LE 
Based on the reported BLR and WLR findings, the ESAC WG agrees with the conclusions of the VMG 
that the SkinEthic™ HCE SE and LE protocols proved to be easily transferable between properly 
equipped and staffed laboratories, including those having no prior experience in performance of 
similar test methods (i.e. the two naïve laboratories that participated in the study).  
 
Experienced personnel can readily be trained in the test method, and the necessary equipment and 
supplies can be readily obtained. 
 
The ESAC WG believes that transferability should be re-confirmed if an optimised SkinEthic™ HCE 
model and protocol are validated. 
 
EpiOcular™ EIT 
The ESAC WG agrees with the VMG that the highly reproducible and accurate results obtained 
between operators and laboratories in the EpiOcular™ EIT transfer study demonstrated the 
transferability of the test method to naïve laboratories. 
 
 
The Cosmetics Europe Task Force Eye Irritation Report  
Not applicable to this study. 
 
 
9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
NOTE: How was variability and reproducibility between laboratories assessed? Possible parameters to 
study are (a) intrinsic data variability; (b) concordance in predictions between laboratories. 
EIVS 
 
SkinEthic™ HCE SE and LE protocols 
The BLR figures reported in the VSR, derived from the results for the fraction of complete test 
sequences (100% for the SE protocol, 99.7% for the LE protocol), tend to confirm that the SkinEthic™ 
HCE SE and LE protocols are highly reproducible between laboratories.  
The BLR reported 92.3% concordance of classification for both SE and LE protocols. These values are 
significantly above the acceptance criteria set by the VMG (BLR ≥ 80%). 
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EpiOcular™ EIT 
As testing using the EpiOcular™ EIT protocol optimised for the testing of solid chemicals (SOP V8.0) 
was only undertaken by one laboratory, a three laboratory BLR calculation is only available for the 
use of the original protocol and SOP (V6.0) and the original 107 test chemicals. 
 
On that basis the EpiOcular between-laboratory reproducibility (BLR) was reported as 91.3% and 
93.3% concordance of classifications for the 50% and 60% cut-offs analysed in this study. 
 These values are significantly above the acceptance criteria set by the VMG (BLR ≥ 80%).  
There was no between laboratory study conducted using the optimised protocol for solids (SOP V8.0), 
the only BLR data provides is based on data generated using (SOP V6.0). The ESAC WG believes 
confidence in the revised protocol would have been strengthened had such a three laboratory study 
been conducted.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
This was not a conventional BLR study. Each laboratory measured formazan levels by suitably 
qualified HPLC/UPLC systems – but the technical specification of the HPLC/UPLC systems varied 
between laboratories. 
Three laboratories each analysed all the formazan extracts prepared from the RhT test methods used 
to test the chemicals within this study, having suitably qualified their HPLC/UPLC systems. The 
laboratories that conducted the RhT tests measured formazan levels using the OD-photometric 
endpoint described in the SOP for the RhT test methods. 
 
Eye Irritation 
The low SD values calculated from the HPLC/UPLC results obtained by the three laboratories 
demonstrate that the cell viabilities derived from the HPLC/UPLC measurements in each of the 
participating laboratories were comparable. The SD values were lower than the values normally 
associated with endpoint measurement by OD-photometry using the same RhT test methods. 
 
In the view of ESAC WG the results detailed in the Cosmetics Europe Report demonstrate a very high 
level of reproducibility between the participating laboratories when measuring formazan solvent 
extracts from the EpiOcular™ EIT test method using HPLC/UPLC as an endpoint detection system. 
 
However, the OD-photometry values are systematically, marginally higher than the HPLC/UPLC 
values: this suggests that HPLC/UPLC measurements, when judged against formazan levels estimated 
by OD-photometry, may slightly under-estimate the underlying level of cytotoxicity. 
 
The HPLC/UPLC data were also compared to the OD-photometry data obtained during the study. 
Regression analysis of that for the 22 chemicals for which appropriate data were available confirmed 
a 91% concordance between measurement of the formazan extract samples by OD-photometry and 
HPLC/UPLC. This is also presented as evidence that the endpoint measurement using OD-photometry 
or HPLC/UPLC was consistent within the participating laboratory that performed the in vitro test 
method.  
 
For the 21 tests substances where viability measurements could be derived from both OD-
photometry and HPLC analysis there was 100% concordance. 
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Skin Corrosion 
The low SD values calculated from the HPLC/UPLC results obtained by the three laboratories 
demonstrate that the cell viabilities derived from the HPLC/UPLC measurements in each of the 
participating laboratories were comparable. The SD values were lower than the values normally 
associated with endpoint measurement by OD-photometry. 
 
In the view of ESAC WG the results detailed in the Cosmetics Europe Report demonstrate a very high 
level of reproducibility between the participating laboratories measuring formazan solvent extracts 
from the SkinEthic test method using HPLC/UPLC as an endpoint detection system. 
 
The HPLC/UPLC data were also compared to the OD-photometry data obtained during the study. 
Using the prediction model set out in the RhT test method SOP classification as Corrosive or Non- 
Corrosive was determined from the viability values obtained by both OD-photometry (by the 
laboratory that performed the in vitro test method) and HPLC/UPLC (outcome from the three 
laboratories). Comparison of the classification by OD and HPLC/UPLC identified 100 % concordance 
for all test substances for which measurements could be made in both endpoint detection systems. 
 
Skin Irritation 
The low SD values calculated from the HPLC/UPLC results obtained by the three laboratories 
demonstrate that the cell viabilities derived from the HPLC/UPLC measurements in each of the 
participating laboratories were comparable. The SD values were lower than the values normally 
associated with endpoint measurement by OD-photometry. 
 
In the view of ESAC WG the results detailed in the Cosmetics Europe Report demonstrate a very high 
level of reproducibility between the participating laboratories of measuring formazan solvent 
extracts from the EpiOcular™ EIT test method using HPLC/UPLC as an endpoint detection system. 
 
The HPLC/UPLC data was also compared to the OD-photometry data obtained during the study. 
Regression analysis, having removed the four chemicals referred to at 4.3 above, of the findings for 
the remaining 21 chemicals for which appropriate data were available confirmed a 100% 
concordance between measurement of the formazan extract samples by OD-photometry and 
HPLC/UPLC. This is also presented as evidence that the endpoint measurement using OD-photometry 
or HPLC/UPLC was consistent within the participating laboratory that performed the in vitro test 
method.  
 
 
9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
NOTE: Are the conclusions justified by the data generated? 
EIVS  
 
SkinEthic™ HCE SE and LE protocols 
The BLR acceptance criterion (BLR ≥ 80%), as established by the VMG, was fulfilled. 
The SkinEthic™ HCE test method was found to be highly reproducible. 
 
EpiOcular™ EIT 
The BLR acceptance criterion (BLR ≥ 80%), as established by the VMG, was fulfilled using SOP V6.0. 
The EpiOcular™ EIT test method, using the original study protocol (V6.0), was found to be highly 
reproducible between laboratories.  
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No BLR value is available for SOP V8.0.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
The Cosmetics Europe Report concludes that for test substances that do not exhibit colour 
interference nor direct MTT reduction, the viability values obtained are almost identical whether 
using absorbance (OD-photometry) or HPLC/UPLC as the endpoint detection system for 
measurement of formazan, with the OD-photometry values being consistently, marginally above the 
values obtained with the HPLC/UPLC test method. 
 
 
10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the purpose 
NOTE: How was the predictive capacity assessed? Where the reference data used in an appropriate 
manner? Are the conclusions justified based on the data evaluated and in view of the test method's 
purpose? 
EIVS 
The ESAC WG believes that the VMG’s determination of confidence limits for the predictive capacity 
based on the number of test runs, rather than the number of chemicals tested, produces confidence 
limits which may be inappropriately narrow.  
Furthermore, the ESAC WG considers that the accuracy figures should reflect the way decisions will 
be made in practice. Specifically, as chemical classification will be based upon one qualifying test run, 
the study results should have been evaluated to produce an accuracy range determined by the best 
and worst cases based on data from single runs rather than aggregating data from different test runs 
with the same chemical. 
The ESAC WG requested additional analysis with confidence limits derived from the number of 
chemicals tested rather than the number of test runs, and accuracy values based on the base-
case/worst-case combinations of individual test runs. See Section 1.4. 
 
SkinEthic™ HCE 
 
The same prediction model was used to evaluate the predictive capacity of both the SE and LE 
protocols. A mean estimated tissue viability of 50% was used as the threshold differentiating 
classified (UN GHS Category 1 and Category 2) from non-classified (UN GHS No Category) chemicals. 
 
The predictive values obtained with the SkinEthic™ HCE protocol are summarised in the VSR as: 
 
1. SE: 89% specificity, 43% sensitivity and 66% overall accuracy. 
 
2. LE: 66% specificity, 72% sensitivity and 69% overall accuracy. 
 
3. Test Strategy with EPRA (Reactive  SE; Non-Reactive  LE): 77% specificity, 55% sensitivity 
and 66% overall accuracy. 
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The SkinEthic™ HCE, SE and LE protocols, failed to meet the 'definitely acceptable' criteria for 
sensitivity and overall accuracy defined by the VMG (specificity ≥ 60%; sensitivity ≥ 90%, overall 
accuracy ≥ 75%) for any of the options above. 
 
The SkinEthic™ HCE sensitivity, as judged by the criteria (specificity < 50%; sensitivity < 80%, overall 
accuracy < 65%) by the VMG, was 'definitely unacceptable' 3. 
 
The pre-study rationale for different LE and SE exposures based on chemical reactivity was not 
confirmed, indeed this component of test method optimisation may have contributed to the 
identification of a number of Category 1 substances as non-irritants.   
 
The use of EPRA data to assign chemicals to an LE (for EPRA non-reactive chemicals) or SE protocol 
(for EPRA reactive chemicals) was found to be not useful, and the ESAC WG agrees with the VMG 
decision not to conduct a reproducibility assessment of EPRA data. 
 
EpiOcular™ EIT 
The means by which the values reported in the VSR were calculated are described above, and the 
results are summarised in the table immediately below. 
 50 % cut-off 60% cut-off 
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity 
(A) Results obtained during main study (before optimization of solids protocol) 
(1) Liquids 
82.5% 96.2% 69.8% 81.9% 98.3% 
66.7% 
 
(2) Solids  
73.0% 66.7% 79.7% 75.9% 76.9% 
74.8% 
 
(3) Liquids 
and solids  
 
77.9% 81.4% 74.5% 79.0% 87.6% 70.5% 
(B) Results obtained through post-optimisation testing (solids) and during main study 
(liquids) 
(4) Solids 
 
76.8% 88.2% 64.3% 78.0% 93.5% 60.7% 
(5) Liquids 
and solids  
 
79.4% 91.8% 66.5% 79.7% 95.7% 63.0% 
 
The VMG 'definitely acceptable' criteria for specificity, sensitivity and overall accuracy were - 
specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy ≥ 75%.  
 
Looking first at the data generated by testing 107 chemicals with the original ring trial using SOP 
V6.0: 
1. Using the 50% cell viability cut-off:  74.5% specificity, 81.4% sensitivity and 77.9% overall 
accuracy values were reported when considering all chemicals, irrespective of physical state 
(solid/liquid).  
                                                 
3
 The VMG set used an unusual convention to assign acceptable values: they devised a three category system – 
“definitely acceptable”, and “definitely unacceptable”, with the values between these figures being borderline 
acceptable. 
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a. For liquid chemicals only the values were: 69.8% specificity, 96.2% sensitivity, and 
82.5% overall accuracy. 
b. For solid chemicals only the values were: 79.7% specificity, 66.7% sensitivity, and 
73% overall accuracy. 
 
The sensitivity and overall accuracy values for solid chemicals, and sensitivity value for solids 
and liquids taken together, failed to meet the VMG “definitely acceptable” values. 
 
2. Using the 60% cell viability cut-off:  70.5% specificity, 87.6% sensitivity and 79% overall 
accuracy values were reported when considering all chemicals irrespective of physical state 
(solid/liquid).  
a. For liquid chemicals only the values were: 66.7% specificity, 98.3% sensitivity, and 
81.9% overall accuracy. 
b. For solid chemicals only the values were: 74.8% specificity, 76.9% sensitivity, and 
75.9% overall accuracy. 
 
The sensitivity and overall values for solid chemicals, and for solids and liquids taken together, 
were improved but still failed to meet the VMG “definitely acceptable” values. 
 
3. The values obtained when the solid chemicals were tested  in one laboratory by the protocol 
optimised for solid chemicals (SOP V 8.0) were: 
a. Using the 50% cell viability cut-off:  64.3% specificity, 88.2% sensitivity and 76.8% 
overall accuracy values were reported when considering all chemicals, irrespective of 
physical state (solid/liquid).  
b. Using the 60% cell viability cut-off:  60.7% specificity, 93.5% sensitivity and 78% 
overall accuracy values were reported when considering all chemicals, irrespective of 
physical state (solid/liquid).  
 
With the 50% cut-off the sensitivity value falls marginally short of the minimum acceptable 
value set by the VMG. 
 
With the 60% cut-off all of the VMT minimum acceptable values were achieved. 
 
4. By combining the data for liquid chemicals obtained during the ring trial (SOP V 6.0) with the 
data obtained by the one laboratory which retested the solid chemicals using the protocol 
optimised for solids (SOP V 8.0) the following values are obtained: 
a. Using the 50% cell viability cut-off:  66.5% specificity, 91.8% sensitivity and 79.4% 
overall accuracy values were reported when considering all chemicals, irrespective of 
physical state (solid/liquid).  
b. Using the 60% cell viability cut-off:  63.0% specificity, 95.7% sensitivity and 79.7% 
overall accuracy values were reported when considering all chemicals, irrespective of 
physical state (solid/liquid).  
 
All of the values thus derived meet the minimal acceptance values set by the VMG, with the 
60% cut-off giving the better values for overall accuracy and sensitivity. 
 
The ESAC WG notes that the EpiOcular™ EIT optimised solid chemicals protocol (SOP V 8.0) was 
found to be at least as reproducible as the original solid chemicals protocol (SOP V 6.0), with 93.2% 
and 96.6% concordance of classifications (based on 59 chemicals) being obtained by Beiersdorf with 
the optimised protocol for the 50% and 60% cut-offs analysed in this study, respectively, as 
compared to 92.0% and 94.0% obtained by the same laboratory with the original protocol (based on 
50 chemicals). 
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The ESAC WG can see no obvious physico-chemical feature shared by the chemicals that were 
misclassified (but we understand a more detailed analysis may be undertaken by others), and 
mindful of the limitations of the Draize eye test (from which the classification reference data was 
obtained) the ESAC WG notes that the false positive results (as judged on classification by the Draize 
eye test reference data) tended to have DET scores close to the values used to distinguish no-
category chemicals from eye irritants by that method.  
 
As stated above the ESAC WG considers that the accuracy figures should reflect the way decisions 
will be made in practice. Specifically, as chemical classification will be based upon one qualifying test 
run, the study results should have been evaluated to produce an accuracy range determined by the 
best and worst cases based on data from single runs rather than aggregating data from different test 
runs with the same chemical or by using a bootstrap approach to produce a more representative 
value. The ESAC WG commissioned additional analyses based on this approach.  
 
The table below shows both the best- and worse-case predictive capacities derived when the data 
generated for the individual runs are used to produce an accuracy range based on the best- and 
worst-case values using the 60% cut-off value. Each cell gives the proportion, the absolute frequency 
and the exact 95%-Confidence Interval for the proportion. The VMG 'definitely acceptable' criteria 
for specificity, sensitivity and overall accuracy (specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy 
≥ 75%) are almost satisfied even using the worst-case outcomes.  
 EUROPEAN COMMISSION 
DIRECTORATE-GENERAL 
JOINT RESEARCH CENTRE 
Directorate F - Health, Consumers and Reference Materials 
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Laboratory Protocol 
Worst-case scenario 
(60% cut-off) 
Best-case scenario 
(60% cut-off) 
Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity 
Results obtained through post-optimisation testing (solids) and during main study (liquids) 
TOTAL 
(Beiersdorf + 
IIVS + Harlan) 
Liquids (plus #27; 
minus #37) 
75.5% (40/53) 
[0.62,0.86] 
 
92.3% (24/26) 
[0.75,0.99] 
 
59.3% (16/27) 
[0.39,0.78] 
 
84.9% (45/53) 
[0.72,0.93] 
 
100% (26/26) 
[0.87,1.00] 
 
70.4% (19/27) 
[0.50,0.86] 
 
Liquids (plus #27; 
plus #37) 
75.9% (41/54) 
[0.62,0.87] 
 
92.3% (24/26) 
[0.75,0.99] 
 
60.7% (17/28) 
[0.41,0.78] 
 
85.2% (46/54) 
[0.73,0.93] 
 
100% (26/26) 
[0.87,1.00] 
 
71.4% (20/28) 
[0.51,0.87] 
 
Solids (plus #37) 
 
76.3% (45/59) 
[0.63,0.86] 
 
93.5% (29/31) 
[0.79,0.99] 
 
57.1% (16/28) 
[0.37,0.76] 
 
79.7% (47/59) 
[0.67,0.89] 
 
93.5% (29/31) 
[0.79,0.99] 
 
64.3% (18/28) 
[0.44,0.81] 
 
Liquids (plus #27; 
minus #37) 
And 
Solids (plus #37) 
75.9% (85/112) 
[0.67,0.83] 
 
93.0% (53/57) 
[0.83,0.98] 
 
58.2% (32/55) 
[0.44,0.71] 
 
82.1% (92/112) 
[0.74,0.89] 
 
96.5% (55/57) 
[0.88,1.00] 
 
67.3% (37/55) 
[0.53,0.79] 
 
Liquids (plus #27; 
plus #37) 
And 
Solids (plus #37) 
76.1% (86/113) 
[0.67,0.84] 
 
93.0% (53/57) 
[0.83,0.98] 
 
58.9% (33/56) 
[0.45,0.72] 
 
82.3% (93/113) 
[0.74,0.89] 
 
96.5% (55/57) 
[0.88,1.00] 
 
67.9% (38/56) 
[0.54,0.80] 
 
 
 EUROPEAN COMMISSION 
DIRECTORATE-GENERAL 
JOINT RESEARCH CENTRE 
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The ESAC WG considers that the relevant predictive capacity will fall somewhere between the best- and 
worst-case summarised in the above table. The ESAC WG notes that even the worst-case values satisfy 
VMG criteria for sensitivity and accuracy, and that the worst-case specificity is close to the VMG 
criterion. The ESAC WG therefore considers that the VMG criteria for predictive capacity can be deemed 
to have been met with the 60% cut-off value.   
 
The Cosmetics Europe Task Force Eye Irritation Report 
Not applicable.  
However the study co-ordinator supplied some additional information and analysis relevant to this issue 
at the ESAC WG meeting in March 2014. 
Where comparisons can be made between HPLC/UPLC data and in vivo classification data, the 
HPLC/UPLC data did not under-estimate the in vivo classification. That is not surprising bearing in mind 
that the OD-photometry formazan values were systematically, marginally higher than those obtained by 
the qualified HPLC/UPLC endpoint measurement system. 
 
10.2 Overall relevance (biological relevance and accuracy) of the test method in view of the 
purpose 
NOTE: Are the conclusions reg. biological/mechanistic relevance and relevance in terms of making 
accurate predictions/measurements for the specific toxicity effect justified by the evaluated data? 
EIVS 
SkinEthic™ HCE 
Although the test method results were highly reproducible within and between laboratories, the 
estimated predictive capacity with the SE and LE protocols and the Prediction Model used necessitate 
that predictive capacity must be improved before the method could be considered for use in any in vitro 
eye irritation testing strategy. 
 
In consultation with the VMG the test developer has agreed to optimise the test method outside the 
EIVS study. 
 
The ESAC WG believes that the VMG advice was sound, and that this was the correct decision. 
 
EpiOcular™ EIT 
 
All of the VMG 'definitely acceptable' criteria for specificity, sensitivity and overall accuracy defined by 
the VMG (specificity ≥ 60%; sensitivity ≥ 90%, overall accuracy ≥ 75%) were met by the liquids protocol 
and the optimized solids protocol using a 60% cut-off in the prediction model. 
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The Cosmetics Europe Task Force Eye Irritation Report 
This study results allow comparison of the classification of the test chemicals using three RhT test 
methods, each of which is relevant to a different toxicological endpoint. The evidence presented 
suggests that for chemicals compatible with these RhT methods comparable classifications based on 
estimations of formazan values are obtained using both OD-photometry and HPLC/UPLC endpoint 
detection systems. 
Furthermore, taking account of the in vivo classification data, the Cosmetics Europe Report has provided 
good evidence that with these same RhT test methods HPLC/UPLC endpoint detection measurement 
can be used in the case of strongly coloured chemicals which are incompatible with formazan 
measurement by OD-photometry.  
 
 
11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, limitations and 
exclusions 
NOTE: When considering the objective of the study, was the study designed in a way to enable 
conclusions on the applicability domain, the limitations and possible exclusions (e.g. technical 
incompatibility of the test method with specific chemicals)? 
EIVS 
The EIVS study took account of the known limitation of RhT test methods that rely upon an estimation 
of cytotoxicity by OD-photometry measurement of the MTT reduction product formazan. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
This study compared the classification of test chemicals using three RhT test methods, each of which is 
relevant to a different toxicological endpoint. The evidence presented suggests that for chemicals 
compatible with these RhT methods comparable classifications are obtained using both OD-photometry 
and HPLC/UPLC endpoint detection systems. 
Furthermore, taking account of the in vivo classification data, the Cosmetics Europe Report has provided 
good evidence that with these same RhT test methods HPLC/UPLC endpoint detection measurement 
can be used in the case of strongly coloured chemicals which are incompatible with formazan 
measurement by OD-photometry.  
The Cosmetics Europe Report also sets out plausible and reasoned arguments for why this might be 
applicable to other RhT test methods relying on measurement of the same endpoint. 
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11.2 Quality of the description of applicability domain, limitations, exclusions 
NOTE: When considering the objective of the study and the data generated/analysed, have the 
applicability domain, the limitations and the exclusions of the method been sufficiently described?  
EIVS 
The EpiOcular™ EIT and SkinEthic™ HCE test methods were not developed, designed, or evaluated to 
differentiate between UN GHS / EU CLP Category 1 (serious eye damage) and Category 2 (eye irritation) 
classifications. 
Gases and aerosols cannot be tested using either of the EIVS RhT test methods.  
Chemicals that are MTT-reducers and/or highly coloured resulting in interference with the endpoint 
measurement of formazan by OD-photometry may not be appropriate for RhT test methods using this 
endpoint measure. See for example the findings with EIVS chemicals #33 and #96. 
There is limited information available on the performance of the test methods with chemical mixtures. 
EpiOcular™ EIT 
The VMG and ESAC WG reviews of the chemicals that were misclassified when the EpiOcular™ EIT 
findings were judged against the Draize eye test reference data and identified no specific additional 
limitations or exclusions. 
Other than the known limitations of RhT test methods that rely on the OD-photometric measurement of 
the MTT reduction product formazan the ESAC WG identified no specific limitation or inclusions likely to 
improve the test method reliability or accuracy. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The use of HPLC/UPLC would overcome the current limitation of RhT test methods with respect to 
problems encountered with chemicals which interfere with the measurement of formazan levels by OD-
photometry. 
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12. Performance standards (Module 7)  
NOTE: This section is only relevant in case Performance Standards have been suggested upon completion 
of a validation study. 
12.1 Adequacy of the proposed Essential Test Method Components 
NOTE: Are the proposed Essential Test Method Components adequate with respect to the key elements 
of the validated method as evidenced by existing information and testing data generated during the 
study? 
EIVS 
Currently there is no Performance Standard for RhT eye irritation test methods, no proposal to develop 
such a standard, and the VSR does not propose or provide essential test method components. 
Once a suitable RhT test method for eye irritation is developed and validated, its performance 
characteristics (WLR, BLR, specificity, sensitivity and over all accuracy) should serve as the performance 
benchmarks when performance standards are developed and other RhT test methods enter the 
validation process. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Not relevant to this study.  
However, the Cosmetics Europe Report should inform on the development of Performance Standards 
for RhT test methods that rely on the measurement of the MTT-reduction product formazan as the 
endpoint detection measurement.  
12.2 Adequacy of the Reference Chemicals 
NOTE: Are the Reference Chemicals adequately mapping the accuracy values of the validated method? 
Do they provide a representative range of the applicability domain of the test substances used during 
validation? Do they map an appropriate range of toxicity effects of the particular health endpoint in 
question? Are they commercially available? 
EIVS 
In the view of the ESAC WG the EIVS chemicals set could form the basis of, or starting point for, a 
reference chemicals set when a Performance Standard for RhT test methods for evaluating chemically 
induced serious eye damage/eye irritation is developed.  
As noted elsewhere in this report, only a limited range of chemical mixtures have to date been identified 
as potential reference chemicals. However, chemical mixtures, already classified, e.g. by using additivity 
approach according to GHS or CLP could be integrated in a reference chemicals set.   
 
The Cosmetics Europe Task Force Eye Irritation Report 
Not relevant to this study. 
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13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
NOTE: Is the test method ready for regulatory purposes? If yes, why? If no – what impediments currently 
exclude application for regulatory purposes? 
EIVS 
SkinEthic™ HCE 
The performance data for this test method in this study confirms it is not ready for consideration for use 
for regulatory purposes. 
EpiOcular™ EIT 
The EIVS study findings justify the EpiOcular™ EIT test method (SOP V 8.0) being considered within a test 
strategy to determine the eye irritation potential of chemicals, specifically to detect non-irritants as part 
of a Top-Down or Bottom-Up approach (Scott et al, 2010). 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The evidence presented tends to confirm that for RhT test methods suitably qualified HPLC/UPLC 
endpoint measurement is as reliable as the established OD-photometry (albeit the values obtained are 
systematically marginally lower than those obtained by OD-photometry), and overcomes one of the 
current technical limitations of these RhT test methods. 
 
13.2. Assessment of the readiness for other uses  
NOTE: Is the test method ready for other uses (e.g. screening purposes, testing to gain mechanistic 
insight, to generate supportive information for hazard/risk assessment). 
 
SkinEthic™ HCE 
The performance data for this test method in this study confirms it is not ready for consideration for use 
for these purposes. More reliable test methods are already available. 
EpiOcular™ EIT 
The EIVS study findings justify the EpiOcular™ EIT test method being considered as a means of 
identifying chemicals which are not eye-irritants in non-regulatory contexts. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Not applicable. 
 
13.3 Critical aspects impacting on standardised use 
Note: What are the factors that may impact on standardised use (in regulatory or non-regulatory 
settings)? 
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EIVS 
ESAC WG notes that RhT test methods of the types evaluated in the EIVS study may be sufficiently 
robust to withstand minor variations in the manufacturing process (e.g. changes to the inserts) and 
transport. 
We do however consider that there are two critical aspects to standardized use: 
1. It is necessary to make proper use of control materials to properly evaluate test performance to 
ensure that any tissue damage in transit or storage does not compromise the data obtained. 
2. The post-exposure rinsing must be properly performed to prevent over-exposure of the tissue to 
the test material or mechanical damage to the tissue itself.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
All HPLC/UPLC systems have to be suitably qualified (FDA, 2001). 
 
13.4 Gap analysis 
NOTE: Identify, if appropriate, gaps in the study design and/or conduct that may have impacted on the 
stated study objective or the conclusions drawn. 
EIVS 
1. RhT test methods could form components of future integrated testing strategies for determining the 
eye irritancy potential of chemicals (Scott et al, 2010). The other components of such a testing 
strategy and the precise role of these RhT test methods have yet to be formally defined. 
2. As mentioned above the ESAC WG notes that there is an absence of chemical mixtures (other than 
polymers, co-polymers, and quasi-polymers) that can be used as test chemicals within validation 
studies of test methods to identity chemically induced eye irritation potential. In the case of the 
EpiOcular™ EIT test method confidence would be increased if EIVS chemical #102 was correctly 
classified by additional laboratories using the test protocol optimised for solids , and EIVS chemical 
#102 was used as a part of training and proficiency testing chemical set when the test method is 
introduced to naïve laboratories, and supplementary studies confirm that the test method correctly 
classifies a sample of labelled products.  
3. The RhT test methods evaluated in the EIVS study essentially evaluate the corneal component of 
chemically-induced eye irritancy: additional test methods may be required to evaluate chemically-
induced eye irritation produced by other mechanisms. 
4. For RhT test methods that use cytotoxicity as a surrogate measure of eye irritancy potential it is 
plausible that related test methods could be developed to allow histological and other evaluation of 
the tissue damage to provide additional insights into the mechanism of injury.   
5. The ESAC WG understands, although it is not immediately relevant to the determination of chemical 
induced eye irritation, that 3D RhT models and test methods may be developed and evaluated that 
include immune competent cells (e.g. Langerhans cells). Subject to defining suitable immune 
cascade activation markers and prediction models, these may find applications relevant to 
evaluating sensitisation potential and mechanisms.   
6. The WG acknowledges that including a wide range of chemical mixtures in validation studies 
currently raises several problems, e.g. availability of in vivo data, selection of test mixtures, and 
continuity of supply. However, most of the chemicals which have to be classified are mixtures and 
there is a need to confirm that in vitro methods can be used for the classification of chemical 
mixtures. The ESAC WG recommends the inclusion of a broader range of chemical mixtures in future 
validation studies, and proposes  consideration of the use of  reference data available for the 
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classification of mixtures, using the additivity approach recommended by the UN-GHS as well as the 
CLP, and/or the use of mixtures already assessed and classified as eye irritants or non-irritants. 
 
EpiOcular™ EIT 
1. The ESAC WG believes confidence in the test method would have been enhanced had the 
performance of the SOP V 8.0 protocol optimised for solids been evaluated in more than one 
laboratory. 
2. The VMG acceptance criteria require that no Category 1 chemicals be misclassified. Solid chemical 
#102, a Category 1 eye irritant, was misclassified in the ring-trial (SOP 6.0) by all 3 laboratories when 
the 50% cut-off was applied, and by 2 of the laboratories when the 60% cut-off was applied. Using 
the protocol optimised for solid chemicals and the 60% cut-off at one of the 2 laboratories that 
misclassified #102 using the original protocol gave the correct classification. The other laboratory 
that misclassified this chemical did not retest it using the optimised for solids protocol.  However, 
chemical #102 was one of the test materials blind-tested at the MatTek laboratory to optimise the 
protocol for testing solid chemicals, and using SOP V 8.0, it was reliably and consistently identified as 
a chemical requiring classification with tissue viabilities very similar to those obtained by the one 
laboratory which performed the post-protocol optimisation testing of solid chemicals. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
The Report does not address the potential problem of co-elution that can occur with HPLC/UPLC 
systems and how this is recognised and remedied. 
 
 
14. Other considerations 
NOTE: Please address any other consideration you might have in relation to the proposed approach 
under this section. 
EIVS 
1. The ESAC WG notes that within the SOPs used within the EIVS and Cosmetics Europe study there 
are references to procedural activities that should or should not take place at “room 
temperature”. As some elements of the testing procedures are temperature dependent the 
ESAC WG believes that whenever possible this term should be replaced by a specified 
temperature range.  
 
2. The ESAC WG endorses the view set out by the VMG that due to the variability of individual 
animal responses within the in vivo Draize eye test that there is >= 12% probability, if chemicals 
are retested, of chemicals currently classified as UN GHS Category 2 by the in vivo test being 
reclassified as UN GHS No Category (Adriaens et al, 2014). As in vivo Draize eye test data served 
as reference data for chemical selection and Predictive Capacity within validation studies, the 
reported performance of the in vivo test should be borne in mind when evaluating the reported 
performance, and validity, of alternative methods and testing strategies for detecting chemically 
induced eye irritation. 
  
3. The SkinEthic™ HCE and the EpiOcular™ EIT test methods were developed for maximum 
sensitivity (ability to detect positives, with low rate of false negatives) rather than for optimal 
overall accuracy with balanced sensitivity and specificity (ability to detect negatives, with an 
acceptably low rate of false positives), in view of their likely role of identifying non-irritant 
chemicals. 
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SkinEthic™ HCE 
 
1. The study findings failed to show that the use of the EPRA to determine chemical reactivity for 
protocol optimisation was useful, however there are early indications that there may be a trend 
for LogP values tending to equate to liquid chemical eye irritancy potential.  
  
2. The performance values obtained with the EpiOcular test method should serve as the required 
performance benchmarks when the optimised SkinEthic™ HCE test method re-enters the 
validation process. 
 
EpiOcular™ EIT 
 
1. The VMG observed that a change in the insert used in the EpiOcular™ EIT test kit resulted in 
minor changes in reported test method performance with respect to reproducibility. The ESAC 
WG considers this as evidence in support of the external validity of these test methods, but 
believes that as and when a Performance Standard is developed consideration should be given 
as to whether any similar manufacturing change to a validated test method would require 
formal catch-up re-evaluation of the validation status of the test method with the expectation 
being that any such change should result in test performance equivalent or better to the original 
test method. 
 
Cosmetics Europe UPLC/HPLC Study 
1. The ESAC WG notes that the Cosmetics Europe HPLC/UPLC report does not describe the 
outcome of a study intended, designed, conducted or reported in support of the formal 
validation of a test method. It is an assessment of the performance of a suitably qualified bio-
analytical system for the measurement of the MTT reduction product formazan. 
2. This study addresses Scientific Committee on Consumer Safety (SCCS) of the European 
Commission Directorate General for Health and Consumers advice that  “...for coloured 
substances, a different endpoint, not involving Optical Density (OD) quantification, should be 
envisaged. Analytical methods such as HPLC/UPLC might be more appropriate to detect 
formazan in the in vitro assay...” (McNamee et al. 2009). 
 
3. HPLC/UPLC should not be required or used as a routine replacement for OD-photometric 
determination of formazan levels – rather, it should be used as an alternative endpoint 
measurement system when OD-photometry is not a suitable or reliable measurement system. 
 
4. The development and acceptance of HPLC/UPLC should not preclude the development and 
consideration of other appropriate analytical methods for measuring formazan levels. 
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15. Conclusions on the study 
NOTE: This section should present a brief summary of the study results and conclusions as described in 
the VSR (subsection 15.1), discuss to which extent the conclusions drawn in the study reports are justified 
by the study results on their own (subsection 15.2) and evaluate to which extent the conclusions are 
plausible with respect to other information (subsection 15.3). 
 
15.1 ESAC WG summary of the results and conclusions of the study 
 
EIVS 
 
The RhT test methods evaluated with EIVS were developed to identify eye-irritancy potential. 
 
 
EpiOcular™ EIT  
 
With respect to the VMG conclusions and recommendations:  
 
1. The VMG considered that the EpiOcular™ EIT original liquids protocol and the optimised solids 
protocol are scientifically valid (reproducible and accurate) to identify chemicals not requiring 
classification for serious eye damage/eye irritation under UN GHS.   
 
2. The VMG recommended that the 60% cut-off (as submitted by the method developer) is used 
rather than the 50% cut-off due to higher sensitivity and accuracy, and lower number of total 
misclassifications.  
 
The ESAC WG believes the study data fully support this conclusion and recommendation. 
 
3. The VMG considered that although a wide range of chemical types, chemical classes, molecular 
weights, LogP, chemical structures, etc were tested, no clear additional limitations regarding 
applicability could be identified. The VMG therefore recommended that EpiOcular™ EIT is 
considered applicable to the testing of all types of chemicals, until proven contrary.   
 
The ESAC WG has noted that currently there is only a limited range of chemical mixtures 
available for use as test substances within eye irritation validation studies, and would like to see 
more data presented with respect to the test method performance in the case of chemical 
mixtures requiring the classification for eye irritancy potential. 
 
4. The VMG recommended the use of positive control(s) and associated acceptance criteria that 
are strict enough to allow easy detection of inappropriate conduct of the assay (e.g., in the 
optimised SkinEthic™ HCE).  
 
The ESAC WG agrees. 
 
5. The VMG concluded that the use of 2 tissue replicates in similar or modified RhT/MTT-based 
test method aiming at identifying chemicals not requiring classification for serious eye 
damage/eye irritation is statistically and scientifically justified.  
 
The ESAC WG believes the data (submissions by the test developer, the study findings, and the 
conclusions of the VMG) tends to support this, as does the principle of lean study design.  
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However, we do not accept that this can be generalised to all RhT test methods on the basis of 
the available evidence. 
 
6. The VMG considered the current endpoint detection system using standard OD-photometry as 
appropriate to assess direct MTT-reducers and coloured chemicals, when tissue viability falls 
within the linear range of the spectrophotometer (e.g., < 140%), or when the uncorrected 
viabilities already identify the test chemical as requiring classification.   
 
The ESAC WG tends to agree. 
 
7. For coloured chemicals interfering too strongly with the MTT-reduction assay an alternative 
endpoint detection system should be used (e.g., HPLC/UPLC-photometry).  
 
The ESAC WG agrees, and believes the suitably qualified HPLC/UPLC endpoint measurement 
system described in the Cosmetics Europe study report is suitable for this purpose. 
 
The ESAC WG concludes that with respect to the results and conclusions of the EIVS study and VSR 
that in relation to the EpiOcular test method: 
 
1. The EpiOcular test method does not represent a stand-alone full replacement for the currently 
accepted in vivo test method.  
2. Its primary purpose will be as a means of identifying UN GHS eye irritation “no category” solid 
and liquid chemicals, as a tool used within an integrated testing strategy.  
3. The test method has been shown to be sufficiently relevant and reliable to be considered for 
that purpose. 
 
The Cosmetics Europe Task Force Eye Irritation Report 
Section 5 of the Cosmetics Europe Report sets out 5 conclusions: 
1. Using the approach based on the FDA guidance on validation of bio-analytical methods, 
HPLC/UPLC systems were established and qualified through meeting acceptance criteria of key 
parameters in the three participating laboratories. Any new HPLC/UPLC system could be 
considered for such analysis once the system has been suitably qualified. This approach is 
transferable and applicable to any laboratory. 
 
2. The reproducibility of measuring formazan extract samples by HPLC/UPLC was established as 
being very high through evaluation of the same samples in three independent laboratories. 
 
3. For test substances that do not exhibit colour interference nor direct MTT reduction, cell 
viability values are almost identical using either absorbance (OD-photometry) or HPLC/UPLC as 
endpoint detection systems for measurement of formazan. 
 
4. HPLC/UPLC is capable of measuring formazan resulting in a viability measurement that can be 
translated into a classification for strongly coloured test substances when this is not possible by 
using OD-photometry absorbance for endpoint detection. Examples of this in one or more of the 
RhT test methods are test substance #10 that was excluded from the EURL ECVAM EIVS based 
on pre-checks colour interference and test substance #26 identified from the SCCS 
memorandum (SCCS, 2010). 
 
5. Analysis of the use HPLC/UPLC as an endpoint detection system for coloured test substances 
was conducted using selected test systems for the different endpoint in vitro RhT test methods. 
ESAC WORKING GROUP REPORT  Page | 96 
On the basis of the results obtained, it is concluded that this analytical endpoint detection 
system is relevant to all RhT test methods irrespective of test system and test method and can 
be applied to any of the other RhT test systems within OECD Test Guideline 431 (skin corrosion) 
and 439 (skin irritation). For eye irritation, this will be equally applicable to different test 
systems in an OECD Test Guideline developed based on the EIVS outcome. 
 
The ESAC WG agrees on all five points. 
 
The ESAC WG also concludes that with respect to the Cosmetics Europe Report: 
 
1. The qualified HPLC/UPLC systems described in the Cosmetics Europe study report are capable of 
reliably and reproducibly detecting and accurately quantifying the MTT-reduction product 
formazan in extracts prepared using the RhT models used within the study: and that it is 
plausible that this will be true of if the same, or similarly qualified, HPLC/UPLC systems, are 
applied to these and other RhT test methods which rely on the detection and quantification of 
the MTT-reduction product formazan.  
2. The use of HPLC and HPLC technology overcomes one of the current limitations of RhT test 
methods which rely on the OD-photometry detection and quantification of the MTT-reduction 
product formazan: that is the assessment of the relevant toxicological properties of highly-
coloured chemicals which themselves produce colour interference with the OD-photometric 
methods of detecting and quantifying formazan.  
 
3. When using the RhT test methods and test chemicals used for this study HPLC/UPLC was capable 
of consistently and reliability identifying and quantifying formazan, with the values obtained 
permitting an estimation of percentage cell viability that translated into a toxicity endpoint 
classification that did not under-classify the toxicity of the reference chemicals; and for strongly 
coloured test chemicals where the formazan measurement by OD-photometric methods would 
not have permitted an in vitro classification using these RhT systems.  
 
4. The formazan levels as measured by HPLC/UPLC were systematically slightly below the values 
obtained when formazan levels were estimated by OD photometry. 
5. With the RhT test methods used within the study the derived cell viability values were also 
almost identical using OD-photometric absorbance and HPLC/UPLC as the endpoint detection 
systems for measurement of formazan test substances not producing colour interference nor 
direct MTT reduction, that suitably qualified HPLC/UPLC should be appropriate as an alternative 
endpoint detection system with this larger class of chemicals. However, the ESAC WG notes that 
the values obtained using HPLC/UPLC were systematically, marginally lower than those obtained 
by OD photometry: there may be a case for considering whether this necessitates re-evaluation 
of the cut-offs developed using OD photometry. 
 
15.2 Extent to which study conclusions are justified by the study results alone 
All of the ESAC WG conclusions given above can be derived and argued or justified from the study 
results reported in the EIVS VSR and the Cosmetics Europe study report, the appendices to those reports, 
and the additional information supplied to or commissioned by the ESAC WG. 
 
15.3 Extent to which conclusions are plausible in the context of existing information 
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In reaching its conclusions the ESAC WG has also taken account of the larger body of information and 
knowledge set out in the references cited in the study documents. It is on consideration of both the 
study findings, and that larger body of knowledge of information, that the ESAC WG established and 
confirmed the plausibility of the conclusions set out above.  
The Cosmetics Europe Task Force Eye Irritation Report 
All of the above conclusions are plausible in the context of the study findings and supporting documents. 
 
 
16. Recommendations 
Note: This section should provide recommendations on the test method (e.g. further work, possible use) 
and their constituting elements (e.g. test system, prediction model, SOP). 
16.1 General recommendations 
 
1. The ESAC WG believes that potential problems with the reliability of historical Draize eye test 
data must also be taken into account when evaluating the predictive capacity of alternative test 
methods and testing strategies. 
 
2. The ESAC WG supports the VMG recommendation that “…RhT/MTT-based test method aiming 
at identifying chemicals not requiring classification for serious eye damage/eye irritation (using 
tissues modelling the corneal epithelium), including an optimised SkinEthic™ HCE test method, 
use positive control(s) and associated acceptance criteria that are strict enough to allow easy 
detection of inappropriate conduct of the assay…”.  
 
3. The ESAC WG, considers that when evaluating multiple tests runs for each test chemical the 
predictive capacity values should be calculated on the basis of the best and worse outcomes for 
all qualified test runs, or using a “boot-strap” approach. 
 
4. The ESAC WG recommends insights into test performance with chemical mixtures be obtained 
by testing mixtures based on their current classification, or based on the base of the properties 
of their components.  
 
5. The VMG concluded that based on the highly reproducible data acquired with both EpiOcular™ 
EIT and SkinEthic™ HCE in EIVS using multiple exposure times and post-treatment incubation 
periods, it is reasonable to conclude that the reproducibility of this type of test methods is not 
affected by varying the exposure or the post-treatment incubation times. The ESAC WG would 
recommend a more conservative approach: variations in exposure and post-treatment 
incubation periods do alter the test results: we would therefore recommend that any such 
protocol variations are evaluated on a case by case basis. 
 
6. “The VMG considers the current endpoint detection system using standard photometry as 
appropriate to assess direct MTT-reducers and coloured chemicals, when the observed 
interference with formazan is not extreme i.e., the viabilities of the tests before correcting for 
direct MTT reduction and/or colour interference (with the viabilities obtained with the killed 
and/or living/colour controls) are within the linear range of the spectrophotometer (e.g., below 
140% of the negative control) or when the uncorrected viabilities already identify the test 
chemical as irritant. Moreover, the VMG recommends that, for MTT reducers and colorants that 
strongly interfere with the MTT measurement (i.e., killed and/or living/colour control values > 
50% of the negative control), three independent tests are conducted and that within test 
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variability is compared to that obtained with non-interfering chemicals in EIVS. If the variability 
of the interfering chemical is not significantly higher than normal, correction using adapted 
controls should be allowed as long as the interference is not extreme (as explained above). If 
variability is significantly higher than normal, it is assumed that the amount of chemical retained 
by the tissue after exposure and post-treatment incubation varies significantly between different 
tests. In this situation the VMG recommends that the following rules are applied:  
a. RULE 1 – IF the mean of % Non-Specific Color (NSC) or % Non-Specific MTT reduction 
(NSMTT) of three qualified tests is less than or equal to (≤) 50%, THEN the chemical is 
considered to be compatible with the test method.  
b. RULE 2 – IF the mean of %NSC or %NSMTT of three qualified tests is greater than (>) 50% 
AND their classification (I or NI) remains the same upon correction, THEN the chemical is 
considered to be compatible with the test method.  
c. RULE 3 – IF the mean of %NSC or %NSMTT of three qualified tests is greater than (>) 50% 
AND the classification of at least one of the qualified tests changes upon correction, 
THEN this chemical is considered to be incompatible with the test method. In this case, 
use of another method (analytical or test method not relying on MTT reduction) or of a 
default classification as irritant should be considered.” 
 
The ESAC WG tends to agree. 
 
 
7. The VMG commented: “For coloured chemicals interfering too strongly with the MTT-reduction 
assay an alternative endpoint detection system may be required (e.g., HPLC/photometry, see 
complementary report on Cosmetics Europe HPLC-Project). In this case, one single test (the 
chosen measurement system) should be sufficient independently of how strong the colour 
interference is, unless the chemical is also a strong MTT reducer (i.e., killed control values > 50% 
of the negative control) and correction from control tissues is required. If the latter occurs, the 
conduct of three independent tests is still recommended.“  
 
The ESAC WG agrees in principle BUT both endpoints might be measured and compared to in 
vivo reference data, and the Cosmetics Europe report suggests HPLC/UPLC might be useful for 
this. In addition, as the study showed formazan levels were maintained in samples stored for 
one month, supplementary HPLC/UPLC measurements could be arranged for test samples 
where the colour of the test material is believed to have interfered with the formazan 
estimation by OD photometry. 
 
8. EURL  ECVAM should consider providing supplementary statistical guidance to those planning 
and managing validation studies – specifically in relation to the identification of the appropriate 
experimental unit,  calculation of appropriate confidence limits and accuracy values based on 
the number of test chemicals rather than the number of test runs, and means of supplementing 
regression analysis as a means of addressing correlation between the performance of two test 
methods particularly when the true value of the variable of interest is unknown (Bland and 
Altman, 1986).   
 
 
 
The Cosmetics Europe Task Force Eye Irritation Report 
That ESAC WG accepts the conclusions set out in the Study Report, but in addition recommends that in 
future where different endpoint measurement systems are being evaluated and compared that the 
statistical methods recommended by Bland and Altman (1986) be used instead of or in addition to 
standard correlation measures and regression analyses. 
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16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
The ESAC WG offers the following recommendations for consideration. 
EIVS 
Not all of the relevant in vivo mechanisms of ocular toxicity are addressed by the EpiOcular™ Eye 
Irritation Test (EIT) and the SkinEthic™ HCE test methods. These RhT test methods are by design most 
relevant for the assessment of epithelial responses. If these test methods are to be used to identify non-
irritants within an integrated testing strategy the ESAC EG Eye Irritation believes other test methods will 
be needed to assess other adverse outcome pathways.  
The ESAC WG supports the VMG recommendation: “...that all viscous, waxy and gel-like chemicals are 
placed in a water bath for 15 minutes at 37°C before deciding if they should be tested with the liquids or 
the solids protocol. Moreover, the test chemical should not be brought to room temperature before 
testing and should be applied directly from the water bath.” , and would also recommend that within 
SOPs the term “room temperature” be replaced by an appropriate specified temperature range. 
 
 
SkinEthic™ HCE 
 
The ESAC WG concludes, as does the VMG, that the SkinEthic™ HCE TS LE and the SE protocols as used 
in the validation study are not considered suitable to identify chemicals not requiring classification for 
serious eye damage/eye irritation. We note the test method proved to be highly reproducible within 
and between laboratories, and that the EPRA data was not useful, support the VMG recommendations 
for optimisation of the SkinEthic™ HCE test method, including considering developing and evaluating 
different protocols for liquid chemicals and solid chemicals. We note that the test method optimisation 
is not being done within EIVS.  
 
The ESAC WG agrees with the VMG conclusion that the use of EPRA to orient chemicals to the LE (non-
reactive) or SE (reactive) protocols as proposed in the SkinEthic™ HCE TS is not useful in the context of 
eye irritation with this RhT test method. 
 
On the basis of the independent statistical analysis of the data acquired in EIVS with SkinEthic™ HCE SE 
and LE protocols using three replicate tissues per test the VMG concluded and recommended the use of 
two tissue replicates per test in any similar or modified RhT/MTT-based test method aiming at 
identifying chemicals not requiring classification for serious eye damage/eye irritation is statistically and 
scientifically justified. The ESAC WG would recommend a more conservative approach – with the 
appropriate minimum number of replicates being identified for each RhT test method on a case by case 
basis.  
 
The Cosmetics Europe Task Force Eye Irritation Report 
 
Mindful that OD-photometry estimation of formazan levels is systematically slightly higher than 
formazan values estimated from HPLC/UPLC measurements, consideration should be given as to 
whether and to what extent this should impact on the prediction models used with different endpoint 
measurement systems. 
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Appendix 1 – Description of contentious issue (Majority/Minority Position) 
The ESAC Working Group has reached consensus on all but one point as outlined below.  
A) BACKGROUND 
 One of the acceptance criteria defined at the beginning of the validation study was that no UN GHS 
Category 1 chemical should be under-classified (i.e. no Category 1 false negatives).However, during 
EIVS, one Cat. 1 chemical was, by two of the three laboratories (Beiersdorf and IIVS), predicted as a 
non-irritant (i.e. false negative prediction). The chemical was disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene) bis(benzene sulphonate; INCI name: DISODIUM DISTYRYLBIPHENYL DISULFONATE) 
(EIVS Chemical No. 102). 
 These data were generated using the EpiOcularTM protocol V6.0, i.e. the version before optimisation 
of the protocol's specifications for testing of solids that took place in the context of EIVS.  
 Following optimisation, the final protocol version (V 8.0) was then only used at Beiersdorf which 
produced a correct Category 1 classification with chemical No. 102. In contrast, IIVS, which had also 
under-classified the chemical using protocol V 6.0, did not retest the chemical using the optimised 
protocol. 
 However, during this optimisation phase, the test developer (MatTek) tested No. 102 in a coded 
fashion with an exposure time of 6 hours, i.e. the exposure time that is now set in the final optimised 
protocol. The Mattek testing data obtained during optimisation classified EIVS chemical No. 102 as a 
Category 1 eye irritant (true positive). The testing data by Mattek thus were obtained (1) with the 
same parameters as those of the final optimised protocol and (2) under blind conditions.  
 This information is not, however, to be found within the EIVS VSR, but was communicated to the 
ESAC WG during the course of the scientific review by EURL ECVAM. Thus, when judging only on the 
basis of the validation study report, apparently only one laboratory (Beiersdorf) had tested No. 102 
with the optimised protocol, while in reality additional testing data by Mattek with the same 
protocol, but from the optimisation phase, were available but not reported in the VSR.  
 When reflecting on this it should be noted that the in vivo classification of EIVS chemical No. 102 as a 
UN GHS Category 1 chemical is on the basis of persistence of conjunctival effects only: this in vivo 
classification is based on a conjunctival score of 1 in two out of three animals at day 21, by which 
time all the other acute tissue effects had resolved. For the purposes of the US EPA classification, 
which does not take account of conjunctival effects, the chemical is classified as EPA Category II. 
B) WG MAJORITY POSITION: On the basis that two laboratories used the EpiOcularTM optimised for 
solids protocol for testing coded chemicals and produced the correct classification for chemical No. 102, 
a majority of the Working Group is satisfied that there is sufficient information to conclude that protocol 
V 8.0 is capable of correctly classifying this chemical and that false predictions of Category 1 substances 
are unlikely to occur (c.f. EIVS acceptance criterion). 
C) WG MINORITY POSITION: One WG member considers that, as IIVS did not subsequently re-test using 
the amended protocol, the relevant EIVS acceptance criterion cannot be deemed to have been met, and 
support for the use of the test method for regulatory purposes must be conditional (i.e. depending on 
additional testing of No. 102 in another laboratory). Specifically, support for the use of the EpiOcularTM 
protocol V8.0 for regulatory use (for testing solids) must be conditional upon one or more laboratories 
correctly classifying EIVS chemical No. 102 as UN GHS Category 1. In addition confidence in the reliability 
of the test method would be increased if EIVS chemical No. 102 is used as part of a required training and 
proficiency protocol for transferring the test method to other laboratories, and supplementary studies 
confirm that the protocol can correctly classify a sample of labelled products. 
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